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The triterpenoids comprise a diverse family of plant natural products with potential 
applications in many sectors, including medicine, food, agriculture, and home and 
personal care. Triterpenoids are derived from the cyclisation of 2,3-oxidosqualene by 
an oxidosqualene cyclase (OSC), to generate a triterpene, which can then be oxidised 
by cytochromes P450 to produce triterpenoids, and glycosylated by UDP-
glycosyltransferases (UGTs) to produce triterpenoid saponins. More than 150 
triterpene structures have been identified to date, which can be modified in a myriad 
of ways, resulting in the huge diversity of triterpenoids found in nature. The 
modifications are often crucial for bioactivity. Numerous saponins have industrial 
potential as vaccine adjuvants, feeding deterrents, detergents and gelling agents, 
their amphipathic properties being critical to this activity. Meanwhile, many 
triterpenoid aglycones have potential as therapeutics (including anti-cancer, anti-HIV 
and hepatoprotective drugs) and insecticides. Many of these compounds are derived 
from oleanolic acid, which is produced from the triterpene β-amyrin by oxidation of 
carbon-28 (C-28; a methyl group) to a carboxyl group. 
Despite this great potential, it is currently challenging to obtain triterpenoids in the 
quantities required for industrial exploitation. Plants typically accumulate triterpenoids 
in low abundance and under specific conditions, and many triterpenoids are produced 
by non-crop plants that are difficult to cultivate. Furthermore, plants often produce 
numerous structurally similar triterpenoids, making it difficult to purify the desired 
compound(s). Meanwhile, the complexity of triterpenoids, which contain multiple 
chiral centres and often undergo stereo- and regiospecific oxygenations, makes their 
chemical synthesis challenging and economically prohibitive. Triterpenoid production 
in the budding yeast Saccharomyces cerevisiae could be a means to address the 
shortfall in production. S. cerevisiae is a genetically tractable and well characterised 
microorganism that naturally produces 2,3-oxidosqualene, and is widely used in 
industrial fermentations for a variety of products. The present work focuses on the 
production of oleanane triterpenoids and saponins (i.e. derived from β-amyrin) in S. 
cerevisiae. 
In Chapter 3, a gas chromatography-mass spectrometry (GC-MS) method to monitor 




In Chapter 4, twelve β-amyrin synthase (BAS) homologues are systematically 
compared for productivity in yeast, and a difference in β-amyrin production of > 10-
fold was observed. The homologues from Artemisia annua (AaBAS) and 
Chenopodium quinoa (CqBAS1) were the most productive, each yielding 10.6 mg/L 
β-amyrin. Expression of most BAS homologues resulted in considerably slower 
growth indicative of metabolic burden. However, a BAS from Avena strigosa (AsBAS) 
had a negligible effect on growth while still producing a relatively high amount of β-
amyrin (8.8 mg/L). 
In Chapter 5, sixteen C-28 oxidase P450s (co-expressed with AaBAS and the 
cytochrome P450 reductase ATR2) are compared for the production of oleanolic acid. 
All strains grew slowly compared with a control strain carrying an empty vector. 
Product profiles varied considerably, and a 6.8-fold difference in oleanolic acid titre 
was observed. The CYP716AL1 enzyme from Catharanthus roseus produced the 
most oleanolic acid in the initial screen (14.1 mg/L), but also accumulated substantial 
amounts of β-amyrin (7.1 mg/L) and the intermediate compounds erythrodiol (6.7 
mg/L) and oleanolic aldehyde (titre undetermined) compared with the other BASs. Co-
expression of CYP716AL1 with AsBAS resulted in faster growth and the production 
of mainly oleanolic acid, with very little β-amyrin, erythrodiol, or oleanolic aldehyde 
accumulating. 
Finally, in Chapter 6, saponins derived from β-amyrin and oleanolic acid are produced 
in yeast through the additional expression of UGT enzymes. This study identified 
glycosylations at different positions on the triterpenoid backbone, and is the first 






The triterpenoids are a group of plant chemicals with potential applications in 
medicine, agriculture, cosmetics and numerous other sectors. Triterpenoids are 
traditionally obtained by extraction from the plants that naturally produce them. 
However, plants usually produce very low amounts of triterpenoids, while high 
quantities are required for commercial exploitation. As such, an alternative method of 
production is required if triterpenoids are to be fully exploited for commercial and 
medical uses. 
One such method is to utilise microorganisms such as baker's yeast. Triterpenoids 
are produced through a series of chemical reactions, and plants contain sets of genes 
that enable them to perform these reactions and produce triterpenoids. These genes 
can be introduced into yeast to produce triterpenoids. This approach has the potential 
to produce much higher quantities of triterpenoids than can be obtained from their 
natural sources. This is possible because, unlike plants, yeast cultures can be grown 
in large fermenters. However, this method is currently in its infancy and much work is 
required before commercially-relevant quantities can be produced in yeast. In 
addition, many triterpenoids have yet to be produced in yeast due to their structural 
complexity. 
The present work attempts to address some of the current challenges in this field. In 
particular, two key reaction steps were optimised in order to boost triterpenoid 
production in yeast. Furthermore, a set of structurally complex triterpenoids whose 
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The numbering convention for oleanane triterpenes (β-amyrin and its derivatives) is 
shown below. Carbons are numbered one to thirty, and the rings are labelled A to E. 
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Chapter 1: Introduction 
The triterpenoids are a large family of plant natural products with diverse bioactivities. 
In plants, they are important for resistance to pathogens and pests, with many having 
antimicrobial and anti-feedant activities (Moses et al., 2014a), and may also be 
involved in responses to abiotic stresses, such as nutrient starvation, light and 
temperature levels, and dehydration (Moses et al., 2014a; Thimmappa et al., 2014). 
Furthermore, triterpenoids have also been implicated in plant growth and 
development (Thimmappa et al., 2014). Due to their diverse bioactivities, triterpenoids 
have applications in numerous sectors, including in medicine, food, agriculture, and 
home and personal care (Moses et al., 2014a, 2013; Osbourn et al., 2011). They are 
derived from the cyclisation of 2,3-oxidosqualene, which is also a precursor to the 
sterols. Specifically, the cyclisation of 2,3-oxidosqualene by an oxidosqualene cyclase 
(OSC) generates a triterpene, and many different OSCs and triterpene cyclisation 
products have been identified to date (Hoshino, 2017; Ghosh, 2016; Thimmappa et 
al., 2014). The triterpenes can subsequently be modified by various enzymes to 
produce triterpenoids, resulting in the huge structural diversity that explains the 
diverse properties and applications of this family of metabolites (Moses et al., 2014a; 
Thimmappa et al., 2014). 
Unfortunately, current methods of obtaining triterpenoids have severe limitations that 
often make them unsuitable for commercial exploitation, which requires triterpenoids 
to be produced in high quantities and purities at relatively low cost (Moses et al., 
2013). Triterpenoids are traditionally obtained by extraction from plants, which can be 
low-yielding, time-consuming, and expensive (Moses et al., 2013). Furthermore, the 
structural complexity of triterpenoids makes their chemical synthesis challenging (Zhu 
et al., 2008; Cheng et al., 2009; Xiao and Yu, 2013; Deng et al., 1999; Kim et al., 
2013). An alternative method is to produce triterpenoids in a microorganism 
expressing the appropriate biosynthetic pathway, and the yeast Saccharomyces 
cerevisiae has been successfully used for this purpose (Kirby et al., 2008; Fukushima 
et al., 2013; Moses et al., 2014b; Czarnotta et al., 2017; Zhuang et al., 2017a; Arendt 
et al., 2017; Zhao et al., 2018; Zhu et al., 2018; Zhao et al., 2017). In this chapter, the 
biosynthesis, properties, and methods of obtaining triterpenoids, with a focus on their 
biotechnological production in yeast, are discussed. 
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1.1 Triterpenoid biosynthesis in plants 
All terpenoids are synthesised from the five-carbon molecules isopentenyl 
pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) (Fig. 1.1) (Kirby and 
Keasling, 2009). The end-to-end joining of IPP and DMAPP, catalysed by 
prenyltransferases, produces linear terpene backbones that contain multiples of five 
carbons (Figure 1.1), and these can be cyclised by a variety of terpene synthases to 
produce cyclic terpenes (Kirby and Keasling, 2009). A terpene is thus defined by the 
number of carbons it contains, and those containing 30 carbons are called triterpenes. 
Triterpenoids are modified derivatives of triterpenes, polycyclic terpenes that are 
produced from the cyclisation of the 30-carbon 2,3-oxidosqualene by an 
oxidosqualene cyclase (OSC) (Figure 1.2, Figure 1.3) (Thimmappa et al., 2014). 
Different triterpenes can be produced depending on the OSC (Figure 1.3), with more 
than 100 OSCs and 150 different triterpenes having been identified to date (Hoshino, 
2017; Ghosh, 2016). Following cyclisation, the resulting triterpenes can be modified 
by a variety of enzymes. The most common modifications are oxygenations catalysed 
by cytochromes P450 (producing triterpenoids; Figure 1.4), and glycosylations 
catalysed by UDP-glycosyltransferases (UGTs) (producing triterpenoid saponins; 
Figure 1.5) (Moses et al., 2014a; Thimmappa et al., 2014). These modifications can 
occur at various positions along the numerous triterpene backbones, resulting in the 
vast diversity of triterpenoid structures and bioactivities found in nature (Moses et al., 
2014a). 
This section provides an overview of triterpenoid biosynthesis, from the generation of 
2,3-oxidosqualene and its cyclisation to a triterpene, to the decoration of triterpene 
backbones by P450s and UGTs to produce triterpenoids and saponins.  
1.1.1 Generation of 2,3-oxidosqualene 
In plants, IPP and DMAPP are synthesised via two pathways: (i) the mevalonate 
(MEV) pathway, which is localised to the cytosol, and (ii) the 1-deoxy-D-xylulose-5-
phosphate (DXP) pathway, which is localised to the plastids (Kirby and Keasling, 
2009). In general, eukaryotes and archaea possess the MEV pathway (with plants 
also having the DXP pathway), while bacteria typically possess the DXP pathway 
(Kirby and Keasling, 2009). 
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Plants produce triterpenoids via the MEV pathway (Kirby and Keasling, 2009). Here, 
acetyl-CoA is converted to IPP through a series of six reactions, in which mevalonate 
is an intermediate (Figure 1.1) (Miziorko, 2011). First, the condensation of two acetyl-
CoA molecules by acetyl-CoA thiolase generates acetoacetyl-CoA. Subsequently, the 
addition of another acetyl-CoA molecule by HMG-CoA synthase generates 3-hydroxy-
3-methylglutaryl-CoA (HMG-CoA), which is then reduced to mevalonate in an 
NADPH-dependent reaction catalysed by HMG-CoA reductase (HMGR). The 
phosphorylation of mevalonate by mevalonate kinase then generates mevalonate-5-
phosphate, which is further phosphorylated by phosphomevalonate kinase to produce 
mevalonate-5-pyrophosphate. Finally, mevalonate-5-pyrophosphate is converted to 
IPP in a decarboxylation reaction catalysed by mevalonate pyrophosphate 
decarboxylase (Miziorko, 2011). 
After the generation of IPP, the enzyme IPP-DMAPP isomerase (IDI) catalyses the 
reversible isomerisation between IPP and DMAPP (Figure 1.1) (Moses et al., 2014a; 
Kirby and Keasling, 2009). These two molecules are combined by the 
prenyltransferase geranyl pyrophosphate synthase to produce the 10-carbon geranyl 
pyrophosphate (GPP) (Kirby and Keasling, 2009). Subsequently, the addition of 
another IPP molecule to GPP by farnesyl pyrophosphate synthase produces the 15-
carbon farnesyl pyrophosphate (FPP), and the fusion of two FPP molecules by 
squalene synthase produces the 30-carbon squalene (Moses et al., 2014a; Kirby and 
Keasling, 2009). This is then oxidised to 2,3-oxidosqualene by squalene epoxidase, 
which introduces an epoxide group (Figure 1.1) (Moses et al., 2014a), and the 
cyclisation of 2,3-oxidosqualene produces a triterpene (30-carbon terpene) 
(Thimmappa et al., 2014). Similarly, the cyclisation of GPP and FPP produces 
monoterpenes and sesquiterpenes (10- and 15-carbon terpenes), respectively (Kirby 
and Keasling, 2009). In the biosynthesis of diterpenes (20 carbons), the addition of 
IPP to FPP generates the 20-carbon geranylgeranyl pyrophosphate (GGPP), which 
is then cyclised to a diterpene (Kirby and Keasling, 2009). Meanwhile, the fusion of 
two GGPP molecules produces the 40-carbon tetraterpenes (Nisar et al., 2015). 
1.1.2 Cyclisation of 2,3-oxidosqualene 
The OSC-catalysed cyclisation of 2,3-oxidosqualene to a triterpene is the first 
committed step in triterpenoid biosynthesis (Figure 1.2) (Thimmappa et al., 2014). 
Sterols are also derived from the cyclisation 2,3-oxidosqualene by an OSC 
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Figure 1.1. Generation of 2,3-oxidosqualene from acetyl-CoA via the mevalonate 
pathway. See next page for full legend. 
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(Figure 1.2) (Thimmappa et al., 2014); in animals and fungi, lanosterol synthase 
cyclises 2,3-oxidosqualene to lanosterol, which is then converted to the essential 
membrane sterols cholesterol (in animals) or ergosterol (in fungi) (Thimmappa et al., 
2014). In plants, cycloartenol synthase converts 2,3-oxidosqualene to cycloartenol, a 
precursor to the phytosterols, although lanosterol also occurs in plants (Thimmappa 
et al., 2014; Moses et al., 2014a). In general, sterol and triterpene biosynthesis can 
be distinguished by the conformations of the first three rings during cyclisation. In 
sterol biosynthesis they take on a chair-boat-chair (CBC) conformation, while in 
triterpene biosynthesis they have a chair-chair-chair (CCC) conformation (Figure 1.2) 
(Thimmappa et al., 2014). The cyclisation of 2,3-oxidosqualene thus represents an 
important branch point between triterpenoid and sterol biosynthesis. 
During cyclisation the OSC first binds 2,3-oxidosqualene, which folds into either the 
CBC or CCC conformation, depending on whether the OSC is a sterol or triterpene 
synthase, respectively (Thimmappa et al., 2014). The catalytic aspartate residue of 
the OSC then protonates the epoxide group of 2,3-oxidosqualene, which initiates 
cyclisation (Figure 1.3) (Hoshino, 2017). Cyclisation involves numerous ring 
generations, ring expansions and skeletal rearrangements, and proceeds through a 
series of carbocation intermediates (Hoshino, 2017; Thimmappa et al., 2014). 
Deprotonation or water capture of an intermediate terminates the reaction and 
generates a triterpene, and the intermediate at which the reaction was terminated 
determines which triterpene is produced (Figure 1.3). This explains the huge diversity 
of triterpenes that occur in nature, as there are many possible carbocation 
intermediates generated during the cyclisation reaction and each leads to the 
production of a different triterpene (Thimmappa et al., 2014). 
 
Figure 1.1. Generation of 2,3-oxidosqualene from acetyl-CoA via the mevalonate 
pathway. The mevalonate pathway converts acetyl-CoA to the five-carbon molecule 
isopentenyl pyrophosphate (IPP) through six reactions, where mevalonate is an intermediate. 
Subsequently, IPP is isomerised to dimethylallyl pyrophosphate (DMAPP). The end-to-end 
joining of IPP and DMAPP generates geranyl pyrophosphate (GPP; 10 carbons) then farnesyl 
pyrophosphate (FPP; 15 carbons), and the joining of two FPP molecules generates the 30-
carbon squalene. Finally, epoxidation of squalene produces 2,3-oxidosqualene, the precursor 
to the triterpenes. Names of the corresponding S. cerevisiae genes are shown in parentheses. 
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Figure 1.2. Cyclisation of 2,3-oxidosqualene to sterols and triterpenes. In the formation 
of sterols, 2,3-oxidosqualene folds into the chair-boat-chair (CBC) conformation and is 
cyclised by a lanosterol synthase or a cycloartenol synthase (left). Lanosterol is the precursor 
to the essential membrane lipids cholesterol (in animals) and ergosterol (in fungi). Cyclisation 
to a triterpene proceeds via the chair-chair-chair (CCC) conformation (right). Many OSCs 
catalysing the cyclisation of 2,3-oxidosqualene to a variety of triterpenes have been identified; 
two such triterpenes (β-amyrin and lupeol) are shown here. Dashed arrows represent multiple 
reactions. 
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Figure 1.3. Oxidosqualene cyclisation cascade to generate triterpenes. See next page 
for legend. 
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Protonation of 2,3-oxidosqualene results in the generation of the six-membered A-
ring with a positive charge at carbon-6 (C-6; 2,3-oxidosqualene numbering) (Figure 
1.3). This generates a monocyclic cation, which is the first carbocation intermediate 
in the cyclisation cascade (Hoshino, 2017). The A-ring contains the hydroxyl group 
that is derived from the epoxide of 2,3-oxidosqualene. Subsequently, the six-
membered B-ring forms, generating a bicyclic cation with a positive charge at C-10 
(Hoshino, 2017). Rings C to E are then formed sequentially, and each is generated 
through the initial formation of a five-membered ring followed by ring expansion to a 
six-membered ring (Hoshino, 2017). The ring forming reactions result in the further 
movement of the positive charge across the molecule. This, combined with additional 
rearrangements in the form of 1,2-hydride and 1,2-methyl shifts, generates a variety 
of carbocation intermediates having the positive charge and methyl groups at different 
positions (Hoshino, 2017; Thimmappa et al., 2014). Thus, a range of carbocation 
intermediates, with different numbers and sizes of rings, different positions of methyl 
groups, and with the positive charge at different positions, are generated throughout 
the cyclisation cascade (Figure 1.3) (Hoshino, 2017; Thimmappa et al., 2014).  
Termination of the reaction through deprotonation or water capture results in the 
formation of a double bond or a second hydroxyl group, respectively, at the site of the 
positive charge, and generates a triterpene (Figure 1.3) (Thimmappa et al., 2014; 
Salmon et al., 2016). For example, the dammarenyl cation is generated after the 
formation of the five-membered D-ring, and is therefore a 6/6/6/5 tetracycle (i.e. 
containing three six-membered rings and one five-membered ring). Water capture at 
C-19 (2,3-oxidosqualene numbering), which holds the positive charge, results in the 
 
Figure 1.3. Oxidosqualene cyclisation cascade to generate triterpenes. After binding the 
OSC, 2,3-oxidosqualene folds into the chair-chair-chair (CCC) conformation. Protonation of 
the epoxide group by the catalytic aspartate (red) initiates cyclisation, which proceeds through 
a series of carbocation intermediates formed through ring generations, ring expansions, and 
1,2-hydride and -methyl shifts. Deprotonation of a carbocation intermediate by the OSC (or 
occasionally water capture) terminates the cyclisation cascade and generates a triterpene. 
Different triterpenes can be produced depending at which intermediate the reaction is 
terminated. Formation of the triterpenes dammarenediol-II, lupeol, α-amyrin and β-amyrin, as 
well as the highly rearranged triterpene friedelin, are shown (blue boxes). Carbon atoms are 
labelled according to 2,3-oxidosqualene numbering (orange), and rings A through E are 
labelled. The dashed arrow represents multiple reaction steps. 
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addition of a second hydroxyl group and termination of the reaction, generating the 
tetracyclic triterpene dammarenediol-II (Figure 1.3) (Hoshino, 2017; Salmon et al., 
2016). Alternatively, ring expansion of the dammarenyl cation D-ring to a six-
membered ring, followed by generation of the five-membered E-ring, gives the 
6/6/6/6/5 pentacyclic lupanyl cation, deprotonation of which generates the triterpene 
lupeol (Figure 1.3) (Thimmappa et al., 2014; Hoshino, 2017). The widespread 
triterpene β-amyrin is produced from deprotonation of the oleanyl cation, which is 
generated through ring expansion of the lupanyl cation E-ring (giving the 6/6/6/6/6 
pentacyclic germanicyl cation) followed by two 1,2-hydride shifts (Figure 1.3) 
(Thimmappa et al., 2014; Hoshino, 2017). Alpha-amyrin, which differs from β-amyrin 
only in the position of a methyl group, is derived from the ursanyl cation, whose 
formation from the germanicyl cation involves a 1,2-methyl shift (Figure 1.3) 
(Thimmappa et al., 2014). The most highly rearranged carbocation intermediate is the 
friedelyl cation, whose formation involves ten 1,2 shifts from the dammarenyl cation. 
Reaction termination at this intermediate produces the triterpene friedelin and occurs 
by nucleophilic attack of the positive charge at C-2 by the C-3 hydroxyl group. This 
generates a ketone at C-3, and friedelin thus has no C-C double bond (Figure 1.3) 
(Thimmappa et al., 2014). 
Oxidosqualene cyclases can be classed as monofunctional or multifunctional. 
Monofunctional OSCs produce a single triterpene (usually with trace amounts of other 
triterpenes), while multifunctional OSCs generate multiple triterpene cyclisation 
products, often β-amyrin, α-amyrin and/or lupeol (Thimmappa et al., 2014; Ghosh, 
2016). For example, the Arabidopsis thaliana baruol synthase produces 23 different 
triterpenes, with baruol as its major product (Shan et al., 2005). By contrast, examples 
of monofunctional OSCs include numerous β-amyrin and lupeol synthases 
(Thimmappa et al., 2014). The existence of multifunctional OSCs can be understood 
by considering the nature of the cyclisation reaction. Failure to terminate at a particular 
carbocation intermediate would allow cyclisation to continue, resulting in termination 
at a different intermediate and the production of a different triterpene (Figure 1.3) 
(Thimmappa et al., 2014). Thus, OSCs that are highly effective at terminating the 
reaction at a specific carbocation intermediate are monofunctional, while those that 
are less effective at this produce multiple triterpenes and so are multifunctional. 
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1.1.3 Decoration of the triterpene scaffold to produce 
triterpenoids and triterpenoid saponins 
Following cyclisation, the triterpene can be modified by various enzymes in decoration 
(or tailoring) reactions. The most common modifications are oxygenations catalysed 
by P450s (Figure 1.4) and glycosylations catalysed by UGTs (Figure 1.5) (Moses et 
al., 2014a; Thimmappa et al., 2014). Other modifications include acylations, 
methylations and malonylations (Moses et al., 2014a). Such modified triterpenes 
containing heteroatoms are called triterpenoids, and in the case of a glycosylated 
triterpene/triterpenoid the term triterpenoid saponin is used. These modifications have 
a substantial impact on the properties of the triterpenoid and are crucial for bioactivity 
(for more information see section 1.2). Oxygenations, glycosylations and other types 
of tailoring reactions are discussed in this section. 
1.1.3.1 Cytochrome P450-catalysed oxygenations to produce triterpenoids 
Cytochromes P450 are a superfamily of monooxygenases that catalyse diverse 
reactions, often stereo- and regiospecific oxygenations (e.g. hydroxylations) (Bak et 
al., 2011). They are found in all kingdoms of life (Sezutsu et al., 2013) and are 
especially abundant in plants, where they represent the largest family of biosynthetic 
enzymes (Nelson and Werck-Reichhart, 2011). They are involved in a host of plant 
processes, from the detoxification of xenobiotics, to the biosynthesis of signalling 
hormones and the production of secondary metabolites (Bak et al., 2011), and are 
extensively involved in triterpenoid biosynthesis (Thimmappa et al., 2014). Catalysis 
involves the reduction of molecular oxygen at the active site haem group to generate 
a reactive oxygen radical, which then oxygenates the substrate (Werck-Reichhart and 
Feyereisen, 2000). Plant P450s receive the electrons for this reaction through 
interaction with an NADPH-cytochrome P450 reductase (CPR), which accepts 
electrons from NADPH and shuttles them through its FMN and FAD domains to the 
P450 haem group (Werck-Reichhart and Feyereisen, 2000; Bak et al., 2011; Jensen 
and Møller, 2010). Plant P450s thus require molecular oxygen, the co-factors 
NADPH, FMN, FAD and haem, and the co-expression of a CPR for activity. 
Numerous P450s involved in triterpenoid biosynthesis have been identified (Ghosh, 
2017; Miettinen et al., 2017). They are highly regio- and stereospecific, usually 
catalysing oxygenations that introduce a hydroxyl, ketone/aldehyde, or carboxyl group 
to various positions on the triterpene backbone (Augustin et al., 2011; Thimmappa et 
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al., 2014). Epoxidation has also been reported (Geisler et al., 2013; Miettinen et al., 
2017), as have non-oxygenation reactions such as desaturations and carbon-carbon 
bond cleavage (Field and Osbourn, 2008; Castillo et al., 2013). Many functional 
groups introduced by P450s can be targeted for further modification, such as by UGTs 
or acyltransferases (Thimmappa et al., 2014; Moses et al., 2014a). In addition, 
multiple P450s can act on the same triterpene backbone to generate more highly 
oxygenated triterpenoids (Han et al., 2018; Seki et al., 2011; Moses et al., 2014b; 
Arendt et al., 2017). While most reported P450s involved in triterpenoid biosynthesis 
are monofunctional, catalysing a single reaction, some catalyse multiple reactions. 
For example, CYP51H10 from Avena strigosa introduces both a hydroxyl and an 
epoxide group to β-amyrin (Geisler et al., 2013), while CYP716A2 from A. thaliana 
hydroxylates β-amyrin at the C-16, C-22 or C-28 positions to generate three different 
products (Figure 1.4) (Yasumoto et al., 2016). To date, more than fifty P450s involved 
in triterpenoid biosynthesis have been identified, oxidising numerous positions across 
the triterpene backbone (Ghosh, 2017). 
Cytochromes P450 are grouped into families and subfamilies based on amino acid 
sequence identity, with family members typically having ≥ 40 % amino acid sequence 
identity and subfamily members ≥ 55 % sequence identity (Bak et al., 2011). They are 
named systematically after their family and subfamily by a nomenclature committee 
(http://drnelson.uthsc.edu/CytochromeP450.html) (Nelson, 2009). For example, 
CYP51H10 is the tenth member of family 51, subfamily H. To date, P450s involved in 
triterpenoid biosynthesis have been identified across 10 families and 17 subfamilies 
(Ghosh, 2017). Cytochromes P450 are also divided into clans, where a clan is simply 
a clade of P450s (Werck-Reichhart and Feyereisen, 2000). Each clan thus contains 
one or multiple P450 families, and clans are named after the lowest-numbered P450 
family that they contain (Werck-Reichhart and Feyereisen, 2000). For example, the 
CYP85 clan contains several families including CYP85, CYP88 and CYP716, and is 
named CYP85 as this is the lowest-numbered family. Land plants contain 11 clans 
(Nelson and Werck-Reichhart, 2011) and P450s involved in triterpenoid biosynthesis 
are found in five of these clans (Miettinen et al., 2017).  
Many P450s involved in triterpenoid biosynthesis belong to the CYP716 family 
(Ghosh, 2017). In particular, members of the CYP716A subfamily typically catalyse 
the C-28 oxygenation of pentacyclic triterpenes such as the β-amyrin, α-amyrin and 
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Figure 1.4. Oxygenation of β-amyrin by cytochromes P450 generates diverse 
triterpenoids. The P450-catalysed oxygenation of a triterpene such as β-amyrin can occur 
at multiple positions, generating a variety of triterpenoid products (red). These triterpenoids 
can be further oxygenated by additional P450s (blue and green), resulting in a huge diversity 
of triterpenoid products. 
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lupeol, oxidising the C-28 methyl group to a carboxyl group (Figure 1.4) (Miettinen et 
al., 2017; Seki et al., 2011; Fiallos-Jurado et al., 2016; Khakimov et al., 2015; 
Yasumoto et al., 2017; Moses et al., 2015b, 2015a; Yasumoto et al., 2016). The C-28 
carboxyl is a particularly important functional group because it is a common site of 
glycosylation (Thimmappa et al., 2014), and numerous bioactive triterpenoids and 
saponins contain this moiety (see section 1.2 for more information) (Nielsen et al., 
2010; Ragupathi et al., 2011; Smith et al., 2007; Pollier and Goossens, 2012; Tsao et 
al., 2010; Suh et al., 2012; Tong et al., 2017). This oxygenation reaction appears to 
occur through intermediates containing a hydroxyl or aldehyde group at C-28 (Figure 
1.4). For example, expression of the C-28 oxygenase CYP716A12 in a yeast strain 
engineered to produce β-amyrin resulted in the production of erythrodiol, oleanolic 
aldehyde and oleanolic acid, which are the C-28 hydroxy, aldehyde and carboxyl 
derivatives of β-amyrin, respectively (Figure 1.4) (Fukushima et al., 2011). While most 
CYP716As catalyse C-28 oxygenation, others such as CYP716A2 (a β-amyrin C-16, 
C-22 and C-28 hydroxylase) catalyse different reactions (Figure 1.4) (Miettinen et al., 
2017; Ghosh, 2017; Yasumoto et al., 2016). The CYP716 family contains several 
other subfamilies that catalyse a range of oxygenations against tetracyclic and 
pentacyclic triterpenes (Figure 1.4), but only the CYP716As catalyse C-28 
oxygenation (Miettinen et al., 2017). 
1.1.3.2 UGT-catalysed glycosylations to produce triterpenoid saponins 
Triterpenoids are commonly glycosylated to produce triterpenoid saponins (Augustin 
et al., 2011; Moses et al., 2014a). Glycosylation is performed by family 1 UDP-
glycosyltransferases (UGTs), which use UDP-sugar donors to glycosylate their 
substrates (Thimmappa et al., 2014). Sugars are added as monosaccharides in a 
sequential fashion, rather than as previously synthesised oligosaccharides 
(Thimmappa et al., 2014; Shibuya et al., 2010; Wang et al., 2015), and the most 
common sugar donors in saponin biosynthesis include UDP-glucose, -galactose, -
rhamnose, -arabinose, -xylose, and -glucuronic acid (Thimmappa et al., 2014; 
Augustin et al., 2011). 
Glycosylations typically occur at the hydroxyl or carboxyl groups of the triterpenoid, 
most commonly at the C-3 hydroxyl and C-28 carboxyl groups for pentacyclic 
triterpenoids (such as those derived from β-amyrin) (Figure 1.5) (Thimmappa et al., 
2014). While the C-3 hydroxyl is present in unmodified triterpenes, being derived from 
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the epoxide group of 2,3-oxidosqualene, the C-28 carboxyl must be introduced by a 
P450 (see above; Figure 1.4). Glycosylation can also less commonly occur at other 
oxygenated positions on the backbone of pentacyclic triterpenoids (Augustin et al., 
2011; Sayama et al., 2012). By contrast, the ginsenosides, saponins that are derived 
from the tetracyclic dammarane-type triterpenoids, are commonly glycosylated at the 
C-3, C-6 and C-20 hydroxyl groups (Wang et al., 2015; Wei et al., 2015; Yan et al., 
2014), of which the C-6 hydroxyl must be introduced by a P450 (Han et al., 2012). 
Thus, P450s, particularly those of the CYP716A subfamily that introduce the C-28 
carboxyl group, are important for the biosynthesis of saponins, introducing the 
additional reactive oxygen moieties that can be glycosylated by UGTs (Moses et al., 
2014a). 
Saponins can contain one or multiple sugar chains, which can be linear or branched, 
and each sugar chain usually contains between two and five monosaccharides 
(Augustin et al., 2011). The sugar chains can be subject to further modifications, such 
as acylations (Ragupathi et al., 2011). Saponins containing a single sugar chain are 
monodesmosidic, while those with two sugar chains are bidesmosidic, and saponins 
containing a greater number of sugar chains are uncommon (Augustin et al., 2011). 
Monodesmosidic saponins are usually glycosylated at the C-3 hydroxyl group, while 
bidesmosidic saponins are typically glycosylated at the C-3 hydroxyl and C-28 
carboxyl groups (for pentacyclic saponins) (Augustin et al., 2011; Erthmann et al., 
2018; Augustin et al., 2012; Meesapyodsuk et al., 2007; Naoumkina et al., 2010; 
Shibuya et al., 2010). For example, QS-21, a mixture of predominantly two saponins 
derived from an extract from Quillaja saponaria, contains a branched trisaccharide 
(glucuronic acid, xylose and galactose) at the C-3 hydroxyl group and a linear 
tetrasaccharide (fucose, rhamnose, xylose, and apiose/xylose) at the C-28 carboxyl 
group  (Figure 1.6) (Ragupathi et al., 2011). By contrast, mono- and bidesmosidic 
ginsenosides, which are tetracyclic, are typically glycosylated at the C-3, C-6 and/or 
C-20 hydroxyl groups (Wei et al., 2015; Wang et al., 2015; Yan et al., 2014). 
Similar to P450s, UGTs are grouped into families and subfamilies based on amino 
acid sequence identity, with families and subfamilies typically sharing > 40 % and > 
60 % sequence identity, respectively (Augustin et al., 2011). To date, more than 20 
UGTs involved in triterpenoid biosynthesis have been identified across at least four 
families and seven subfamilies, many of which belong to the UGT73 family (Augustin 
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Figure 1.5. Glycosylation of triterpenoids produces diverse saponins. (A) Glycosylation 
of oleanolic acid and its oxygenated derivatives at the C-3 hydroxyl and C-28 carboxyl groups, 
and the generation of a disaccharide chain at C-3 through the sequential action of two UGTs. 
(B) Glycosylation of the dammarenediol-II derivatives protopanaxadiol and protopanaxatriol 
at C-3, C-6 and C-20 to produce ginsenosides. Dashed arrows represent multiple reactions. 
Moieties introduced by P450s are highlighted red, while sugars are labelled blue and green. 
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et al., 2012; Erthmann et al., 2018; Meesapyodsuk et al., 2007; Naoumkina et al., 
2010; Achnine et al., 2005; Shibuya et al., 2010; Sayama et al., 2012; Wei et al., 2015; 
Wang et al., 2015; Yan et al., 2014). The identified UGTs predominantly glycosylate 
pentacyclic triterpenoids at the C-3 hydroxyl and C-28 carboxyl groups (Augustin et 
al., 2012; Erthmann et al., 2018; Meesapyodsuk et al., 2007; Naoumkina et al., 2010), 
tetracyclic dammarane-type triterpenoids at the C-3, C-6 and C-20 hydroxyl groups 
(Wei et al., 2015; Yan et al., 2014; Wang et al., 2015), and/or extend existing saponin 
sugar chains on both tetracyclic and pentacyclic saponins (Shibuya et al., 2010; 
Sayama et al., 2012; Wang et al., 2015). 
1.1.3.3 Other tailoring reactions 
In addition to oxygenations and glycosylations, numerous other modifications can also 
occur, including acylation, malonylation and methylation (Moses et al., 2014a). For 
example, Avena strigosa (oat) produces β-amyrin-derived saponins called avenacins, 
which are important for disease resistance (Papadopoulou et al., 1999). They are 
acylated at the C-21 hydroxyl by AsSCPL1 (A. strigosa serine carboxypeptidase-like 
acyltransferase 1), which transfers either an N-methyl anthranilate moiety (producing 
avenacins A-1 and B-1) or a benzoate moiety (producing avenacins A-2 and B-2) 
(Mugford et al., 2009). Mutants of A. strigosa lacking a functional AsSCPL1 
accumulate avenacins lacking the acyl group (des-acyl avenacins) and are more 
susceptible to disease (Papadopoulou et al., 1999; Qi et al., 2004). 
Meanwhile, QS-21 contains an acyl chain attached to the fucose moiety of its C-28 
tetrasaccharide, and this acyl chain is further glycosylated with an arabinose moiety 
(Figure 1.6) (Ragupathi et al., 2011). The acyl chain may be important for the ability 
of QS-21 to act as an adjuvant, as it may stimulate the proliferation of T-killer cells 
(Ragupathi et al., 2011). Other examples include the saponin vaccaroside B from 
Saponaria vaccaria, which has 2-hydroxy-2-methylglutarate attached to its C-28 
tetrasaccharide chain (Meesapyodsuk et al., 2007), and the triterpenoid cinnamoyl-
lupeol, which has a 4-hydroxy-cinnamoyl moiety at the C-3 hydroxyl (Williams, 1999). 
In summary, saponin biosynthesis involves four main types of enzymes: (i) OSCs, 
catalysing the cyclisation of 2,3-oxidosqualene to a triterpene scaffold, (ii) P450s that 
oxygenate the scaffold, (iii) UGTs that perform glycosylation reactions at various 
functional groups, and (iv) other tailoring enzymes, such as acyltransferases. 
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1.2 Properties and applications of triterpenoids 
The huge structural diversity of triterpenoids results in diverse properties and 
bioactivities, with applications in numerous sectors (Moses et al., 2014a). While 
triterpenes are hydrophobic, typically containing a single hydroxyl group derived from 
the epoxide of 2,3-oxidosqualene, oxygenation of triterpenes by P450s increases their 
polarity (Moses et al., 2014a). Meanwhile, glycosylation introduces a large hydrophilic 
sugar moiety and the resulting saponin is therefore amphipathic (Moses et al., 2014a). 
As such, saponins can act as surfactants, foaming agents or even permeabilise cell 
membranes (Augustin et al., 2011; Moses et al., 2014a). The tailoring reactions thus 
have a major impact on the properties of the molecule and are essential for bioactivity 
(Moses et al., 2014a; Ragupathi et al., 2011; Nielsen et al., 2010; Geisler et al., 2013; 
Papadopoulou et al., 1999). Examples of triterpenoids and saponins with medically 
and commercially relevant properties are discussed (Figure 1.6). 
The ginsenosides are a class of saponin produced by the glycosylation of 
dammarane-type triterpenoids, specifically protopanaxadiol and protopanaxatriol, 
which are derived from the oxygenation of the tetracyclic triterpene dammarenediol-II 
(Dai et al., 2013). They are produced by Panax spp. (ginseng), a traditional Chinese 
medicine, and have shown anti-cancer activities in clinical trials (Nag, 2012). 
Furthermore, ginsenoside compound K (Figure 1.6) is being investigated in clinical 
trials in China for the treatment of arthritis (Chen et al., 2017; Yang et al., 2015).  
Various triterpenoids of the lupane class, which are derived from the triterpene lupeol, 
also display interesting bioactivities. Betulinic acid, which is the C-28 carboxyl 
derivative of lupeol, is a potential anti-cancer compound that has been investigated in 
clinical trials (Figure 1.6) (Moses et al., 2013). Meanwhile, bevirimat, a betulinic acid 
derivative that inhibits the replication of HIV type 1, was evaluated in a phase II clinical 
trial to treat HIV (Figure 1.6) (Smith et al., 2007). In contrast, cinnamoyl-lupeol, which 
is derived from lupeol by the addition of a cinnamoyl group, showed insecticidal 
activities against Cylas formicarius (sweet potato weevil), a pest of sweet potato 
(Williams, 1999). 
The oleanane triterpenoids, which are derived from the triterpene β-amyrin, contain 
numerous molecules with diverse properties and bioactivities. Oleanolic acid (Figure 
1.6), the C-28 carboxyl derivative of β-amyrin, has hepatoprotective activities and is 
used to treat viral hepatitis in China (Pollier and Goossens, 2012). Furthermore, 
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preliminary results from a clinical trial indicated that it has potential as a hypolipidemic 
drug (Lin et al., 2016). Oleanolic acid has also shown anti-cancer and anti-
inflammatory activities (Pollier and Goossens, 2012), which lead to the development 
of a series of synthetic oleanolic acid derivatives with enhanced activities (the 
bardoxolone series) (Figure 1.6). The first derivative, bardoxolone, was evaluated in 
a phase I clinical trial with leukaemia patients (Tsao et al., 2010), while bardoxolone 
methyl underwent phase II and III clinical trials for patients with chronic kidney disease 
and type II diabetes, although it showed adverse effects (Moses et al., 2013). 
Meanwhile, bardoxolone imidazolide and bardoxolone ethylamide have the potential 
to treat osteoarthritis due to their anti-inflammatory activities and ability to induce 
chondrogenesis (Suh et al., 2012). Finally, the synthetic oleanolic acid derivative RTA 
408 (Figure 1.6) is under clinical development by Reata Pharmaceuticals Inc., and is 
currently undergoing a phase II clinical trial for the treatment of the neurodegenerative 
disease Friedreich’s ataxia (Strawser et al., 2017). 
Numerous saponins of the oleanane class also display medically relevant 
bioactivities. For example, QS-21 is being investigated as an adjuvant in various 
vaccines including against HIV and malaria, and is commercially available in a 
veterinary vaccine against feline leukaemia virus (Moses et al., 2013; Ragupathi et 
al., 2011; Mahmoudi and Keshavarz, 2017; Sun et al., 2009). The biosynthesis of QS-
21 from β-amyrin involves multiple oxygenations, glycosylations, and an acylation 
(Figure 1.6). The acyl chain is critical for adjuvant activity, as its removal results in 
loss of its immunostimulatory activity (Ragupathi et al., 2011). The sugar chains, the 
aldehyde group at C-23, and its amphipathic structure are also important for its 
adjuvant activity (Ragupathi et al., 2011). 
Saponins derived from hederagenin (23-hydroxy-oleanolic acid) have been identified 
as having anti-feedant properties against plant pests, and may therefore have 
agricultural applications. Hederagenin cellobioside (3-O-[glucose-glucose]-
hederagenin), α-hederin (3-O-[rhamnose-arabinose]-hederagenin), and 3-O-glucose-
hederagenin (Figure 1.6) all acted as feeding deterrents against Phyllotreta nemorum 
(flea beetle) (Nielsen et al., 2010; Augustin et al., 2012). Hederagenin cellobioside 
also inhibited feeding by Plutella xylostella (diamondback moth) (Shinoda et al., 
2002). Meanwhile, the corresponding saponins with oleanolic acid aglycones 
(oleanolic acid cellobioside and 3-O-glucose-oleanolic acid), which lack the C-23 
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Figure 1.6. Triterpenoids and saponins with industrial potential. For the bardoxolone 
series, the R group is H (bardoxolone), methyl (bardoxolone methyl), imidazolide 
(bardoxolone imidazolide) or ethylamide (bardoxolone ethylamide). Triterpenoid aglycones 
and saponins are labelled in red and green, respectively. Glc: glucose; Ara: arabinose; Rham: 
rhamnose; GlcA: glucuronic acid; Gal: galactose; Xyl: xylose; Fuc: fucose; Api: apiose; NMA: 
N-methyl anthranilate 
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hydroxyl group, had much weaker anti-feedant activities, indicating that this moiety is 
important for activity (Nielsen et al., 2010; Augustin et al., 2012). Neither of the 
corresponding aglycones (hederagenin and oleanolic acid) inhibited feeding, 
demonstrating the importance of glycosylation for activity (Nielsen et al., 2010). 
Similarly, the avenacins (Figure 1.6) are required for disease resistance (against 
fungal pathogens) in oat (Avena spp.) (Papadopoulou et al., 1999) and therefore also 
have potential applications in agriculture (Haralampidis et al., 2001). The avenacins 
have a β-amyrin backbone that is oxygenated at four to five positions (depending on 
the avenacin), contain a branched trisaccharide at the C-3 hydroxyl, and are acylated 
with either benzoate or N-methyl anthranilate at the C-21 hydroxyl (Figure 1.6) 
(Mugford et al., 2009). It was reported that the C-12,13 epoxide, which is introduced 
by CYP51H10, is important for their anti-fungal activities (Geisler et al., 2013). 
Furthermore, Avena strigosa mutants that don’t accumulate acylated avenacins are 
more susceptible to fungal attack than wild type plants, indicating that acylation of the 
avenacins may also be important for disease resistance (Papadopoulou et al., 1999; 
Qi et al., 2004). 
In addition to its ability to act as a feeding deterrent, α-hederin displayed anti-cancer 
activities in mouse models (Liu et al., 2014; Bang et al., 2005). However, it also 
exhibited a strong haemolytic activity, lysing red blood cells, that may preclude its use 
in the clinic (Gauthier et al., 2009; Tong et al., 2017). Indeed, numerous oleanane 
saponins have haemolytic activities (Moses et al., 2014a). This is due to their ability 
to permeabilise cell membranes, which can be attributed to the amphipathic structure 
of saponins (Augustin et al., 2011). However, not all saponins have this activity. For 
example, lupane-type saponins do not permeabilise cell membranes, and nor do 
some oleanane saponins (Moses et al., 2014a). Indeed, the oleanane saponins 
produced by Medicago truncatula can be classed as haemolytic or non-haemolytic, 
the former having a C-28 carboxyl group (being derived from oleanolic acid) and the 
latter having a C-24 hydroxyl group (being derived from 24-hydroxy-β-amyrin); the C-
28 carboxyl may therefore be important for haemolytic activity (Seki et al., 2011; 
Moses et al., 2014a). 
Hederacolchiside A, which is derived from α-hederin by the addition of a glucose 
moiety to the existing sugar chain, showed stronger antitumour activity than α-hederin 
in mouse models (Bang et al., 2005). This activity was even greater than the 
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commercially available anti-cancer drugs taxol and doxorubicin (Bang et al., 2005). 
However, as with α-hederin, it exhibits considerable haemolytic activity (Gauthier et 
al., 2009). By generating a series of synthetic derivatives of α-hederin and its aglycone 
hederagenin, Tong et al. (2017) identified a hederagenin derivative that showed 
strong cytotoxicity against human cancer cell lines and minimal haemolytic activity. 
Finally, the oleanane saponin glycyrrhizin (Figure 1.6) is responsible for the 
sweetness of liquorice and is widely used as a sweetener (Osbourn et al., 2011), 
having a sweetness approximately 170 times greater than sucrose (Mizutani et al., 
1994). In addition, glycyrrhizin has anti-viral activities, showing promise in clinical trials 
for the treatment of HIV/AIDs and is currently being used in Japan to treat chronic 
hepatitis (Fiore et al., 2008). Glycyrrhizin is derived from β-amyrin via two 
oxygenations and the sequential transfer of two glucuronic acid moieties to the C-3 
hydroxyl, generating a disaccharide sugar chain (Seki et al., 2008, 2011; Xu et al., 
2016). 
1.3 Methods to produce triterpenoids and saponins 
Because of their diverse applications there is great interest in the medical and 
commercial exploitation of triterpenoids and saponins. However, current approaches 
to triterpenoid production have considerable limitations, and are typically unable to 
provide triterpenoids in the high abundances and purities required for commercial 
exploitation (Moses et al., 2013). Methods of obtaining plant natural products such as 
triterpenoids include extraction from the native plant, chemical synthesis and 
biotechnological production, in which organisms (often microbes) are engineered to 
produce the compounds of interest (Moses et al., 2013; Osbourn et al., 2011; Kotopka 
et al., 2018). The latter approach has many advantages for the production of complex 
metabolites such as triterpenoids and saponins. These approaches are discussed 
below. 
The traditional approach of obtaining triterpenoids and saponins (and many other 
plant natural products besides) is extraction from the native plant (Moses et al., 2013). 
For example, the triterpenoid oleanolic acid is currently obtained from olive (Pollier 
and Goossens, 2012). However, plants typically produce numerous structurally 
related triterpenoids and saponins in low abundance, and often under specific 
conditions (e.g. stress or pathogen attack), which complicates the isolation of 
individual molecules, leading to low yields and purities (Moses et al., 2013, 2014a). 
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Indeed, natural saponin extracts, such as QuilA from Quillaja saponaria, comprise a 
mixture of saponins instead of a single structure (Moses et al., 2014a). Furthermore, 
most such plants are not crop plants and are therefore difficult to cultivate. Yields can 
vary due to environmental fluctuations and the timescale for production is typically 
many months or years (Moses et al., 2013; Paddon and Keasling, 2014). As such, 
this method of production can be challenging and time-consuming, requiring either 
large areas of land for the cultivation of crops or the environmentally destructive 
process of extracting metabolites from wild plants. 
A second approach is chemical synthesis, which is used for the production of various 
natural products (Nicolaou et al., 1998). However, this method is often unsuitable for 
the synthesis of complex molecules such as triterpenoids and saponins, whose 
biosynthesis involves the generation of multiple chiral centres and regio- and 
stereospecific oxygenations (Hoshino, 2017; Thimmappa et al., 2014). While the total 
chemical synthesis of several saponins has been reported, these involved numerous 
reaction steps and repeated purifications, during which much of the product was lost 
(Zhu et al., 2008; Cheng et al., 2009; Xiao and Yu, 2013; Deng et al., 1999; Kim et 
al., 2013). 
An alternative method to produce plant natural products is the application of 
biotechnology to produce saponins in microorganisms, in which the relevant plant 
biosynthetic enzymes are heterologously expressed in a chosen microorganism. This 
approach has the potential to overcome many of the limitations of the above methods. 
Complex molecules with multiple chiral centres and regio- and stereospecific 
modifications can be produced relatively easily, as this approach utilises the plant 
enzymes that naturally catalyse such reactions. Furthermore, because heterologous 
pathways are free from their native regulation, expression can be increased or fine-
tuned to maximise flux through the pathway, enabling high-level production of the 
chosen product (Kotopka et al., 2018; Moses et al., 2013). Model microorganisms 
such as S. cerevisiae and Escherichia coli are genetically tractable and well 
characterised, which enables extensive engineering of their native metabolism to 
redirect metabolic flux towards the heterologous pathway (Moses et al., 2013). In 
addition, the high growth rates of microorganisms reduces the production time 
compared with plants (Kotopka et al., 2018; Moses et al., 2013), and because 
microbial fermentation processes are performed in closed fermenters, they are not 
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affected by the environmental fluctuations that affect the yields of plant production 
systems. Purification is also often easier, as the engineered microorganisms 
accumulate fewer metabolites that are structurally similar to the product (Kotopka et 
al., 2018; Moses et al., 2013). 
The biotechnological approach is exemplified by the semi-synthetic production of the 
sesquiterpene artemisinin (Paddon and Keasling, 2014). This antimalarial drug has 
traditionally been obtained through the farming of Artemisia annua (sweet 
wormwood), however, large fluctuations in the price and availability of artemisinin 
have caused difficulties in supplying the drug to the developing countries where it is 
needed (Paddon and Keasling, 2014). These fluctuations were attributed to the long 
(18 month) period required to produce and supply artemisinin, as well as fluctuations 
in weather and harvest (Paddon and Keasling, 2014). In the semi-synthetic approach, 
S. cerevisiae was engineered to produce artemisinic acid, the precursor to 
artemisinin, and through a combination of metabolic engineering and process 
development, titres of 25 g/L artemisinic acid were achieved (Paddon et al., 2013). 
Artemisinic acid could be purified from the culture with a yield of 93 % and a purity of 
98 % (by weight), and then converted to artemisinin through a synthetic chemical 
approach (Paddon et al., 2013). Semi-synthetic artemisinin has since entered 
commercial production (Paddon and Keasling, 2014). 
The yeast S. cerevisiae is a promising host for the industrial-scale production of 
triterpenoids and saponins. It is genetically tractable, fast growing, has a well-
characterised metabolism and physiology (Kotopka et al., 2018), and numerous tools 
have been developed to aid engineering efforts (Lee et al., 2015; Apel et al., 2017; 
Curran et al., 2013; Ryan et al., 2014; Horwitz et al., 2015; Rajkumar et al., 2016; 
Blazeck et al., 2012; Redden and Alper, 2015; Curran et al., 2014). Furthermore, it is 
widely used in established industrial production processes (e.g. for bioethanol and 
artemisinin production (Mohd Azhar et al., 2017; Paddon et al., 2013; Paddon and 
Keasling, 2014)), and has been successfully used to produce a range of terpenoids 
at laboratory scale (Immethun et al., 2013). Yeast also produces 2,3-oxidosqualene, 
the first dedicated intermediate in triterpenoid biosynthesis (Moses et al., 2013), and 
is an effective host for the functional expression of plant P450s, which are typically 
localised to the ER and are extensively involved in triterpenoid biosynthesis (Kotopka 
et al., 2018; Thimmappa et al., 2014; Bak et al., 2011). Indeed, S. cerevisiae has been 
Chapter 1: Introduction 
 24 
successfully used for the laboratory-scale production of triterpenoids and saponins, 
as well as to characterise numerous enzymes involved in their biosynthesis (Kirby et 
al., 2008; Fukushima et al., 2011, 2013; Seki et al., 2011; Moses et al., 2014b; 
Czarnotta et al., 2017; Zhao et al., 2017; Zhuang et al., 2017a; Arendt et al., 2017; 
Zhao et al., 2018; Zhu et al., 2018; Fiallos-Jurado et al., 2016; Moses et al., 2015b, 
2015a). Efforts to engineer yeast for the high-level production of triterpenoids and 
saponins are discussed in the following section. 
1.4 Production of triterpenoids and saponins in 
Saccharomyces cerevisiae 
Yeast engineering efforts have focused primarily on three classes of triterpenoids: (i) 
the oleananes, which are derived from the pentacyclic β-amyrin; (ii) the dammaranes, 
which are derived from the tetracyclic triterpene dammarenediol-II; and (iii) the 
lupanes, which are derived from the pentacyclic lupeol (Figure 1.3). While saponins 
of the dammarane and oleanane classes have been produced in yeast (Moses et al., 
2014b; Arendt et al., 2017; Wang et al., 2015; Wei et al., 2015; Zhuang et al., 2017a), 
for the lupane class only aglycones have been produced to date (Huang et al., 2012; 
Moses et al., 2014b; Zhou et al., 2016; Czarnotta et al., 2017). Other types of 
triterpenoids, such as those belonging to the ursane class of α-amyrin derived 
triterpenoids, have also been produced to a more limited extent (Dong et al., 2018; 
Fukushima et al., 2011; Moses et al., 2014b). 
1.4.1 Studies focusing on the production of oleananes 
The first reported production of a triterpene in S. cerevisiae was by Kirby et al. (2008), 
who produced β-amyrin at a titre of 6 mg/L. This was achieved through the co-
expression of the β-amyrin synthase (BAS) from Artemisia annua (AaBAS) and an N-
terminally truncated variant of the yeast HMG-CoA reductase 1 gene (tHMG1), 
together with repression of the yeast lanosterol synthase gene (ERG7) using a 
methionine-repressible promoter (pMET3). By comparison, expression of AaBAS 
alone resulted in β-amyrin titres of 4 mg/L (Kirby et al., 2008). Yeast has two isozymes 
of HMG-CoA reductase (Hmg1p and Hmg2p), which catalyse the rate-limiting 
conversion of HMG-CoA to mevalonate in the MEV pathway (Figure 1.1), and it was 
previously shown that overexpression of tHMG1 increased squalene production 
(Donald et al., 1997; Polakowski et al., 1998). Meanwhile, Erg7p competes with the 
BAS for the substrate 2,3-oxidosqualene, and its repression should therefore redirect 
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flux towards β-amyrin biosynthesis (Kirby et al., 2008). The additional overexpression 
of ERG1, the yeast squalene epoxidase that catalyses the rate-limiting conversion of 
squalene to 2,3-oxidosqualene (Figure 1.1), did not improve production further (Kirby 
et al., 2008). 
Shortly thereafter, Seki et al. (2008) reported the production of 1.6 mg/L 11-oxo-β-
amyrin, an intermediate in the biosynthesis of the saponin glycyrrhizin. This titre was 
achieved through the co-expression of Lotus japonicus BAS (LjBAS), a β-amyrin C-
11 oxidase from Glycyrrhiza uralensis (CYP88D6) and a cytochrome P450 reductase 
from L. japonicus (LjCPR1). The CYP88D6 enzyme oxidises C-11 of β-amyrin to a 
ketone group, but small amounts (0.2 mg/L) of 11-hydroxy-β-amyrin were also 
observed, indicating that the reaction proceeds through a hydroxyl intermediate (Seki 
et al., 2008). In a follow-up to their study, Seki et al. (2011) additionally expressed 
CYP72A154 from G. uralensis, which oxidises the C-30 methyl group of 11-oxo-β-
amyrin to a carboxyl group. This generated glycyrrhetinic acid, the aglycone of 
glycyrrhizin, with titres of 15 μg/L (Seki et al., 2011). Derivatives of 11-oxo-β-amyrin 
with hydroxyl or aldehyde groups at C-30 (30-hydroxy-11-oxo-β-amyrin and 
glycyrrhetaldehyde, respectively) were also observed, indicating that the reaction 
occurs through hydroxyl and aldehyde intermediates. In addition, 30-hydroxy-β-
amyrin was detected (indicating that CYP72A154 can also oxidise β-amyrin), as well 
as an isomer of glycyrrhetinic acid, considered to most likely have a C-29 carboxyl 
group instead of a C-30 carboxyl (Seki et al., 2011). 
Fukushima et al. (2013) used a combinatorial approach to produce a variety of M. 
truncatula oleanane triterpenoids in yeast. This involved the co-expression of different 
pairs of P450s with LjBAS and LjCPR. Using this approach, they produced 
soyasapogenol B and gypsogenic acid, which are intermediates in the biosynthesis 
of the non-haemolytic (soyasaponin) and haemolytic classes of M. truncatula 
saponins, respectively (Fukushima et al., 2013). Furthermore, by co-expressing 
P450s involved in soyasaponin and haemolytic saponin biosynthesis, they were able 
to produce rare triterpenoids that do not accumulate in considerable abundance in M. 
truncatula. For example, co-expression of M. truncatula CYP716A12 (encoding a β-
amyrin C-28 oxidase involved in haemolytic saponin biosynthesis) and CYP93E2 
(encoding a C-24 hydroxylase involved in soyasaponin biosynthesis) produced 4-epi-
hederagenin, which has not been reported in M. truncatula (Fukushima et al., 2013). 
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This report highlighted another advantage of microbial production systems: the ability 
to produce novel or rare triterpenoids through the co-expression of new combinations 
of tailoring enzymes such as P450s, an approach known as combinatorial 
biosynthesis (Moses et al., 2013). 
The studies discussed so far reported either low titres (up to 6 mg/L) or no titres at all. 
By contrast, industrial-scale production would require titres of at least the gram per 
litre scale (for example, the 25 g/L artemisinic acid reported by Paddon et al. (2013)). 
Through a combination of metabolic engineering and process optimisation, Moses et 
al. (2014b) achieved β-amyrin titres of ~ 50 mg/L in shake flasks. Initially, BASs from 
M. truncatula and Glycyrrhiza glabra (MtBAS and GgBAS) were compared in a strain 
engineered to enhance flux towards triterpene biosynthesis, giving β-amyrin titres of 
19 and 36 mg/L, respectively (Moses et al., 2014b). This strain overexpressed tHMG1 
and had the ERG7 gene repressed using the pMET3 promoter, the same strategy 
used by Kirby et al. (2008). In addition, expression of the A. thaliana lupeol synthase 
(AtLUS1) gave lupeol titres of 46 mg/L. These titres were considerably higher than 
those of Kirby et al. (2008), who achieved only 6 mg/L β-amyrin. This could be 
explained by the different BASs used, or due to differences in culturing and metabolite 
extractions. Notably, Moses et al. induced ERG7 repression (by addition of 1 mM 
methionine) at 24 h, while Kirby et al. added methionine only at 43 h. Furthermore, it 
is possible that MtBAS and GgBAS have greater activities than AaBAS, which was 
used by Kirby et al. (2008).  
Subsequently, co-expression of GgBAS or an α-amyrin synthase from Centella 
asiatica (CaDDS) with CYP716Y1 (a 16α-hydroxylase) and the A. thaliana CPR 
AtATR1 produced 16α-hydroxy-β-amyrin or 16α-hydroxy-α-amyrin, respectively 
(Moses et al., 2014b). By contrast, co-expression of AtLUS1 with CYP716Y1 and 
AtATR1 produced no additional product, indicating that CYP716Y1 could not oxidise 
lupeol (Moses et al., 2014b). Because the ratio between the P450 and CPR has been 
reported to be important for activity (Paddon et al., 2013), different ratios were tested 
by expressing CYP716Y1 from a high copy plasmid and AtATR1 from an integrated, 
low or high copy plasmid (Moses et al., 2014b). The integrated gene resulted in very 
low levels of 16α-hydroxy-α-amyrin, while expression from the high and low copy 
plasmids gave considerably higher titres (Moses et al., 2014b). The addition of methyl-
β-cyclodextrin (MβCD) to the culture medium further increased β-amyrin and 16α-
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hydroxyl-β-amyrin levels, with β-amyrin titres of ~ 50 mg/L reported (Moses et al., 
2014b). MβCD is a toroidal shaped molecule with a hydrophobic interior and 
hydrophilic exterior, which may allow it to encapsulate and solubilise the hydrophobic 
triterpenoids, sequestering them into the growth medium (Moses et al., 2014b). This 
could minimise growth defects or feedback inhibition caused by the intracellular 
accumulation of triterpenoids. Finally, co-expression of GgBAS, CYP716A12, 
CYP716Y1 and AtATR1 produced echinocystic acid (16α-hydroxy-oleanolic acid) 
(Moses et al., 2014b). The additional expression of UGT73C11, encoding a 
glucosyltransferase from Barbarea vulgaris with specificity for the C-3 hydroxyl group, 
produced the saponin 3-O-glucose-echinocystic acid, which was the first reported 
production of an oleanane saponin in yeast (Moses et al., 2014b). 
By integrating GgBAS under the control of a constitutive promoter, Dai et al. (2014) 
achieved β-amyrin titres of 78 mg/L, approximately ~ 2-fold higher than the 36 mg/L 
titre reported by Moses et al. (2014b) when expressing GgBAS. Interestingly, whereas 
the strain used by Moses et al. overexpressed tHMG1 and had ERG7 repressed, Dai 
et al. used a “wild-type” strain that was not engineered to boost triterpenoid production 
(Dai et al., 2014; Moses et al., 2014b). Notably, Moses et al. (2014b) expressed 
GgBAS from the galactose-inducible GAL1 promoter on a high copy plasmid, which 
required the use of synthetic dropout media lacking glucose (which represses the 
GAL1 promoter). By using a constitutive promoter and integrating GgBAS, Dai et al. 
(2014) were able to grow the cells in rich media containing glucose, which is the 
preferred carbon source of S. cerevisiae (Timson, 2007). Furthermore, the culture 
period was seven days, whereas Moses et al. (2014b) used a three day culture period. 
Together, these differences could explain the observed differences in β-amyrin titres.  
Dai et al. (2014) also compared a BAS from Panax ginseng (PgBAS1) with GgBAS, 
but PgBAS1 gave far lower titres (2 mg/L compared with 78 mg/L). Using GgBAS, 
they further enhanced β-amyrin production to 107 mg/L by overexpressing tHMG1, 
ERG9 and ERG1 from constitutive promoters. The ERG9 gene encodes yeast 
squalene synthase, which catalyses the joining of two molecules of FPP to produce 
squalene (Figure 1.1). Overexpression of these genes should thus increase flux 
towards β-amyrin biosynthesis. Finally, the additional expression of CYP716A12, 
AtATR1 and an additional copy of GgBAS allowed the production of 71 mg/L oleanolic 
acid (Dai et al. 2014). Beta-amyrin also accumulated at 88.6 mg/L in this strain, 
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indicating that the conversion of β-amyrin to oleanolic acid was rate-limiting (Dai et al. 
2014). 
Meanwhile, Zhang et al. (2015) integrated and expressed GgBAS and the Candida 
albicans squalene epoxidase (CaERG1) from constitutive promoters, giving β-amyrin 
titres of 24.5 mg/L. The additional expression of E. coli IPP-DMAPP isomerase 
(EcIDI), yeast FPP synthase (ERG20) and ERG9 increased titres to 36.5 mg/L. Next, 
the sterol regulatory element, to which the transcriptional activator Upc2p binds and 
regulates the sterol pathway, was inserted into all promoters that controlled 
expression of the overexpressed genes. This increased β-amyrin titres to 49 mg/L. 
Finally, ethanol fed-batch fermentation, in which cells were grown in a 5 L fermenter 
and ethanol was fed every 12 h, produced 138 mg/L β-amyrin after 6 days (Zhang et 
al., 2015).  
More recently, Zhao et al. (2018) reported oleanolic acid titres of 186 mg/L in shake 
flasks and 607 mg/L in a fermenter. To optimise the conversion of β-amyrin to 
oleanolic acid, they initially compared four CPRs: AtATR1, LjCPR, MtCPR (from M. 
truncatula) and GuCPR (from G. uralensis). The interaction between the heterologous 
P450 and CPR is important for activity (Zhao et al., 2016; Zangar et al., 2004), and 
an arbitrary choice of CPR may not result in optimal conversion of β-amyrin into 
oleanolic acid in yeast. The CPRs were co-expressed with GgBAS and CYP716A12 
on a high copy plasmid, controlled by the galactose-inducible GAL1 and GAL10 
promoters, and cells were grown with galactose as the carbon source (Zhao et al., 
2018). Expression of MtCPR gave the highest oleanolic acid titre (9 mg/L); by 
comparison, the least productive strain expressed AtATR1 and produced only 2.5 
mg/L oleanolic acid. Next, the pathway encoding MtCPR was integrated and the GAL1 
gene, which is responsible for the metabolism of galactose, was knocked out (Zhao 
et al., 2018). This should prevent galactose from being utilised as a carbon source, 
ensuring that galactose levels remain high and continue to induce expression of the 
oleanolic acid pathway throughout the fermentation. Cells were grown with both 
glucose and galactose, which served as the carbon source and inducer, respectively, 
and the maximum oleanolic acid titre reported was 41.3 mg/L (Zhao et al., 2018).  
Interestingly, the additional knock out of the GAL80 gene further improved oleanolic 
acid titres to 70.3 mg/L (Zhao et al., 2018). In the absence of galactose, Gal80p binds 
and inhibits Gal4p, the transcriptional activator of the GAL promoters (Timson, 2007). 
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When galactose is present, Gal3p prevents Gal80p from inhibiting Gal4p, leading to 
the activation of the GAL promoters (Timson, 2007). Thus, a GAL80 knockout 
removes the need for galactose to induce expression of the GAL promoters. Given 
that galactose was provided in the medium, it is surprising that the knockout of GAL80 
improved titres, as the promoters should have been activated by the galactose. A 
possible explanation is that the amount of galactose used did not allow for full 
inhibition of Gal80p (note that galactose should not be depleted during the 
fermentation due to the GAL1 knockout, which prevents metabolism of galactose). 
They next additionally overexpressed tHMG1, ERG9 and ERG1, which increased 
oleanolic acid titres > 2.5-fold to 186 mg/L. Finally, batch fermentation in a 5 L 
fermenter enabled the production of 607 mg/L oleanolic acid, which is the highest 
reported titre to date (Zhao et al., 2018). Use of glucose as the carbon source probably 
limited expression of the oleanolic acid pathway, as glucose represses the GAL 
promoters through a mechanism mediated by the transcriptional repressor Mig1p 
(Timson, 2007). Using a different carbon source or promoters that are not repressed 
by glucose might therefore further boost production. 
Recently, the production of glycyrrhetinic acid at titres of 19 mg/L was reported (Zhu 
et al., 2018). This was ~1300-fold higher than the 15 μg/L reported by Seki et al. 
(2011). Initially, a glycyrrhetinic acid pathway (GgBAS, G. uralensis C-11 oxidase 
CYP88D6, G. uralensis C-30 oxidase CYP72A154, and AtATR1) was expressed in a 
strain overexpressing EcIDI, ERG20, ERG9, CaERG1 (as used by Zhang et al. 
(2015), see above). This resulted in the production of low amounts of glycyrrhetinic 
acid (33.7 μg/L), but much greater amounts of its precursor 11-oxo-β-amyrin (7.5 
mg/L). Furthermore, β-amyrin accumulated to relatively high levels (14 mg/L), 
indicating that flux through the P450-catalysed oxygenation steps was limiting. To 
address this, they compared CYP88D6 with another C-11 oxidase from G. uralensis 
(Uni25647) for 11-oxo-β-amyrin production, finding that using the latter enzyme 
doubled titres. Six CPRs were then compared for glycyrrhetinic acid production in a 
strain expressing Uni25647 and CYP72A154. The CPRs were MTR2 and MTR3 (M. 
truncatula), ATR1 and ATR2 (A. thaliana), LjCPR1 (L. japonicus), and GuCPR1 (G. 
uralensis). The latter gave the highest glycyrrhetinic acid (517 μg/L) and 11-oxo-β-
amyrin (15.3 mg/L) titres yet (Zhu et al., 2018). Two C-30 oxidases (CYP72A154 and 
M. truncatula CYP72A63), which convert 11-oxo-β-amyrin to glycyrrhetinic acid, were 
then compared for glycyrrhetinic acid production in the strain expressing Uni25647 
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and GuCPR1. Using CYP72A63 gave much greater titres, increasing glycyrrhetinic 
acid production ~ 14-fold from 517 μg/L to 7.4 mg/L (Zhu et al., 2018). Finally, ethanol 
fed-batch fermentation in a 5 L fermenter further increased glycyrrhetinic acid 
production to 19 mg/L (Zhu et al., 2018). 
The comparison of CPR and P450s performed by Zhao et al. (2018) and Zhu et al. 
(2018) highlight the benefit of comparing homologues of biosynthetic enzymes to 
boost triterpenoid production. Indeed, Moses et al. (2014c) previously compared eight 
P450s for the CYP93E subfamily for the C-24 hydroxylation of β-amyrin, the first 
committed step in the biosynthesis of soyasaponins. The P450s showed a range of 
activities, accumulating varying amounts of 24-hydroxy-β-amyrin, the side-product 
24-carboxy-β-amyrin, and the substrate β-amyrin (Moses et al., 2014c). In particular, 
whereas CYP93E2 had poor activity, accumulating predominantly β-amyrin and very 
little 24-hydroxy-β-amyrin, CYP93E9 produced 52-fold more 24-hydroxy-β-amyrin 
and accumulated ~ 4-fold less β-amyrin substrate (Moses et al., 2014c). Thus, 
comparison of homologues is an effective strategy to relieve the commonly observed 
bottlenecks at the P450-catalysed oxygenations of triterpenoids (Moses et al., 2014c; 
Zhu et al., 2018; Zhao et al., 2018). 
Finally, Arendt et al. (2017) reported that knocking out the yeast PAH1 gene 
considerably boosts the production of various triterpenoids and saponins. The PAH1 
gene encodes phosphatidic acid phosphatase, and its knockout was previously 
shown to cause proliferation of the ER (Santos-Rosa et al., 2005). Because numerous 
enzymes involved in the biosynthesis of 2,3-oxidosqualene, as well as the plant 
OSCs, P450s and CPRs involved in triterpenoid biosynthesis, are believed to be 
localised to the ER, such a proliferation could increase the intracellular concentrations 
of these proteins and boost productivity (Arendt et al., 2017). Indeed, Arendt et al. 
(2017) showed that the ER was greatly expanded and that levels of GgBAS and 
especially CYP716A12 proteins were enhanced compared with wild-type. Notably, 
the PAH1 knockout increased titres of β-amyrin and medicagenic acid, which is 
derived from β-amyrin through the action of three P450s, ~ 8- and 6-fold (Arendt et 
al., 2017). In addition, production of the saponin 28-O-glucose-medicagenic acid was 
increased by an even greater degree (~ 16-fold) (Arendt et al., 2017). This strain also 
produced substantially higher amounts of saponin glucosides of bayogenin, 
hederagenin and gypsogenic acid (whose aglycones are intermediates in the 
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biosynthesis of medicagenic acid). This study therefore brings the total number of 
oleanane saponins produced in yeast to five (including the 3-O-glucose-echinocystic 
acid produced by Moses et al. (2014b)). 
1.4.2 Studies focusing on the production of dammaranes 
Much work has also been done in the production of dammarane-type triterpenoids, 
where considerably higher titres (up to 4.25 g/L) have been reported than for 
oleanane-type triterpenoids (Dai et al., 2013; Zhao et al., 2016, 2017). Notably, 
numerous studies have reported the production of ginsenosides, which are Panax 
spp. saponins derived from the dammarane triterpenoids protopanaxadiol and 
protopanaxatriol, with titres as high as 292 mg/L (Wei et al., 2015; Wang et al., 2015; 
Zhuang et al., 2017a). By contrast, no titres have been reported for oleanane saponins 
to date (Moses et al., 2014b; Arendt et al., 2017). 
Dai et al. (2013) reported protopanaxadiol titres of 1189 mg/L. They initially integrated 
a protopanaxadiol biosynthetic pathway encoding P. ginseng dammarenediol-II 
synthase (PgDDS), P. ginseng CYP716U1 and the A. thaliana CPR AtATR1. PgDDS 
cyclises 2,3-oxidosqualene to dammarenediol-II, while CYP716U1 catalyses the C-
12 hydroxylation of dammarenediol-II to produce protopanaxadiol. This initial strain 
gave protopanaxadiol titres of 0.5 mg/g dry cell weight (DCW) (Dai et al., 2013). 
Subsequently, they overexpressed tHMG1, ERG20, ERG9 and ERG1, which 
increased protopanaxadiol titres 17-fold to 8.45 mg/g DCW, with 10.96 mg/g DCW of 
dammarenediol-II accumulating. The overexpression of additional copies of tHMG1, 
AtATR1 and CYP716U1 shifted the product ratio towards protopanaxadiol, with 13.1 
mg/g DCW protopanaxadiol and 8.2. mg/g DCW dammarenediol-II (Dai et al., 2013). 
Glucose fed-batch fermentation of the optimised strain produced 812 mg/L 
protopanaxadiol (Dai et al., 2013). However, 776 mg/L dammarenediol-II still 
accumulated, indicating that its conversion to protopanaxadiol was limiting. To further 
improve production, Dai et al. used a two-phase fermentation method where an 
organic solvent was added to the culture to extract triterpenoids from the culture 
throughout the fermentation run. This is conceptually similar to the use of 
cyclodextrins by Moses et al. (2014b) to sequester triterpenoids in the culture medium, 
and has been successfully utilised for the production of artemisinic acid in yeast (Ro 
et al., 2006). Using methyl oleate as the solvent, titres of 1189 mg/L protopanaxadiol 
were achieved (Dai et al., 2013). However, in contrast with the previous single-phase 
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fermentation, dammarenediol-II was produced in greater amounts than 
protopanaxadiol (at titres of 1548 mg/L) (Dai et al., 2013). It is possible that extraction 
of dammarenediol-II by the organic solvent prevented it from being converted to 
protopanaxadiol, thus shifting the product ratio. 
Zhao et al. (2016) reported slightly improved protopanaxadiol titres than the above 
study, but in contrast were able to achieve almost complete conversion of 
dammarenediol-II into protopanaxadiol. They initially followed a similar strategy to Dai 
et al. (2013), integrating the protopanaxadiol pathway, tHMG1, ERG20, ERG9 and 
ERG1, which gave titres of 155.3 mg/L protopanaxadiol and 96.5 mg/L 
dammarenediol-II (Zhao et al., 2016). However, they subsequently sought to improve 
the conversion of dammarenediol-II into protopanaxadiol through fusion of the P450 
and CPR, which may facilitate electron transfer from CPR to P450 and thus improve 
catalytic activity. Removal of the N-terminal membrane anchor of AtATR1 and fusion 
to the C-terminus of CYP716U1 greatly improved protopanaxadiol titres, which 
reached 265.7 mg/L, with only 8.7 mg/L dammarenediol-II accumulating (Dai et al., 
2013). Thus, the fusion strategy allowed almost complete conversion of 
dammarenediol-II to protopanaxadiol. Finally, glucose fed-batch fermentation gave a 
protopanaxadiol titre of 1437 mg/L, with only 19.7 mg/L dammarenediol-II 
accumulating. Similar to the results of Dai et al. (2013), two-phase fed-batch 
fermentation using dodecane as the solvent resulted in a dramatic shift in product 
ratios, with the strain now accumulating mostly dammarenediol-II (524 mg/L) 
compared to 312.0 mg/L protopanaxadiol (Zhao et al., 2016). Thus, use of an organic 
overlay limits conversion of dammarenediol-II to protopanaxadiol, presumably by 
sequestration of dammarenediol-II that prevents it from being oxygenated by the 
P450. 
The highest titre for a triterpenoid produced in yeast corresponds to 4.25 g/L 
protopanaxadiol, reported by Zhao et al. (2017). They reasoned that the generation 
of reactive oxygen species (ROS) and ethanol stress limited the productivity of the 
strain reported by Zhao et al. (2016). Poor coupling between the P450 and CPR can 
generate ROS through electron leakage (Zangar et al., 2004; Renault et al., 2014), 
and the ethanol produced as a waste product during fermentation can cause stress 
and even exacerbate the generation of ROS (Zhao et al., 2017). Indeed, the strain 
expressing the CYP716U1-AtATR1 fusion protein had significantly higher ROS levels 
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than a strain lacking this fusion protein (Zhao et al., 2017). Therefore, to increase 
tolerance towards ROS and ethanol, Zhao et al. (2017) overexpressed the yeast 
genes YBP1 and SSD1. The former gene is essential for the activity of Yap1p, a 
transcriptional activator that mediates the yeast oxidative stress response. 
Meanwhile, SSD1 is a translational repressor involved in cell wall maintenance, and 
enhancing cell wall integrity may improve tolerance to ethanol (Zhao et al., 2017). The 
resulting strain produced 1255 mg/L protopanaxadiol. Furthermore, by adding an 
ethanol feed to serve as an additional carbon source, titres were further improved to 
1806 mg/L. Finally, a two-stage fermentation process, in which cells were grown in a 
fermenter with glucose, followed by the addition of ethanol to serve as the main 
carbon source once glucose was depleted, increased protopanaxadiol titres to 4.25 
g/L (Zhao et al., 2017). 
Wang et al. 2015 reported the production of the ginsenosides Rh2 and Rg3. The 
former is derived from protopanaxadiol through glycosylation at the C-3 hydroxyl 
group, while Rg3 is produced by the addition of a second glucose to the existing sugar 
chain of Rh2. They initially expressed a protopanaxadiol pathway (PgDDS, 
CYP716U1 and AtATR2) together with overexpression of two copies of tHMG1, 
ERG20, ERG9 and a squalene epoxidase from P. ginseng (PgSQE1). This strain 
produced 8.29 μmol/g DCW protopanaxadiol and accumulated minimal amounts of 
dammarenediol-II (0.14 μmol/g). This contrasts with the strains reported by Dai et al. 
(2013), which accumulated substantial amounts of dammarenediol-II. A possible 
explanation is the difference in CPR used (Dai et al., 2013; Wang et al., 2015). Indeed, 
it was previously reported that AtATR2 has a greater electron transfer activity than 
AtATR1 in vitro (Schückel et al., 2012), while the CPR comparison performed by Zhu 
et al. (2018) (see previous section) found that using AtATR2 gave higher glycyrrhetinic 
acid titres than AtATR1. Next, the additional expression of UGTPg45, which transfers 
a glucose to the C-3 hydroxyl of protopanaxadiol, produced ginsenoside Rh2 (3-O-
glucose-protopanaxadiol) with a titre of 1.45 μmol/g (Wang et al., 2015). Finally, by 
co-expressing UGTPg45 with UGTPg29, which transfers a glucose to the existing 
glucose of Rh2, ginsenoside Rg3 (3-O-[glucose-glucose]-protopanaxadiol) was 
produced with a titre of 3.49 μmol/g (Wang et al., 2015).  
The production of ginsenosides derived from protopanaxatriol, which is produced by 
the C-6 hydroxylation of protopanaxadiol, have also been reported. Wei et al. (2015) 
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produced ginsenosides Rh1 and F1, which are derived from the glucosylation of 
protopanaxatriol at the C-6 and C-20 hydroxyl groups, respectively. Using the 
protopanaxadiol-producing strain reported by Wang et al. (2015), they additionally 
expressed CYP716S1 (encoding a protopanaxadiol C-6 hydroxylase), an additional 
CPR from P. ginseng (PgCPR1), and either UGTPg100 or UGTPg1 (Wei et al., 2015). 
The first UGT transfers a glucose to the C-6 hydroxyl of protopanaxatriol, forming 
ginsenoside Rh1, while UGTPg1 transfers glucose to the C-20 hydroxyl to produce 
ginsenoside F1. Titres of 92.8 mg/L ginsenoside Rh1 and 42.1 mg/L ginsenoside F1 
were achieved (Wei et al., 2015). 
Finally, Zhuang et al. (2017) reported the production of 292 mg/L ginsenoside Rh2, 
the highest reported production of a saponin in yeast to date. They initially tested 
UGT51, a yeast UGT that glucosylates ergosterol, for activity against protopanaxadiol 
and protopanaxatriol in vitro. It had weak activity against these substrates, and the 
glucosylated protopanaxadiol was confirmed as 3-O-glucose-protopanaxadiol 
(ginsenoside Rh2) by NMR (Zhuang et al., 2017a). Subsequently, they engineered 
UGT51 for enhanced activity against protopanaxadiol using an iterative saturation 
mutagenesis method, with the best mutant having 610-fold higher activity against 
protopanaxadiol. Expression of this mutant in a yeast strain engineered for 
protopanaxadiol production resulted in the production of 6.1 mg/L ginsenoside Rh2; 
by comparison, only 0.05 mg/L Rh2 was produced when expressing the wild-type 
enzyme (Zhuang et al., 2017a). Deletion of the yeast EGH1 gene, which encodes a 
glucosidase that was shown to hydrolyse ginsenoside Rh2 in vitro, doubled Rh2 titres 
to 12.2 mg/L, and the expression of three additional copies of the mutant UGT51 
further increased titres to 22.2 mg/L (Zhuang et al., 2017a). Because UGT51 requires 
UDP-glucose as a donor to glycosylate its substrate, the yeast UDP-glucose 
biosynthetic genes PGM1 and UGP1 were overexpressed, resulting in Rh2 titres of 
36.7 mg/L (Zhuang et al., 2017a). Finally, the additional expression of a CYP716U1-
AtATR2 fusion protein, based on the CYP716U1-AtATR1 fusion protein of Zhao et al. 
(2016), increased Rh2 titres to 45 mg/L. Glucose fed-batch fermentation of this strain 
gave titres of 292 mg/L ginsenoside Rh2 (Zhuang et al., 2017a). 
1.4.3 Studies focusing on the production of lupanes 
In the biotechnological production of lupane-type triterpenoids most studies have 
focused on betulinic acid, a potential anti-cancer compound that is the C-28 carboxy 
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derivative of lupeol (see section 1.2). The oxygenation reaction appears to proceed 
through hydroxyl (betulin) and aldehyde (betulinic aldehyde) intermediates 
(Fukushima et al., 2011; Huang et al., 2012). To date, no studies have reported the 
production of lupane-type saponins in yeast. 
An initial study by Huang et al. (2012) produced 0.1 mg/L betulinic acid in yeast 
through the co-expression of a Catharanthus roseus multifunctional OSC (CrAS), the 
C. roseus C-28 oxidase CYP716AL1, and AtATR1 (Huang et al., 2012). Zhou et al. 
(2016) later increased betulinic acid titres to ~ 0.6 mg/L. They initially compared three 
C-28 oxidases for the oxygenation of lupeol to betulinic acid (with co-expression of 
the A. thaliana lupeol synthase AtLUP1 and AtATR1): CYP716AL1, CYP716A15 from 
Vitis vinifera, and CYP716A80 from Barbarea vulgaris. The latter enzyme resulted in 
the highest amounts of betulinic acid, with less accumulation of the hydroxyl 
intermediate betulin and the substrate lupeol compared with the other enzymes (Zhou 
et al., 2016). Finally, because the enzymes were expressed from the galactose-
inducible GAL promoters, they knocked out the GAL80 gene, which removes the 
requirement for galactose to induce GAL promoter expression. This gave titres of 0.6 
mg/L betulinic acid when grown in galactose, which were ~ 2-fold higher than the wild-
type strain (Zhou et al., 2016); improved triterpenoid titres when growing a gal80 strain 
in galactose were also observed by Zhao et al. (2018) (see section 1.4.1). 
The highest reported production of betulinic acid was achieved by Czarnotta et al. 
(2017), who produced 182 mg/L by optimising process conditions. They initially 
generated a strain expressing a betulinic acid pathway (AtLUP1, CYP716AL1 and 
AtATR2) and the ERG1 and tHMG1 genes. This strain was grown in shake flasks with 
50 g/L glucose, and glucose and ethanol levels were monitored. As expected, glucose 
was initially consumed and ethanol accumulated, followed by consumption of ethanol 
after glucose had depleted. Triterpenoids only accumulated during the ethanol 
consumption phase, and titres of betulinic acid and betulin reached 28 mg/L and 91 
mg/L, respectively (Czarnotta et al., 2017). To increase triterpenoid production, an 
ethanol pulsing strategy to supply excess ethanol was investigated. Here, ethanol was 
added to the medium in response to high levels of dissolved oxygen, which are 
indicative of ethanol depletion. This approach increased betulinic acid titres to 57 
mg/L, while betulin reached 167 mg/L (Zhou et al., 2016).  
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A further increase in production was achieved through the use of resting cell 
fermentations (Zhou et al., 2016). Cells were first grown to a high biomass with 
glucose as the carbon source, where triterpenoids were not expected to accumulate. 
Subsequently, the cells were transferred to fresh media lacking nitrogen, and the 
ethanol pulse feed was applied. The absence of nitrogen prevents cell growth, with 
the aim of redirecting metabolic flux from biomass generation to triterpenoid 
production. This strategy substantially increased triterpenoid production, with titres of 
betulinic acid and betulin reaching 182 mg/L and 464 mg/L, respectively (Zhou et al., 
2016). It is notable that betulin accumulated to much higher levels than betulinic acid. 
As betulin is an intermediate in the oxygenation of lupeol to betulinic acid, this step is 
rate-limiting for betulinic acid production and requires optimisation. The strategies 
described to enhance the production of oxygenated oleanane- and dammarane-type 
triterpenoids, such as comparing different CPRs and P450 homologues, or generating 
P450-CPR fusions (Moses et al., 2014c; Zhu et al., 2018; Zhao et al., 2018, 2016; 
Zhuang et al., 2017a), show promise to alleviate this bottleneck in betulinic acid 
production. 
1.5 Scope of this thesis 
Numerous studies have engineered S. cerevisiae for the production of triterpenoids 
and saponins (see section 1.4). However, while high titres were achieved in some 
cases (notably for the dammarane-type triterpenoids), in many cases triterpenoid 
productivities remained low. In addition, a very limited range of oleanane saponins 
have been produced in yeast to date (Moses et al., 2014b; Arendt et al., 2017), despite 
their promising applications across numerous sectors. These saponins were relatively 
simple in structure, being monodesmosides and containing only a single sugar 
(Moses et al., 2014b; Arendt et al., 2017). By contrast, bioactive saponins, such as 
QS-21, can possess many sugars and multiple sugar chains (Ragupathi et al., 2011; 
Nielsen et al., 2010; Bang et al., 2005; Fiore et al., 2008). Thus, there is a need to 
both improve triterpenoid titres and to demonstrate the ability to produce more 
complex saponins in yeast. 
The studies discussed in section 1.4 highlight the benefit of comparing enzyme 
variants to improve flux through a particular step of a biosynthetic pathway. Moses et 
al. (2014b) compared GgBAS and MtBAS for the production of β-amyrin in yeast, 
finding that GgBAS gave ~ 2-fold higher β-amyrin titres, while Dai et al. (2014) found 
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that expression of GgBAS gave a ~ 50-fold improvement in β-amyrin titres compared 
with PgBAS1. Similarly, the comparison of CYP93E enzymes performed by Moses et 
al. (2014c) found a diverse array of productivities, with some homologues converting 
very little of the substrate β-amyrin into 24-hydroxy-β-amyrin, and others having 
considerably higher catalytic activities. Finally, Zhao et al. (2018) and Zhu et al. (2018) 
compared various CPRs to improve the conversion of β-amyrin into oleanolic acid or 
glycyrrhetinic acid, respectively. Again, this strategy considerably boosted triterpenoid 
titres. 
The aim of this thesis is to engineer S. cerevisiae to produce oleanane-type 
triterpenoids and saponins. The oleananes have numerous medically and 
commercially relevant properties (see section 1.2) that make them excellent targets 
for production in yeast. In particular, this study focuses on the production of β-amyrin 
and oleanolic acid, and saponins derived from them. The production of β-amyrin is 
the first committed step in the biosynthesis of oleananes (Thimmappa et al., 2014), 
which contain numerous bioactive compounds, while oleanolic acid is a key oleanane-
type triterpenoid that is the precursor to many of the bioactive oleanane triterpenoids 
and saponins (Ragupathi et al., 2011; Nielsen et al., 2010; Bang et al., 2005; Fiore et 
al., 2008; Augustin et al., 2012; Lin et al., 2016). 
In Chapter 3, a gas chromatography-mass spectrometry (GC-MS) method to monitor 
and quantify triterpenoid production in yeast is presented.  
In Chapter 4, β-amyrin synthase (BAS) homologues are compared for the production 
of β-amyrin in yeast, with the aim of identifying a homologue that enables enhanced 
β-amyrin accumulation. Similarly, in Chapter 5 various cytochromes P450 of the 
CYP716A subfamily are compared for their ability to oxidise β-amyrin to oleanolic 
acid. As this oxygenation proceeds through two intermediates (erythrodiol and 
oleanolic aldehyde), product ratios of the P450s are also compared. 
Finally, Chapter 6 explores the production of saponins derived from β-amyrin, 
oleanolic acid and the intermediates erythrodiol and oleanolic aldehyde. UGTs 
specific for the glucosylation of triterpenoids at the C-3 hydroxyl and C-28 carboxyl 
groups are expressed in strains engineered to produce β-amyrin or oleanolic acid. In 
addition, the co-expression of two UGTs was explored for the production of oleanane 
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saponin diglycosides. To date, only monoglycosides of oleanane-type triterpenoids 
have been produced in yeast (Moses et al., 2014b; Arendt et al., 2017). 
Chapter 2: Materials and Methods 
 39 
Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 Yeast growth 
All OD600 measurements were performed using a WPA biowave CO8000 cell density 
meter, unless otherwise stated. 
All media were autoclaved prior to use. 
YPD: 10 g/L yeast extract, 20 g/L peptone, 20 g/L D-glucose (media kitchen) 
SC-URA + 2 % D-Glc: 6.9 g/L yeast nitrogen base (Sigma Y0626), 0.77 g/L CSM-
URA (Formedium DCS0169), 20 g/L D-glucose 
SC-URA + 2 % D-Gal: 6.9 g/L yeast nitrogen base (Sigma Y0626), 0.77 g/L CSM-
URA (Formedium DCS0169), 20 g/L D-galactose 
SC-URA-LEU + 2 % D-Glc: 6.9 g/L yeast nitrogen base (Sigma Y0626), 0.67 g/L 
CSM-LEU-URA (Formedium DCS0581), 20 g/L D-glucose 
SC-URA-LEU + 2 % D-Gal: 6.9 g/L yeast nitrogen base (Sigma Y0626), 0.67 g/L 
CSM-LEU-URA (Formedium DCS0581), 20 g/L D-galactose 
YPD agar: 10 g/L yeast extract, 20 g/L peptone, 20 g/L D-glucose (Fisher Scientific, 
G/0500/60), 20 g/L agar (Oxoid LP0011) 
SC-URA + 2 % D-Glc agar: 6.9 g/L yeast nitrogen base (Sigma Y0626), 0.77 g/L 
CSM-URA (Formedium DCS0169), 20 g/L D-glucose (Fisher Scientific, G/0500/60), 
20 g/L agar (Oxoid LP0011) 
SC-URA-LEU + 2 % D-Glc agar: 6.9 g/L yeast nitrogen base (Sigma Y0626), 0.67 
g/L CSM-LEU-URA (Formedium DCS0581), 20 g/L D-glucose (Fisher Scientific, 
G/0500/60), 20 g/L agar (Oxoid LP0011) 
 
2.1.2 E. coli growth 
All OD600 measurements were performed using a WPA biowave CO8000 cell density 
meter, unless otherwise stated 
All media was autoclaved prior to use. 
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LB: 10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl 
LB agar: 10 g/L tryptone, 5 g/L yeast extract, 10 g/L NaCl. 20 g/L agar 
 
2.1.3 Antibiotics 
Ampicillin: stock concentration was 100 mg/ml in dH2O; working concentration was 
100 μg/ml 
Chloramphenicol: stock concentration was 40 mg/ml in 100 % ethanol; working 
concentration was 40 μg/ml 
Spectinomycin: stock concentration was 100 mg/ml in dH2O; working 
concentration was 100 μg/ml 
 
2.1.4 Molecular biology 
TFB1 buffer: 30 mM CH3COOK, 100 mM RbCl, 10 mM CaCl2, 50 mM MnCl2, 15% 
(v/v) glycerol; pH adjusted to 5.8 with acetate; sterilised by filtration (0.22 μm) 
TFB2 buffer: 10 mM MOPS (pH 6.5), 75 mM CaCl2, 10 mM RbCl, 15% (v/v) 
glycerol; pH adjusted to 6.5 with KOH; sterilised by filtration (0.22 μm) 
QIAprep Spin Miniprep Kit: purchased from QIAGEN 
E.Z.N.A.® Plasmid Mini Kit I, (Q-spin): purchased from Omega Bio-Tek 
OneTaq: OneTaq® Quick-Load® 2X Master Mix with Standard Buffer was 
purchased from NEB 
GoTaq: 2X GoTaq Green Master Mix was purchased from Promega 
Phusion: 5X High-Fidelity Buffer, 2 mM dNTPs and 2 U/μl Phusion DNA 
Polymerase were purchased from NEB 
Q5: 5X Q5 Reaction Buffer, 2 mM dNTPs and 2 U/μl Q5 High-Fidelity DNA 
Polymerase were purchased from NEB 
Restriction enzymes: all were purchased from NEB 
Agarose: purchased from Invitrogen 
TAE (1X): 40 mM Tris, 20 mM acetate, 1 mM EDTA 
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QIAquick Gel Extraction Kit: purchased from QIAGEN 
10X T4 DNA ligase buffer: purchased from NEB (B0202S) 
T7 DNA ligase: purchased from NEB (M0318) 
 
2.1.5 Yeast transformation 
Salmon sperm DNA (10 mg/ml): purchased from Invitrogen (15632-011) 
Lithium acetate (1 M): purchased from Alfa Aesar 
PEG 3350, 50 % (w/v): 50 g PEG 3350 (Sigma 88276) dissolved in 100 ml dH2O. 
 
2.1.6 Yeast DNA extraction 
Chelex 100: purchased from Sigma 
Glass beads: purchased from Sigma 
 
2.1.7 Chromatography standards 
Coprostanol-3-ol: 50 mg coprostan-3-ol (≥ 98 %, Sigma C7578) dissolved in 100 % 
ethanol to a concentration of 2.57 mM (stored at -20 °C) 
Ergosterol: 100 mg ergosterol (≥ 95 %, Sigma 45480-10G-F) dissolved in 100 % 
methanol to a concentration of 1 g/L (stored at -20 °C) 
β-amyrin: 10 mg β-amyrin (Extrasynthese 0016 S) dissolved in 100 % methanol to 
a concentration of 1 g/L (stored at -20 °C) 
Erythrodiol: 10 mg erythrodiol (Extrasynthese 0040 S) dissolved in 100 % 
methanol to a concentration of 2.5 g/L (stored at -20 °C) 
Oleanolic acid: 20 mg oleanolic acid (Extrasynthese 0041 S) dissolved in 100 % 
methanol to a concentration of 0.5 g/L (stored at -20 °C)  
3-O-Glc-echinocystic acid: 10 mg 3-O-Glc-echinocystic acid (Extrasynthese 0110 
S) dissolved in 100 % methanol to a concentration of 100 mg/L (stored at -20 °C) 
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2.1.8 Metabolite extractions 
Lysis solution: 20 % KOH, 50 % ethanol 
Lysis solution with coprostanol: 20 % KOH, 50 % ethanol, 80 nmol/ml coprostan-
3-ol 
N-Hexane (≥ 99 %): Honeywell Riedel-de Haën 32293 
Ethyl acetate (anhydrous, 99.8 %): Sigma 270989 
Butan-1-ol (≥ 99 %): Acros Organics 167695000 
 
2.1.9 Thin-layer chromatography (TLC) 
TLC plates: Silica gel on TLC Alu foils with fluorescent indicator 254 nm, silica gel 
matrix, L × W 5 cm × 10 cm (Sigma 91835-50EA) 
TLC solvent (triterpenoid extracts): hexane : ethyl acetate (9:1) 
TLC solvent (saponin extracts): chloroform : methanol : H2O (30:6:1) 
Stain (triterpenoid and saponin extracts): glacial acetic acid : p-anisaldehyde : 
concentrated sulphuric acid (48:1:1) 
 
2.1.10 GC-MS and LC-MS 
1.1 ml autosampler vials: 1.1 ml microliter crimp neck vial ND11, 32 x 11.6 mm, 
clear glass, 1st hydrolytic class; Gerstel 093640-121-00 
Crimp caps: 11mm autosampler vial crimp caps with rubber or silicone liner 
(Thermo Scientific 11-MC-8RT1 or Thermo Scientific 11-MC-ST15) 
MSTFA (N-Methyl-N-(trimethylsilyl)trifluoroacetamide with 1% 
trimethylchlorosilane): Sigma 69478 
Pyridine (anhydrous, 99.8 %): Sigma 270970 
LC-MS buffers: formic acid and methanol purchased from VWR 
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2.1.11 Proteomics 
Trypsin: purchased from Worthington Labs 
Omix C18 stage tips: purchased from Agilent 
Nano-HPLC (Dionex Ultimate 3000 RSLC, Thermo-Fisher) coupled to a QExactive 
mass spectrometer (Thermo-Fisher) with a 300 µm x 5 mm pre-column (Acclaim 
Pepmap, 5 µm particle size) joined with a 75 µm x 50 cm column (Acclaim Pepmap, 
3 µm particle size). 
 
2.1.12 Microplate assays 
96-well plates: Costar 3628 
Tape: electrical insulation tape, 12mm x 20m, RS Components 504-2380 
Tecan Sunrise plate reader  
 
2.1.13 SDS-PAGE 
Resolving gel (10 % polyacrylamide): 10 % bisacrylamide, 1X resolving gel buffer, 
0.1 % (w/v) SDS, 0.0005 % (v/v) TEMED, 0.075 % (v/v) ammonium persulphate 
Stacking gel (5.7 % polyacrylamide): 5.7 % bisacrylamide, 1X stacking gel buffer, 
0.1 % (w/v) SDS, 0.001 % (v/v) TEMED, 0.05 % (v/v) ammonium persulphate 
4X resolving gel buffer: 1.5 M Tris base, pH 8.8 
4X stacking gel buffer: 0.5 M Tris base, pH 6.8 
1X running buffer: 3 g/L Tris base, 14.4 g/L glycine, 0.1 % (w/v) SDS. 
Lyse and load buffer: 50 mM Tris-HCl (pH 6.8), 4 % SDS, 8 M urea, 30 % glycerol, 
0.1 M DTT, 0.005 % bromophenol blue 
 
2.1.14 Western blots 
Transfer buffer: 3.03 g/L Tris base, 14.4 g/L glycine, 20 % methanol 
PBS-T: 11.5 g/L Na2HPO4, 2.96 g/L NaH2PO4, 5.84 g/L NaCl, 0.1 % Tween20, pH 
7.5 
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Blocking solution: 3 % milk powder in PBS-T 
Membrane: PVDF membrane purchased from Bio-Rad 
Transfer machine: BioRad Mini Trans-Blot® Electrophoretic Transfer Cell 
Primary antibody: mouse anti-His (Sigma H1029)  
Secondary antibody: peroxidase-conjugated rabbit anti-mouse (Sigma A9044) 
WesternSure Pen (LI-COR) 
WesternSure Premium Chemiluminescent Substrate (LI-COR 926-95000)  
LI-COR C-DiGit Blot Scanner 
 
2.1.15 Reverse transcription-polymerase chain reaction (RT-
PCR) 
QIAGEN RNeasy Mini kit: purchased from QIAGEN 
DNase I: 10X DNase I reaction buffer, DNase I and 25 mM EDTA (pH 8) purchased 
from Invitrogen (18068-015) 
SuperScript III Reverse Transcriptase Kit: purchased from Invitrogen (18080) 
Oligo(dT)20 primer: purchased from Invitrogen (18418020) 
dNTPs: purchased from NEB 
SUPERase-In RNase Inhibitor (20 U/μL): purchased from Invitrogen (AM2694) 
E. coli RNase H: purchased from Invitrogen (18021071) 
 
2.1.16 BioLector fermentations 
FlowerPlate with pH and DO optodes: purchased from m2p-labs (MTP-48-BOH) 
Gas-permeable sealing foil: purchased from m2p-labs 
RoboLector XL (m2p-labs) 
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2.2 Methods 
2.2.1 Storage of E. coli and yeast 
For long term storage, E. coli and yeast strains were stored at -80 °C in 20 % (v/v) 
glycerol. For short term storage, strains were kept on agar plates at 4 °C. 
To prepare E. coli glycerol stocks, 5 ml LB containing the appropriate antibiotic was 
inoculated with the desired E. coli strain and grown at 37 °C for ~ 16 h (shaking at 
200 rpm). To prepare yeast glycerol stocks, 5 ml yeast growth medium was inoculated 
with the desired yeast strain and grown at 30 °C for ~ 24 h (shaking at 200 rpm). Yeast 
strains carrying no plasmids were grown in YPD, while strains with plasmids were 
grown in either SC-URA + 2 % D-Glc or SC-URA-LEU + 2 % D-Glc as appropriate. 
500 μl of culture was mixed with 500 μl 40 % (v/v) glycerol and stored at -80°C. 
2.2.2 Preparation of chemically competent cells 
Chemically competent cells were prepared using the RbCl method. 5 ml of LB was 
inoculated with E. coli TOP10 and grown at 37 °C for ~ 16 h (shaking at 200 rpm). 
The culture was diluted 1:400 in 500 ml LB containing 20 mM MgSO4 and grown at 
37 °C (shaking at 200 rpm) until the OD600 reached ~ 0.5. The cells were transferred 
to ten 50 ml Falcon tubes (50 ml per tube) and incubated on ice for 10 min. The cells 
were kept cold from this point on. The cells were centrifuged (3750 RCF for 5 min at 
4 °C), each was resuspended in 20 ml cold TFB1 buffer, incubated on ice for 5 min, 
centrifuged again (1350 RCF for 10 min at 4 °C), resuspended in 2 ml cold TFB2 
buffer, and incubated on ice for 15 min. Cells were aliquoted, snap-frozen on dry ice 
and 100 % ethanol, and stored at -80°C. 
2.2.3 Plasmid preparation 
5 ml of LB containing the appropriate antibiotic was inoculated with a colony of E. coli 
containing the desired plasmid, and grown at 37 °C for ~ 16 h (shaking at 200 rpm). 
Plasmid extraction was performed using the QIAprep Spin Miniprep Kit or E.Z.N.A. 
Plasmid Mini Kit I according to manufacturer’s instructions, eluting in 30 μl dH2O. 
2.2.4 Polymerase chain reaction (PCR) 
PCR reactions to construct parts for cloning into pYTK001 were performed using 
Phusion DNA Polymerase (constructing the GAL promoters) or Q5 DNA Polymerase 
(removing the transposon from the CqBAS1 gene; constructing the catalytically 
Chapter 2: Materials and Methods 
 46 
inactive AaBAS). For Phusion PCR, the reaction was 1X HF buffer, 0.2 mM dNTP 
(NEB), 0.5 μM each primer, 0.2 μl template and 1 U Phusion DNA Polymerase. The 
thermocycling programme was: 98 °C for 30 s; 35 cycles of 98 °C for 10 s, anneal for 
30 s, extension at 72 °C; 72 °C for 10 min; hold at 16 °C. For Q5 PCR, the reaction 
was 1X Q5 reaction buffer, 0.2 mM dNTPs, 0.5 μM each primer, 0.2 μl template and 
1 U Q5 High-Fidelity DNA Polymerase. The thermocycling programme was: 98 °C for 
30 s; 30 cycles of 98 °C for 10 s, anneal for 30 s, extension at 72 °C; 72 °C for 2 min; 
hold at 16 °C. In both cases the annealing temperature was 3 °C above the melting 
temperature (Tm) of the lower Tm primer, and the extension time was 30 s / kb PCR 
product. The PCR products were purified by gel extraction. 
2.2.5 Restriction digest 
Restriction digests of plasmid minipreps were performed as follows. Mixed 0.5-1.5 μl 
plasmid, 0.5 μl each restriction enzyme (NEB) and 1X CutSmart buffer (NEB) in a final 
volume of 20 μl. Incubated at 37 °C for at least 1 h and analysed by agarose gel 
electrophoresis. 
2.2.6 Agarose gel electrophoresis 
Restriction digests, PCR reactions or total RNA were mixed with 1X Gel Loading Dye, 
Purple (NEB B7024S) and loaded onto an agarose-TAE gel. PCR reactions that used 
GoTaq or OneTaq were loaded directly onto the gel. The percentage of agarose was 
typically 1 % but was adjusted based on the expected size of the bands. The gel was 
run at 100 V in 1X TAE buffer and imaged using a Gel Doc™ XR+ Gel Documentation 
System (BioRad). 
2.2.7 Gel extraction 
PCR reactions were run on agarose-TAE gels and purified using the QIAquick Gel 
Extraction Kit, according to the manufacturer’s instructions. Elution was in 30 μl dH2O. 
2.2.8 Sanger sequencing 
Plasmids were sequenced by MRC PPU DNA Sequencing and Services (University 
of Dundee) using the Sanger sequencing method. 
2.2.9 Plasmid construction 
Plasmids were assembled using MoClo-YTK (Lee et al., 2015). Briefly, individual 
parts (e.g. promoters and open reading frames) are first cloned into an entry vector 
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(pYTK001), transcriptional units (promoter-ORF-terminator) are then constructed by 
cloning these parts into a pCP series plasmid, and pathways are finally constructed 
by cloning multiple transcriptional units into a pMG series plasmid. 
All genes except AsBAS were codon-optimised for S. cerevisiae, synthesised 
(GeneArt, Gen9, or IDT) and cloned into the MoClo-YTK entry vector (pYTK001). For 
AsBAS, a wild-type sequence was provided by Thomas Louveau (Anne Osbourn lab, 
John Innes Centre); PCR was performed to add appropriate BsmBI restriction sites 
and the product was cloned into pYTK001. To make dAaBAS, PCR was performed 
on AaBAS (in pYTK001) to introduce a D484N mutation (G1450A nucleotide) and the 
product was cloned into pYTK001. To generate a transposon-free CqBAS1, PCR was 
performed on CqBAS1 synthetic DNA to introduce silent mutations (C552T, G555A, 
C570A nucleotides) and the product was cloned into pYTK001. The GAL1 and GAL10 
promoters were made by performing PCR on the GAL1/GAL10 bidirectional promoter 
of pESC-URA (using primer pairs PGAL1 fwd/PGAL1 rev and PGAL10 fwd 1/PGAL10 
rev) and cloning the product into pYTK001. The GAL7 and GAL3 promoters were 
made by performing PCR on S. cerevisiae BY4741 genomic DNA (using primer pairs 
(MoClo)-PGAL3 fwd/(MoClo)-PGAL3 rev and (MoClo)-PGAL7 fwd/(MoClo)-PGAL7 
rev), respectively and cloning the product into pYTK001. All other parts were provided 
with the MoClo-YTK. 
For the BAS comparisons (Chapter 4), each BAS was cloned into the plasmid 
pCPS1ULA (CEN6/ARS4, URA3) with the GAL1 promoter and TDH1 terminator, 
generating the pCPS1ULA-BAX series. For the CYP716A comparisons (Chapter 5), 
each CYP716A was cloned into pCP12ULA (CEN6/ARS4, URA3) with the GAL10 
promoter and the ENO2 terminator, and ATR2 was cloned into pCP2EULA 
(CEN6/ARS4, URA3) with the GAL3 promoter and the PGK1 terminator. Plasmids 
encoding the appropriate BAS (pCPS1ULA-BAS), CYP716A (pCP12ULA-CYP716A) 
and ATR2 (pCP2EULA-ATR2) were used to clone these genes into pMGSEULS 
(CEN6/ARS4, URA3), generating the pMGSEULS-OAX series of plasmids. For 
saponin production (Chapter 6), UGTs were cloned into a low copy (CEN6/ARS4) 
pCP plasmid with LEU2 selection marker under the control of either the GAL1, GAL10 
or GAL7 promoter. For the co-expression of UGT73C10, and UGT72P2, both 
transcriptional units were cloned into a pMG plasmid (CEN6/ARS4, LEU2). 
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To clone parts into pYTK001, the appropriate PCR product or synthetic DNA was 
mixed with 20 fmol pYTK001, 1X T4 DNA ligase buffer (NEB), 1500 U T7 DNA ligase 
(NEB), and 5 U BsmBI (NEB) for a final volume of 10 µl. The reaction was 
thermocycled using the following programme: 42 °C for 2 min then 16 °C for 5 min 
(25 cycles); 60 °C for 10 min; 80 °C for 10 min; hold at 16 °C. Assemblies into pCP 
series vectors were performed similarly, except that the reaction contained 20 fmol 
each plasmid (the pCP plasmid and the parts in pYTK001), and 5 U BsaI (NEB) was 
used instead of BsmBI. Assemblies into pMG series vectors were performed the same 
as for pCP vectors, but the restriction enzyme was 5 U BsmBI. 
Assemblies were transformed into E. coli TOP10. 5 µl of reaction was added to 50 - 
200 µl of chemically competent cells, the cells were incubated on ice for 30 min, at 42 
°C for 30 s, then on ice for 2 min. 250 - 500 µl SOC media was added and the cells 
were incubated at 37 °C for 90 min (shaking at 200 rpm). 100 µl was plated onto LB-
agar containing the appropriate antibiotic (40 µg/ml chloramphenicol for assemblies 
into pYTK001, 100 µg/ml ampicillin for pCP plasmids, and 100 µg/ml spectinomycin 
for pMG plasmids), and incubated at 37 °C until colonies had appeared (usually ~ 16 
h). Plasmids were prepared by miniprep and verified by restriction digest and Sanger 
sequencing. 
2.2.10 Yeast transformation 
pCP and pMG plasmids encoding appropriate transcription units / pathways were 
transformed into yeast to generate triterpenoid/saponin production strains. For β-
amyrin and oleanolic acid production (Chapters 4-5), S. cerevisiae BY4741 was 
transformed with the appropriate pCP or pMG plasmids (CEN6/ARS4, URA3). For the 
production of saponins (Chapter 6), S. cerevisiae BY4741 was first transformed with 
pCPS1ULA-BA5 (CEN6/ARS4, URA3; encoding EtBAS) or pMGSEULS-OA7 
(CEN6/ARS4, URA3; encoding EtBAS, CYP716A12 and ATR2) to generate strains 
MD-BA5 and MD-OA7, respectively. These strains were then transformed with pCP 
or pMG plasmids (CEN6/ARS4, LEU2) encoding the appropriate UGTs. 
Yeast transformation was performed as follows. Cells were grown for 24 h in 
appropriate media (YPD for S. cerevisiae BY4741, or appropriate drop-out media for 
strains already carrying a plasmid), diluted into the same media (10 ml per 
transformation) for an OD600 of 0.1, and grown until OD600 0.4-0.6 (~ 5 h). The culture 
was transferred to 50 ml Falcon tubes, pelleted (3000 RCF for 5 min), resuspended 
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in half volume dH2O, pelleted again (3000 RCF for 2 min) and resuspended in 1/10th 
volume dH2O. Cells were transferred to 1.5 ml microtubes (1 ml / tube), spun at 8000 
rpm for 1 min, and resuspended in 54 ul dH2O. Meanwhile, salmon sperm DNA was 
incubated at 100 °C for 8 min. 100-500 ng plasmid and 306 µl of transformation mix 
(10 μl 10 mg/ml salmon sperm DNA, 36 µl 1 M lithium acetate and 260 µl 50 % PEG 
3350) was added, and cells were mixed by vortexing briefly. Cells were incubated at 
30 °C for 30 min, 42 °C for 14 min, pelleted (8000 rpm, 2 min) and resuspended in 
100 µl dH2O, and 100 µl was plated onto appropriate selective media and incubated 
at 30 °C for 48 h. 
2.2.11 Yeast strain verification 
Individual colonies from the transformation were re-streaked and incubated at 30 °C 
for 48 h. DNA was extracted using the GC prep method described by Blount et al. 
(Blount et al., 2016). Cells were picked from the plate, resuspended in 100 µl 5 % 
Chelex 100, and glass beads were added to approximately half sample volume. Cells 
were vortexed at maximum speed for 4 min, incubated at 100 °C for 2 min, pelleted 
(14,000 rpm, 1 min), and the supernatant (containing the DNA) was transferred to a 
fresh tube. 
The extracts were analysed by PCR using a touch-down protocol. The reaction was 
set up as follows: 0.4 µl 5 µM each primer, 0.2 µl DNA extract, 5 µl OneTaq Quick-
Load 2X Master Mix with Green Buffer (NEB M0485), 5 µl dH2O. The cycling 
programme was: 94 °C for 30 s; 20 cycles of 94 °C for 30 s, 70 °C for 45 s (decreasing 
by 1 C per cycle), 68 °C for 1 min; 15 cycles of 94 °C for 30 s, 55 °C for 45 s, 68 °C 
for 1 min; 68 °C for 5 min; hold at 16 °C. 5 ul of PCR reaction was analysed by agarose 
gel electrophoresis. 
2.2.12 Triterpenoid extractions for GC-MS analysis 
Precultures were grown in 50 ml Falcon tubes by inoculating 5 ml SC-URA + 2 % D-
Glc with the desired yeast strain and incubating at 30 °C for 24 h (shaking at 200 rpm). 
The precultures were washed twice in 5 ml dH2O (for each wash spun at 3000 RCF 
for 2 min, then resuspended in 5 ml dH2O), diluted to an OD600 of 0.2 in 5 ml SC-URA 
+ 2 % D-Gal in 55 ml glass culture vials, and incubated at 30 °C for 96 h (shaking at 
200 rpm). The OD600 was measured, then 1 ml of yeast culture was transferred to a 
microtube and pelleted (14,000 rpm, 1 min), and washed twice in 1 ml dH2O (spun at 
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14,000 rpm for 1 min, resuspended in 1 ml dH2O, then spun again). The pellet was 
resuspended in 0.5 ml lysis solution containing 80 nmol/ml coprostan-3-ol and 
incubated at 100 °C for 10 min (with the lids open to allow the ethanol, which is 
miscible with ethyl acetate, to evaporate). The cells were then extracted twice with 
500 μl hexane then twice with ethyl acetate. Extractions were performed by adding 
500 μl hexane or ethyl acetate, vortexing briefly at max speed, centrifuging 14,000 
rpm for 1 min, then removing the organic phase to a separate microtube. For the first 
extraction 400 μl organic phase was removed and for the subsequent extractions 500 
μl was removed, and these were pooled together to give a total of 1900 μl extract. 
600 μl of extract was transferred to a 1.1 ml autosampler vial, evaporated to dryness 
using a GeneVac EZ-2 Elite evaporator (Low BP Mix programme, 40 °C), and sealed 
with crimp caps. The dried extracts were stored at room temperature until analysis. 
2.2.13 Triterpenoid extractions for TLC analysis 
Cultures were grown as for the triterpenoid extractions for GC-MS analysis, except 
that growth in SC-URA + 2 % D-Gal was done in 50 ml Falcon tubes for 90 h. The 
OD600 was measured, and 1 ml of culture was pelleted (14,000 rpm, 1 min) and the 
supernatant was removed. Cells were resuspended in 0.5 ml lysis solution and 
incubated at 75 °C for 2 h. The extract (supernatant and cell debris) was transferred 
a 7 ml glass vial, mixed with 2 ml dH2O, and extracted twice with 1 ml hexane. 
Extractions were performed by adding 1 ml hexane, vortexing at maximum speed 
briefly, letting the aqueous and organic phases separate, transferring the aqueous 
phase to a fresh glass vial, and extracting the aqueous phase again. The organic 
phases and any emulsions were pooled together, washed with 1 ml 20 % NaCl to 
separate the emulsions (added 1 ml 20 % NaCl, vortexed briefly at maximum speed, 
let the phases separate and removed the aqueous phase). The pooled organic 
phases were evaporated to dryness overnight (at room temperature and atmospheric 
pressure). 
2.2.14 Saponin extractions for LC-MS analysis 
Cells were grown as for the triterpenoid extractions for GC-MS analysis, except that 
growth in SC-URA + 2 % D-Gal was for 90 h. The OD600 was measured and 1 ml of 
culture was transferred to a microtube and pelleted (14,000 rpm, 1 min). 500 μl 
supernatant (the “spent medium”) was transferred to a fresh microtube and the pellet 
was washed in 1 ml dH2O (resuspended pellet in 1 ml dH2O then spun at 14,000 rpm 
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for 1 min). The pellet was resuspended in 100 µl TN150-Triton lysis buffer, ~ 250 μl 
glass beads were added, and the cells were lysed by vortexing (three cycles of 
vortexing at maximum speed for 1 min followed by incubating on ice for 30 s). 900 μl 
dH2O was added, then spun at 14,000 rpm for 1 min and transferred 500 μl 
supernatant to a fresh microtube. The lysed cells and spent medium were extracted 
thrice with butan-1-ol. For each extraction, added 500 μl butan-1-ol, vortexed briefly 
at maximum speed, spun at 14,000 rpm for 1 min, and transferred the butan-1-ol 
phase to a separate microtube (the butan-1-ol phases for the three extractions were 
pooled together). 450 μl of extract was transferred to a 1.1 ml autosampler vial, 
evaporated to dryness in a GeneVac EZ-2 Elite evaporator (High BP programme, 50 
°C), and sealed with crimp caps. The dried extracts were stored at -20 °C until 
analysis. 
2.2.15 Saponin extractions for TLC analysis 
Cells were grown as for the triterpenoid extractions for TLC analysis. The OD600 was 
measured and 1 ml of culture was transferred to a microtube and pelleted (14,000 
rpm, 1 min). 700 μl supernatant (the “spent medium”) was transferred to a fresh 
microtube and the pellet was washed twice in 1 ml dH2O (a single wash consisted of 
resuspending the pellet in 1 ml dH2O then centrifuging at 14,000 rpm for 1 min). The 
pellet was resuspended in 100 μl TN150-Triton lysis buffer, glass beads were added 
to ~ 250 μl volume, and the cells were lysed by vortexing (three cycles of vortexing at 
maximum speed for 1 min followed by incubating on ice for 30 s). 1 ml dH2O was 
added, the cells were vortexed briefly at maximum speed, centrifuged (14,000 rpm, 1 
min), and 700 μl supernatant was transferred to a 2 ml microtube. The lysed cells and 
spent medium was extracted twice with 700 μl butan-1-ol, and the pooled extracts 
were evaporated to dryness using a SpinVac. 
2.2.16 Thin Layer Chromatography (TLC) 
Dried extracts were dissolved in 100 μl hexane (triterpenoid extracts) or 100 μl butan-
1-ol (saponin extracts) by vortexing at maximum speed. 10 μl of each extract and 0.6 
μg of authentic standards were loaded onto a TLC plate. This was done by adding 2 
μl of extract or 100 mg/L standard at a time, allowing the plate to dry between each 
addition, until 10 μl or 0.6 μg had been loaded. The plate was placed in a TLC tank 
containing hexane:ethyl acetate (9:1) for the triterpenoid extracts, or containing 
chloroform : methanol : H2O (30:6:1) for the saponin extracts. The tank was sealed 
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and the plate was removed once the solvent front had reached the top of the plate. 
The plate was allowed to dry, stained in glacial acetic acid : p-anisaldehyde : 
concentrated sulphuric acid (48:1:1), then incubated at 100 °C until purple spots 
appeared. 
2.2.17 Gas chromatography-mass spectrometry (GC-MS) 
Triterpenoid extracts were analysed using an Agilent 7200B GC/Q-TOF with Gerstel 
Multi-Purpose Sampler (MPS). Samples were derivatised by trimethylsilylation: 50 μl 
of MSTFA:pyridine (4:1) was added to the dried extract, vortexed for 30 s at 3000 
rpm, incubated at 37 °C for 30 min (shaking at 750 rpm), and centrifuged at 4500 rpm 
for 2 min. Derivatisation was performed by the MPS and samples were derivatised 
sequentially, with each sample being injected immediately after derivatisation. 
Injection was at 1 μl volume with a 10:1 split. Where analyte peak areas were outside 
the linear range of the standard curve, the sample was injected again at a 5:1 split or 
a 25:1 split. The column was an Agilent DB-5ms column (30 m with 10 m guard x 250 
µm x 0.25 µm). The GC parameters were as follows: constant helium flow of 1 ml / 
min; the inlet was set to 250 °C; the oven was initially held at 100 °C for 2 min, then 
increased to 300 °C at a rate of 25 °C / min, then held at 300 °C for 25 min. Ionisation 
was by electron ionisation (EI), and the MS parameters were: 230 °C source 
temperature, 35 μA filament current, 70 eV electron energy, mass range of 60-900 
m/z, acquisition rate of 4 spectra / s, 13 min solvent delay. Total ion chromatograms 
and mass spectra were analysed using the Agilent MassHunter Qualitative Analysis 
B.07.00 software, and peak areas were calculated using the Agile 2 integrator 
method. Hannah Florance (University of Edinburgh) helped develop the protocol and 
provided training on using the instrument. 
2.2.18 Liquid chromatography-mass spectrometry (LC-MS) 
Saponin extracts were analysed using an Agilent 6560 IM Q-TOF LC/MS coupled to 
an Agilent 1290 Infinity II UHPLC. Dried extracts were reconstituted in 100 μl methanol 
(vortexed briefly at maximum speed then centrifuged briefly at 500 RCF). Samples 
were injected at 10 μl volume onto an ACE C18 PFP column (100mm x 2.1mm, 1.8 
µm). The gradient was as follows: 70 % buffer A and 30 % buffer B at 0-1 min, 100 % 
buffer B at 10-12 min, 70 % buffer A and 30 % buffer B at 12.1 min; buffer A was H2O 
with 0.1 % formic acid, and buffer B was methanol with 0.1 % formic acid. The column 
was held at 30 °C and a constant flow rate of 0.2 ml / min was used. For the mass 
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spectrometry, ionisation was by electrospray ionisation (ESI), the acquisition mode 
was ion mobility-QTOF, and positive ion mode was used. The MS parameters were 
as follows: the gas temperature was 325 °C, the drying gas was set to 13 L / min, the 
nebuliser was set to 20 psig, the sheath gas temperature and flow were 275 °C and 
12 L / min, the VCap was 3500 V, the nozzle voltage was 700 V, the fragmenter was 
400 V, the collision energy was 65 V, the mass range was 100-1600 m/z, and the 
acquisition rate was 1 frame / s. Chromatograms and mass spectra were analysed 
using the Agilent MassHunter Qualitative Analysis B.07.00 software. Hannah 
Florance (University of Edinburgh) helped develop the protocol and provided training 
on using the instrument. 
2.2.19 Microplate assays 
The washed precultures used for the triterpenoid extractions were diluted to an OD600 
of 0.2 in 100 μl SC-URA + 2 % D-Glc or 100 μl SC-URA + 2 % D-Gal in 96-well plates. 
Blanks contained only 100 μl SC-URA + 2 % D-Glc. A lid was placed on the plate and 
sealed with tape, and OD595 was read on a Tecan Sunrise plate reader every 15 min 
for 96 h. Temperature was 30 °C, shaking mode was “inside” and shaking intensity 
was “normal”. Data was exported into Microsoft Excel and analysed in MATLAB. 
2.2.20 Western blots 
Precultures were grown as for the triterpenoid extractions, diluted into 5 ml SC-URA 
+ 2 % D-Glc or 5 ml SC-URA + 2 % D-Gal for an OD600 of 0.2, and grown at 30 °C for 
48 h (shaking at 200 rpm). 1 ml of culture was pelleted (14,000 rpm, 1 min) and 
resuspended in an appropriate volume of lyse and load buffer such that the OD600 
was 100. The cells were lysed by incubating at 100 °C for 5 min, then 10 μl was 
immediately loaded onto a 10 % polyacrylamide gel. 8 μl of colour prestained protein 
standard broad range (NEB P7712) was also loaded. The gel as run at 80 V until the 
samples were through the stacking gel, then at 150 V for ~ 45 min (until the 30 kDa 
marker had reached the bottom of the resolving gel). 
The gel was blotted onto a PVDF membrane using a BioRad Mini Trans-Blot® 
Electrophoretic Transfer Cell (100 V for 60 min in cold transfer buffer), and the 
membrane was blocked overnight in blocking solution. The primary antibody was 
mouse anti-His (Sigma H1029) and the secondary antibody was peroxidase-
conjugated rabbit anti-mouse (Sigma A9044). Antibody incubations were performed 
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with 1:1500 concentration of primary antibody or a 1:15,000 concentration of 
secondary antibody in blocking solution, incubating at room temperature for 1 h 
(shaking gently). After each incubation the membrane was washed three times with 
excess PBS-T. The ladder was marked on the membrane using a WesternSure Pen 
(LI-COR), and the membrane was imaged by chemiluminescence using the 
WesternSure Premium Chemiluminescent Substrate (LI-COR 926-95000) on a LI-
COR C-DiGit Blot Scanner. 
2.2.21 Reverse transcription-polymerase chain reaction (RT-
PCR) 
Precultures were grown as for the triterpenoid extractions, diluted to an OD600 of 0.1 
in 5 ml SC-URA + 2 % D-Gal, and grown at 30 °C (shaking at 200 rpm) until they 
reached an OD600 of ~ 0.5. Total RNA was prepared using the QIAgen RNeasy Mini 
Kit, harvesting 1 ml of culture. For the strains expressing CYP716A52v2 and ATR2, 
0.5 ml culture was harvested because the OD600 was ~ 1, while for the strains 
expressing PgBAS1 and GgBAS, 1.5 ml culture was harvested because the OD600 
was ~ 0.3. Lysis was performed on freshly harvested cells using the enzymatic 
method for ≤ 2 x 107 cells. 500 ng of total RNA was analysed by agarose gel 
electrophoresis (using 1 % agarose-TAE gels) to confirm RNA integrity.  
The RNA was treated with DNase I (Invitrogen 18068-015): mixed 200 ng RNA, 1X 
DNase I reaction buffer, and 1 μl DNase I in 10 μl final volume; incubated 15 min at 
room temperature; added 1 μl 25 mM EDTA (pH 8); incubated 10 min at 65 °C. 
Reverse transcription was then performed using the SuperScript III Reverse 
Transcriptase Kit (Invitrogen 18080): mixed 1 μl of 50 μM oligo(dT)20, 1 μl of 10 mM 
dNTPs, and 10 μl of DNase I reaction; incubated at 65 °C for 5 min then on ice for 1 
min; added 4 μl 5X First-Strand buffer, 1 μl 0.1 M DTT, 2 μl 20 U/µl SUPERase-In 
RNase Inhibitor, and 1 µl 200 U/µl SuperScript III RT (negative controls received 1 µl 
RNase-free water instead); incubated at 50 °C for 60 min, then at 70 °C for 15 min. 1 
μl of E. coli RNase H (Invitrogen 18021071) was added to each reaction, and 
incubated at 37 °C for 20 min. PCR of the cDNA was then performed. Reactions 
contained 1X GoTaq Green Master Mix (Promega), 0.5 μM each primer, and 0.4 μl 
cDNA in 10 μl total volume. The thermocycling programme was: 95 °C for 5 min; 30 
cycles of 95 °C for 45 s, 58 °C for 45 s, and 72 °C for 1 min; 72 °C for 5 min; hold at 
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16 °C. The PCR reactions were analysed by agarose gel electrophoresis using 1.5 % 
agarose-TAE gels. 
2.2.22 BioLector fermentations 
Precultures were grown by inoculating 5 ml SC-URA + 2 % D-Glc with the desired 
yeast strains and incubating at 30 °C for 24 h (shaking at 200 rpm). The cultures were 
washed twice in 5 ml dH2O and diluted to an OD600 of 0.2 in 1.2 ml SC-URA + 2 % D-
Gal in a 48-well FlowerPlate with pH and DO optodes (MTP-48-BOH). Blanks 
contained only 1.2 ml SC-URA + 2 % D-Gal. The plates were sealed with gas-
permeable sealing foil, and cells were cultured in an m2p-labs RoboLector XL at 30 
°C for 96 h (shaking at 1200 rpm). Humidity was maintained at 85 % relative humidity 
(rH), and biomass (with a gain of 8), pH and dissolved oxygen (DO) were measured 
every 15 min. At the end of the run, 900 μl of cells were harvested, OD600 was 
measured, and metabolites were extracted as described for the triterpenoid 
extractions for GC-MS analysis. 
2.2.23 Phylogenetic analysis 
Protein sequences were aligned using ClustalW and the phylogenetic tree was 
generated in MEGA7 (Kumar et al., 2016) using the maximum likelihood method, 
bootstrapping with 1000 replicates. The Poisson substitution model was used, rates 
among sites were assumed to be uniform, and gaps and missing data were removed 
using the complete deletion option. The maximum likelihood heuristic method was 
Nearest-Neighbour-Interchange and the initial tree was made using the neighbour 
joining method. 
2.2.24 Proteomics 
Cells were cultured as for the triterpenoid extractions, except that growth in SC-URA 
+ 2 % D-Gal media was for 32 h. The OD600 was measured, 1 ml of culture was 
pelleted (14,000 rpm, 1 min), the supernatant was removed and pellets were stored 
at 4 °C until analysis. The pellets were resuspended in 8 M Urea and lysed using a 
Precellys Tissue Lyser. Protein concentration was determined by Bradford assay 
(Bio-Rad) and 50 µg was digested in 2 M Urea (with 25 mM Ammonium bicarbonate, 
5 mM DTT and 12.5 mM Iodoacetamide) with 1 μg trypsin (Worthington Labs) at room 
temperature overnight. Samples were cleaned using Omix C18 stage tips (Agilent) 
and the eluted peptides were evaporated to dryness using a SpeedVac and stored at 
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-20 °C until analysis. Samples were dissolved in MS-loading buffer (0.05 % v/v 
trifluoroacetic acid in water) to 1 µg/µl final concentration and filtered using a Millex 
filter. The samples were mixed with an equal volume of 0.05 % TFA and 5 μl was 
injected for HPLC-MS analysis. Nano-ESI-HPLC-MS/MS analysis was performed 
using an online system of a nano-HPLC (Dionex Ultimate 3000 RSLC, Thermo-
Fisher) coupled to a QExactive mass spectrometer (Thermo-Fisher) with a 300 µm x 
5 mm pre-column (Acclaim Pepmap, 5 µm particle size) joined with a 75 µm x 50 cm 
column (Acclaim Pepmap, 3 µm particle size). A 90 min multi-step gradient of 2-98 % 
solvent B at a flow rate of 300 nL/min was used to separate the peptides; solvent A 
was 2 % acetonitrile in H2O 0.1 % formic acid; solvent B was 80 % acetonitrile in H2O 
with 0.1% formic acid. Cell lysis through to HPLC-MS analysis was performed by Lisa 
Imrie (Edinomics, University of Edinburgh). 
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2.3 List of yeast strains 
Strain Genotype Notes 
S. cerevisiae 
BY4741 
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 
 
MD-BA1 BY4741, [pCPS1ULA-BA1: CEN6/ARS4-ura3, 
pGAL1-AsBAS (JIC)-tTDH1] 
AsBAS 
MD-BA2 BY4741, [pCPS1ULA-BA2: CEN6/ARS4-ura3, 
pGAL1-PgBAS1 (synth)-tTDH1] 
PgBAS1 
MD-BA3 BY4741, [pCPS1ULA-BA3: CEN6/ARS4-ura3, 
pGAL1-GgBAS (synth)-tTDH1] 
GgBAS 
MD-BA4 BY4741, [pCPS1ULA-BA4: CEN6/ARS4-ura3, 
pGAL1-LjBAS (synth)-tTDH1] 
LjBAS 
MD-BA5 BY4741, [pCPS1ULA-BA5: CEN6/ARS4-ura3, 
pGAL1-EtBAS (synth)-tTDH1] 
EtBAS 
MD-BA6 BY4741, [pCPS1ULA-BA6: CEN6/ARS4-ura3, 
pGAL1-PtBAS (synth)-tTDH1] 
PtBAS 
MD-BA9 BY4741, [pCPS1ULA-BA9: CEN6/ARS4-ura3, 
pGAL1-GhBAS(Sc)-tTDH1] 
GhBAS 
MD-BA14 BY4741, [pCPS1ULA-BA14: CEN6/ARS4-ura3, 
pGAL1-AaBAS(Sc)-tTDH1] 
AaBAS 
MD-BA15 BY4741, [pCPS1ULA-BA15: CEN6/ARS4-ura3, 
pGAL1-BvBAS(Sc)-tTDH1] 
BvBAS 
MD-BA16 BY4741, [pCPS1ULA-BA16: CEN6/ARS4-ura3, 
pGAL1-CqBAS1(Sc)_2-tTDH1] 
CqBAS1 
MD-BA17 BY4741, [pCPS1ULA-BA17: CEN6/ARS4-ura3, 
pGAL1-MtBAS(Sc)-tTDH1] 
MtBAS 
MD-BA18 BY4741, [pCPS1ULA-BA18: CEN6/ARS4-ura3, 
pGAL1-SlBAS(Sc)-tTDH1] 
SlBAS 
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MD-BA1-t BY4741, [pCPS1ULA-BA1-t: CEN6/ARS4-ura3, 
pGAL1-AsBAS(JIC)v2-3xFLAG-6xHis-tTDH1] 
For western blot 
and RT-PCR of 
AsBAS 
MD-BA2-t BY4741, [pCPS1ULA-BA2-t: CEN6/ARS4-ura3, 
pGAL1-PgBAS1(Sc)-3xFLAG-6xHis-tTDH1] 
For western blot 
and RT-PCR of 
PgBAS1 
MD-BA3-t BY4741, [pCPS1ULA-BA3-t: CEN6/ARS4-ura3, 
pGAL1-GgBAS(Sc)-3xFLAG-6xHis-tTDH1] 
For western blot 
and RT-PCR of 
GgBAS 
MD-BA4-t BY4741, [pCPS1ULA-BA4-t: CEN6/ARS4-ura3, 
pGAL1-LjBAS(Sc)-3xFLAG-6xHis-tTDH1] 
For western blot 
and RT-PCR of 
LjBAS 
MD-BA5-t BY4741, [pCPS1ULA-BA5-t: CEN6/ARS4-ura3, 
pGAL1-EtBAS(Sc)-3xFLAG-6xHis-tTDH1] 
For western blot 
and RT-PCR of 
EtBAS 
MD-BA6-t BY4741, [pCPS1ULA-BA6-t: CEN6/ARS4-ura3, 
pGAL1-PtBAS(Sc)-3xFLAG-6xHis-tTDH1] 
For western blot 
and RT-PCR of 
PtBAS 




For western blot 
of CYP716A12 
and ATR2 




For western blot 
of CYP716A15 
and ATR2 
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For western blot 
of CYP716AL1 
and ATR2 








































For RT-PCR of 
ATR2 
MD3 BY4741, [pCPS1ULA-BA5: CEN6/ARS4-ura3, 





MD5 BY4741, [pCPS1ULA-BA5: CEN6/ARS4-ura3, 





MD6 BY4741, [pCPS1ULA-BA5: CEN6/ARS4-ura3, 





MD7 BY4741, [pCPS1ULA-BA5: CEN6/ARS4-ura3, 





MD10 BY4741, [pCPS1ULA-BA5: CEN6/ARS4-ura3, 
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MD-N2 BY4741, [pMGSEULS: CEN6/ARS4-ura3, empty 
vector; pMGSELLS: CEN6/ARS4-leu2, empty 
vector] 
Empty URA3 and 
LEU2 vectors 
Genes with the suffix “(Sc)” or “(synth)” were synthesised with codon-optimisation 
for S. cerevisiae. 
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2.4 List of primers 
All primers were provided by Integrated DNA Technologies (IDT). 
Primer Sequence Notes 
PGAL1 fwd GCATCGTCTCATCGGTCTCAAACGGC 
TATATTGAAGTACGGATTAGAAGCC 
Used to clone pGAL1 from 
pESC-URA into pYTK001 
PGAL1 rev ATGCCGTCTCAGGTCTCACATAGTTTT 
TTCTCCTTGACGTTAAAGTATAGAGG 
Used to clone pGAL1 from 
pESC-URA into pYTK001 
PGAL10 fwd 1 GCATCGTCTCATCGGTCTCAAACGCTT 
TATTGTTCGGAGCAGTGCGG 
Used to clone pGAL10 from 
pESC-URA into pYTK001 
PGAL10 rev ATGCCGTCTCAGGTCTCACATAGTTTT 
GAATTTTCAAAAATTCTTACTTTTTTT 
TTGGATGGACGC 
Used to clone pGAL10 from 





Used to clone pGAL3 from 







Used to clone pGAL3 from 






Used to clone pGAL7 from 







Used to clone pGAL7 from 












Used to clone AsBAS into 
pYTK001 
dAaBAS fwd 1 GCATCGTCTCATCGGTCTCATATGTGG 
CGTTTG 
Used to make dAaBAS 
dAaBAS rev 1 ATCCGTCTCATAGAAACTTGCCAACCA 
TGATCTTG 
Used to make dAaBAS 
dAaBAS fwd 2 ATCCGTCTCATCTAATTGCACTGCTGA 
AGCTTTG 
Used to make dAaBAS 
dAaBAS rev 2 ATGCCGTCTCAGGTCTCAGGATCCAGT 
ACCTTTC 
Used to make dAaBAS 




















ATGCCGTCTCAGGTCTCAG Used to generate CqBAS1 
without transposon 
AsBAS (JIC) RT 
fwd 
CATGGACCCTTTCAAGTGTAGATAATG RT-PCR 






















































(synth) RT fwd 
CCATTTAACTCCGCTATTAAATCCTCC RT-PCR 
716A52v2 








oRH711 GTTACGTCGCCTTGGACTTC Positive control for RT-
PCR, binding ACT1; 
designed by Rebecca 
Holmes 
oRH714 GGTACCACCGGACATAACGA Positive control for RT-
PCR, binding ACT1; 
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Chapter 3: A GC-MS method to measure 
triterpenoid production 
3.1 Introduction 
A major focus of the current work was the generation of yeast strains capable of 
producing triterpenoids, in particular, β-amyrin and its oxygenated derivatives 
erythrodiol, oleanolic aldehyde and oleanolic acid (Figure 3.1). These derivatives are 
generated from β-amyrin by the oxidation of its C-28 methyl group to a hydroxyl, 
aldehyde or carboxyl group, respectively. In addition to these triterpenoids, it was 
important to monitor the accumulation of ergosterol (Figure 3.1), an essential yeast 
metabolite that, like β-amyrin, is derived from oxidosqualene. Expression of 
triterpenoid biosynthetic pathways might therefore affect ergosterol levels by 
redirecting flux to triterpenoid biosynthesis. Central to this work was a method to 
monitor triterpenoid production, and gas chromatography-mass spectrometry (GC-
MS) was chosen for this purpose. Methods to monitor triterpenoid production, and the 
chosen GC-MS method, are discussed below. 
3.2 Methods to detect triterpenoids 
To monitor triterpenoid production it is important to choose an appropriate analytical 
method. The method of choice will differ depending on the nature of the triterpenoid 
in question. Two of the most commonly used techniques to detect triterpenoids, either 
from plant extracts or from heterologous hosts, are GC-MS and liquid 
chromatography-mass spectrometry (LC-MS). They work by chromatographically 
separating analytes in a sample, then ionising and fragmenting them as they are 
eluted into a mass spectrometer. Each analyte gives a unique fragmentation pattern, 
called a mass spectrum, and by comparing the retention time and mass spectrum with 
those of an authentic standard, the analyte of interest can be identified. Even where 
a standard is not available, the identity of an analyte can often be deduced using 
knowledge of the analyte and its predicted fragmentation pattern, and by comparison 
with published mass spectra in the literature. 
These techniques have high sensitivity and resolution, enabling the detection of small 
quantities of analyte and the separation of structurally similar compounds. While 
relatively low throughput, they are amenable to automation, with modern instruments 
capable of automating sample injection using an autosampler, and some instruments 
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Figure 3.1. Chemical structures of β-amyrin, its C-28 derivatives erythrodiol, oleanolic 
aldehyde and oleanolic acid, and the sterols ergosterol and coprostanol. 
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able to perform sample preparation (extraction and derivatisation of metabolites). 
Other techniques such as thin layer chromatography (TLC) and high-performance 
liquid chromatography (HPLC) are also used, but rely only on the retention time to 
identify compounds, as they are not coupled to a mass spectrometer. While TLC is 
fast and inexpensive, it is far less sensitive and is unable to provide absolute 
identification of an analyte. HPLC combines high sensitivity with a greater throughput 
than GC-MS or LC-MS, and is commonly used for screening, but again does not have 
the same accuracy in analyte identification as mass spectrometry-based methods. 
The choice of analytical method depends partly on the nature of the analytes in 
question. GC-MS requires the analytes to be volatile and thermostable, as they are 
first vaporised at high temperatures (e.g. 250 °C) into the gas phase for 
chromatographic separation. To increase their volatility, analytes are often treated 
with a derivatising reagent that reacts with polar moieties (e.g. hydroxyl groups), 
preventing them from forming hydrogen-bonds. Nevertheless, highly polar and non-
volatile analytes still present challenges for GC-MS analysis. By contrast, LC-MS uses 
a liquid mobile phase and does not require the analytes to be volatile or thermostable, 
although they must be soluble in the mobile phase. The ionisation method also differs 
between GC-MS and LC-MS. GC-MS typically uses hard ionisation methods such as 
electron ionisation (EI), which causes extensive fragmentation of the analyte and 
produces more complex mass spectra, facilitating identification of the analyte. By 
contrast, LC-MS uses soft ionisation methods such as electrospray ionisation (ESI), 
resulting in less fragmentation and therefore providing less information about the 
analyte. To overcome this limitation, liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) can be performed. Here, selected ions are fragmented 
again, giving additional mass spectra for each analyte, facilitating their identification. 
Triterpenes are often subject to modification by tailoring enzymes, the most common 
modifications being oxygenations by cytochromes P450 and glycosylations by UGTs 
(Thimmappa et al., 2014). These increase their polarity and are responsible for the 
diverse bioactivities observed in this family of metabolites (Thimmappa et al., 2014). 
Non-glycosylated triterpenoids that have undergone relatively few modifications by 
tailoring enzymes are hydrophobic, as they possess few polar moieties. For example, 
β-amyrin has a single hydroxyl group and is otherwise non-polar. Such triterpenes are 
well suited to GC-MS analysis, as they are thermostable and can be easily vaporised 
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under high temperatures. Prior to analysis, triterpenoids are typically derivatised by 
trimethylsilylation, where a trimethylsilyl (TMS) group reacts with the reactive groups 
(e.g. hydroxyl or carboxyl) of the triterpenoid, preventing hydrogen-bonding and 
increasing volatility. The hard ionisation method used during GC-MS analysis results 
in extensive fragmentation of the triterpenoid. A key fragmentation that occurs for 
many triterpenoids is the retro Diels-Alder (rDA) reaction, which results in cleavage of 
the triterpenoid across the C-ring to produce two fragments (Figure 3.2) (Budzikiewicz 
et al., 1963). Further fragmentation generates an information-rich mass spectrum that 
facilitates compound identification. 
Triterpenoids that have been oxygenated or glycosylated by tailoring enzymes contain 
an increased number of reactive groups, and the hydrogen-bonds they form reduce 
volatility, complicating GC-MS analysis. Although derivatisation can be used to 
increase volatility, oxidised triterpenoids have more sites that must react with the 
derivatising agent. For highly oxidised triterpenoids that possess many reactive 
groups, complete derivatisation can be difficult, prohibiting analysis by GC-MS. 
Furthermore, glycosylated triterpenoids (saponins) are not thermostable, and 
decompose to lose their sugar moieties under high temperatures. As such, saponins 
and highly oxidised triterpenoids are not suitable for GC-MS analysis, and LC-MS 
must be performed instead. The soft ionisation techniques employed by LC-MS 
instruments result in far less fragmentation of the triterpenoid compared with GC-MS, 
and notably do not cause rDA fragmentation. The resulting mass spectra therefore 
provide less information about the triterpenoid. As such, techniques like LC-MS/MS 
are often employed to allow identification of the triterpenoid or saponin. 
In summary, GC-MS is best suited for the analysis of hydrophobic non-glycosylated 
triterpenoids, while saponins and highly oxidised triterpenoids are better analysed by 
LC-MS. Generally, GC-MS is preferable because the more complex fragmentation 
patterns facilitate compound identification. However, the high polarities and 
thermolability of saponins necessitates the use of LC-MS for their analysis. As such, 
GC-MS was chosen to monitor the production of β-amyrin, its C-28 derivatives and 
ergosterol, which are all largely hydrophobic (Figure 3.1), while LC-MS was used to 
monitor saponin production. 




Figure 3.2. Retro Diels-Alder fragmentation of β-amyrin and its C-28 oxygenated 
derivatives under electron ionisation (EI). The rings are labelled, as are carbons 3 and 28. 
C* refers to the fragmented C-ring. 
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3.3 Interpreting triterpenoid chromatograms and 
mass spectra generated by GC-MS 
Following GC-MS analysis, analytes can be identified based on their retention times 
and mass spectra. The retention time is determined by how strongly the analyte 
interacts with the stationary phase, which is a liquid adsorbed to the column. Polar 
analytes interact more strongly with the column and so tend to elute later (i.e. have 
longer retention times), while hydrophobic analytes elute earlier. Thus, in the analysis 
of triterpenoids, simple triterpenes such as β-amyrin should elute earlier, while their 
oxidised derivatives should elute later (Figure 3.3). 
As stated above, GC-MS uses hard ionisation techniques such as electron ionisation 
(EI), which cause extensive fragmentation of the analyte. EI was used in the current 
study and causes the analyte to lose an electron, generating a radical cation called 
the parent ion. This can be identified in the mass spectrum as an ion with a mass-to-
charge ratio (m/z) that is approximately the same as the molecular weight of the 
analyte. The parent ion can then fragment further, producing a characteristic mass 
spectrum. Each fragmentation produces a neutral and a charged fragment, the latter 
being called a fragment ion. For analytes that fragment easily, the parent ion is often 
in low abundance compared to the fragment ions. Only ions can be detected by the 
mass spectrometer, so the neutral fragments are not observed in the mass spectrum. 
Trimethylsilylation of the triterpenoids increases their molecular weight by 72 Da for 
each TMS group added. The parent ion therefore has a correspondingly higher m/z 
value. For example, β-amyrin has a single hydroxyl group and so its molecular weight 
increases from 426 Da to 498 Da after derivatisation. The parent ion thus has an m/z 
of 498 (Table 3.1). Triterpenoids with multiple reactive groups, such as oleanolic acid, 
gain multiple TMS groups, resulting in higher m/z values for the parent ion. 
Pentacyclic triterpenoids with a C-12/C-13 double bond, such as β-amyrin and its 
derivatives, undergo rDA fragmentation after ionisation (Figure 3.2). Here, the C-ring 
is cleaved to produce two fragments: the dienophile, consisting of the ABC* rings, and 
the diene, consisting of the C*DE rings (where C* means a part of ring C) 
(Budzikiewicz et al., 1963). For the most part, the diene retains the charge, while the 
dienophile is neutral and is therefore not observed in the mass spectrum 
(Budzikiewicz et al., 1963). Additional fragmentations include the loss of methyl 
groups from the parent or fragment ions, and the loss of TMS groups, which can  




Figure 3.3. Effect of triterpenoid polarity on retention time. Shown is a total ion 
chromatogram (TIC) of β-amyrin, erythrodiol and oleanolic acid standards generated by GC-
MS. β-amyrin, where C-28 is a methyl group (labelled) elutes first, followed by erythrodiol 
(hydroxyl at C-28) and oleanolic acid (carboxyl at C-28). 
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be accompanied by the loss of the hydroxyl and/or carboxyl groups to which they are 
conjugated. A prominent peak with an m/z of 73 is present in all mass spectra, and 
corresponds to [TMS]•+ ions that have been lost from the triterpenoid. Theoretical 
triterpenoid fragmentation patterns are shown in Table 3.1. 
For β-amyrin, the diene is the most abundant ion and has an m/z of 218 (Figure 3.4 
A). It is accompanied by two additional fragment ions with m/z values of 203 and 189. 
The former likely derives from the loss of a methyl group (15 Da) from the diene, while 
the latter may be due to the loss of the C-28 methyl, the C-17 carbon (of which the C-
28 methyl is a substituent) and two accompanying hydrogens (29 Da total) 
(Budzikiewicz et al., 1963). The dienophile also has an m/z of 189 but as stated above, 
this is typically a neutral fragment so is unlikely to contribute much signal to the mass 
spectrum (Budzikiewicz et al., 1963). In addition, loss of TMSOH (at the C-3 hydroxyl 
position; 90 Da) from the parent ion (m/z 498) generates a fragment ion with an m/z 
of 408, and further loss of a methyl group gives a fragment ion with an m/z of 393. 
However, these ions are in low abundance, and the mass spectrum is dominated by 
the diene and its fragment ions (m/z 218, 203 and 189). The diene does not contain 
a TMS group, so loss of TMSOH is not observed from the rDA fragments. 
Because erythrodiol possesses a hydroxyl group at C-28, its diene contains a TMS 
group and therefore has an m/z of 306 (Figure 3.4 B). However, this is in very low 
abundance, with loss of TMSOH (90 Da) from the diene producing a fragment ion with 
an m/z of 216, which is the most abundant ion. This fragment ion is characteristic of 
β-amyrin derivatives containing a single hydroxyl group in their diene fragment 
(Yasumoto et al., 2016). Loss of the entire C-28 group (TMSOCH2; 103 Da) gives an 
m/z of 203, and further loss of the C-17 carbon and two accompanying hydrogens (14 
Da) gives an m/z of 189. These are equivalent to the 203 and 189 m/z fragment ions 
for β-amyrin. A peak of m/z 188 with a similar abundance to the m/z 189 peak is 
possibly explained by loss of TMSOCH2 and a methyl group (103 and 15 Da) from the 
diene. The erythrodiol parent ion (m/z 586) and a fragment ion corresponding to the 
loss of a methyl group from the parent (m/z 571) are in low abundance. However, an 
ion with an m/z of 496, corresponding to the loss of TMSOH from the parent ion, is far 
more abundant. This contrasts with β-amyrin, whose abundant fragment ions appear 
to be derived from the rDA reaction. In addition, low abundance fragment ions  
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β-amyrin 426 498, parent ion (M+) (+TMS, -H) 
  483, M+ -CH3 
  408, M+ -TMSOH 
  393, M+ -TMSOH, -CH3 
  218, C*DE rings of M+ (diene) 
  203, C*DE rings of M+ -CH3 
  189, C*DE rings of M+ -CH3 at C28, -C at C17, -2H 
   
Erythrodiol 442 586, parent ion (M+) (+ 2TMS, - 2H) 
  571, M+ -CH3 
  496, M+ -TMSOH 
  481, M+ -TMSOH, -CH3 
  406, M+ -2 TMSOH 
  391, M+ -2 TMSOH, -CH3 
  306, C*DE rings of M+ (diene) 
  216, C*DE rings of M+ -TMSOH 
  203, C*DE rings of M+ -TMSOCH2 
  189, C*DE rings of M+ -TMSOCH2, -C at C17, -2H 
  188, C*DE rings of M+ -TMSOCH2, -CH3 
   
Oleanolic  440 512, parent ion (M+) (+TMS, -H) 
aldehyde  497, M+ -CH3 
  232, C*DE rings of M+ (diene) 
  203, C*DE rings of M+ -CHO 
  189, C*DE rings of M+ -CHO, -C at C17, -2H 
   
Oleanolic  456 600, parent ion (M+) (+2TMS, -2H) 
acid  585, M+ -CH3 
  482, M+ -TMSCOOH 
  320, C*DE rings of M+ (diene) 
  203, C*DE rings of M+ -TMSCOO 
  202, C*DE rings of M+ -TMSCOOH 
  189, C*DE rings of M+ -TMSCOOH, -C at C17, -2H 
   
Ergosterol 396 468, parent ion (M+) (+TMS, -H) 
  453, M+ -CH3 
  378, M+ -TMSOH 
  
363, M+ -TMSOH, -CH3 
337, A*BCD rings of M+ 
253, M+ -TMSOH, -C9H17 
131, A* ring of M+ 
   
Coprostanol 388 460, parent ion (M+) (+TMS, -H) 
  445, M+ -CH3 
  370, M+ -TMSOH 
    355, M+ -TMSOH, -CH3 
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with m/z values of 481 and 406 can be observed. The former may be explained by 
the loss of a methyl group from the m/z 496 fragment, and the latter by the loss of two 
TMSOH groups from the parent ion (m/z 586 – 180). A peak with an m/z of 391 is 
consistent with the loss of a methyl group from the m/z 406 fragment ion.  
Oleanolic aldehyde contains an aldehyde at the C-28 position, and this group is not 
trimethylsilylated because it lacks a reactive oxygen. The oleanolic aldehyde diene 
therefore lacks a TMS group and has an m/z of 232 (Figure 3.4 C). The diene gives 
a small peak, while fragment ions with m/z values of 203 and 189, which are 
equivalent to those from β-amyrin and erythrodiol, are more abundant. The parent ion 
(m/z 512) is in very low abundance, as is a fragment corresponding to the loss of a 
methyl from the parent ion (m/z 497). A small peak with an m/z of 483 was also 
observed, and may result from the loss of the aldehyde group (29 Da) from the parent 
ion. Similar to β-amyrin, the low abundance of ions that do not derive from rDA 
fragmentation indicates that this reaction goes almost to completion. 
Oleanolic acid has a carboxyl at C-28 and its diene therefore contains a TMS group, 
giving it an m/z of 320 (Figure 3.4 D). The oleanolic acid diene is more abundant than 
for erythrodiol and has a noticeable peak. However, the most abundant ion has an 
m/z of 203, and corresponds to the loss of TMSCOO (i.e. the TMS group and the 
carboxyl group to which it is attached) from the diene. A slightly less abundant peak 
with an m/z of 202 is possibly due to the loss of an additional hydrogen atom (i.e. loss 
of TMSCOOH), while a fragment ion with an m/z of 189 is equivalent to those 
observed for β-amyrin, erythrodiol and oleanolic aldehyde. The parent ion (m/z 600) 
is in low abundance, and fragment ions corresponding to the loss of a methyl or a 
TMSCOOH group from the parent ion (m/z 585 and 482, respectively) have stronger 
signals. 
In contrast to the above triterpenoids, ergosterol does not have a C-12/C-13 double 
bond (Figure 3.1) and does not appear to undergo rDA fragmentation (Figure 3.4 E). 
Its parent ion is readily apparent (m/z 468), as are fragment ions corresponding to the 
loss of TMSOH from the parent ion (m/z 378) and to the additional loss of a methyl 
group (m/z 363). A weak peak with an m/z of 453 is also observed, and may result 
from the loss of a methyl group from the parent ion. An abundant fragment ion with 
an m/z of 337 may result from fragmentation at the A ring, resulting in the loss of 131 
Da from the parent ion (468 – 131 = 337) (Kenny and Wetzel, 1995). Indeed, a 
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Figure 3.4. Mass spectra of β-amyrin (A), erythrodiol (B), oleanolic aldehyde (C), 
oleanolic acid (D), ergosterol (E) and coprostanol (F). The mass spectra for all analytes 
but oleanolic aldehyde were obtained by analysing authentic standards by GC-MS (1 μl of 50 
ng/μl derivatised standard injected with a 10:1 split). For oleanolic aldehyde, the mass 
spectrum of a putative oleanolic aldehyde peak from strain MD-OA15 (expressing an oleanolic 
acid biosynthesis pathway) is shown. This was obtained by injecting 1 μl of derivatised 
metabolite extract at a 10:1 split. The mass spectrum is consistent with that reported for an 
authentic oleanolic aldehyde standard in the literature (see Fig. S3 of Khakimov et al., 2015). 
The erythrodiol parent ion (m/z 586) and diene (m/z 306) are not labelled as they were not 
detected. 
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fragment ion with an m/z of 131 is also observed, and likely corresponds to the A ring 
fragment (denoted A*). Finally, a fragment ion with an m/z of 253 may result from the 
loss of the aliphatic hydrocarbon chain (125 Da) from the m/z 378 fragment ion. 
Coprostanol, a sterol that is not produced by yeast and was used as an internal 
standard for all GC-MS analyses (see below), also does not appear to undergo rDA 
fragmentation. It has a similar structure to ergosterol, and also lacks a C-12/C-13 
double bond (Figure 3.1). However, in contrast with ergosterol, its parent ion (m/z 
460) is in very low abundance (Figure 3.4 F). In slightly greater abundance is a 
fragment ion with m/z 445, which may result from the loss of a methyl group from the 
parent ion. Similar to ergosterol, it has strong peaks resulting from the loss of TMSOH 
from the parent ion (m/z 370) and the further loss of a methyl group (m/z 355). 
3.4 A GC-MS method to detect triterpenoids 
GC-MS was chosen to monitor the production of non-glycosylated triterpenoids in 
yeast. Indeed, GC-MS is the method of choice to measure triterpenoid production in 
engineered yeast strains (Fukushima et al., 2013; Moses et al., 2014b; Moses et al., 
2014c; Arendt et al., 2017; Miettinen et al., 2017; Zhang et al., 2015; Seki et al., 2011; 
Zhao et al., 2018; Zhu et al., 2018; Dai et al., 2014; Kirby et al., 2008). Metabolites 
are typically extracted one to three times with hexane or ethyl acetate, which favour 
extraction of the largely hydrophobic triterpenoids, and the crude extracts are then 
trimethylsilylated before being injected onto the column for GC-MS analysis 
(Fukushima et al., 2013; Moses et al., 2014b; Moses et al., 2014c; Arendt et al., 2017; 
Miettinen et al., 2017; Zhang et al., 2015; Seki et al., 2011; Zhao et al., 2018; Zhu et 
al., 2018). The trimethylsilylation reaction is usually performed using N-Methyl-N-
(trimethylsilyl)trifluoroacetamide (MSTFA), but incubation times and temperatures 
vary between studies (Fukushima et al., 2013; Moses et al., 2014b; Moses et al., 
2014c; Arendt et al., 2017; Miettinen et al., 2017; Zhang et al., 2015; Seki et al., 2011; 
Zhao et al., 2018). In addition, one study instead used N,O-Bis(trimethylsilyl) 
trifluoroacetamide (BSTFA) (Zhu et al., 2018); it was not clear if the use of BSTFA 
provided any advantage over MSTFA. 
Similar GC columns and GC-MS running parameters were also used in these studies. 
The columns were non-polar with similar stationary phases suitable for the separation 
of triterpenoids: DB-1/DB-1ms (100% dimethylpolysiloxane stationary phase) (Seki et 
al., 2011; Fukushima et al., 2013), DB-5ms (phenyl arylene polymer, equivalent to 
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(5%-Phenyl)-methylpolysiloxane) (Kirby et al., 2008), HP-5/HP-5ms [(5%-phenyl)-
methylpolysiloxane] (Dai et al., 2014; Seki et al., 2011), VF-5ms (5% phenylmethyl) 
(Moses et al., 2014; Moses et al., 2014c; Arendt et al., 2017; Miettinen et al., 2017) 
and Rxi-5Sil MS [1,4-bis(dimethylsiloxy)phenylene dimethyl polysiloxane] (Zhao et al., 
2018; Zhu et al., 2018). Where reported, ionisation was performed by electron 
ionisation (EI) (Moses et al., 2014; Moses et al., 2014c; Arendt et al., 2017; Miettinen 
et al., 2017; Zhao et al., 2018; Dai et al., 2014). Injection temperatures ranged from 
250-300 °C and oven temperatures typically started at 80 °C for 1 min, before being 
ramped to ~ 300 °C at a rate of 20 °C/min and holding at that temperature for 15-30 
min (Fukushima et al., 2013; Seki et al., 2011; Zhao et al., 2018; Dai et al., 2014; Zhu 
et al., 2018). Alternatively, the temperature was ramped to 280 °C, held at 280 °C for 
15-40 min, then ramped again to 300-320 °C (Moses et al., 2014b; Moses et al., 
2014c; Arendt et al., 2017; Miettinen et al., 2017; Zhang et al., 2015; Kirby et al., 
2008). Thus, similar methods to analyse triterpenoids produced by engineered yeast 
are employed across a range of studies. 
A similar method for the analysis of triterpenoids was developed here, with the help 
of Hannah Florance (University of Edinburgh). Initially, a mixture of standards was 
analysed to confirm that they could be detected by GC-MS. These were the 
triterpenoids β-amyrin, erythrodiol and oleanolic acid, and the sterols ergosterol and 
coprostanol, which are structurally similar to the triterpenoids (Figure 3.1). 
Coprostanol is not produced by yeast and was included as an internal standard 
(discussed below). All standards in the mixture were at a concentration of 50 ng/μl, 
except coprostanol, which was at 0.18 mM (70 ng/μl). The standards were also run 
individually to allow each peak in the standards mix to be identified. The dissolved 
standards were evaporated to dryness, derivatised by trimethylsilylation in 50 μl of 
MSTFA:pyridine (4:1), and 1 μl was injected at a 10:1 split, meaning that only 1/11th 
of the sample enters the GC column. The inlet was set to 250 °C, and the oven was 
held at 100 °C for 2 min at the start of the GC program, ramped to 300 °C at a rate of 
25 °C per min, then held at 300 °C for 25 min. Analysis of the total ion chromatograms 
(TICs) revealed distinct and well resolved peaks (Figure 3.5 A) with the expected 
mass spectra for each standard (Figure 3.4), indicating that this is a suitable method 
to monitor triterpenoid production. In addition, peak areas varied depending on the 
analyte (Figure 3.5 A), despite the same concentration of each analyte being injected. 
This indicates that peak areas alone cannot be used to compare the amounts of 
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different analytes. However, use of a standard curve can account for such analyte-
dependent variations in peak area. 
Next, the GC-MS method was applied to analyse a metabolite extract obtained from 
a yeast strain expressing an oleanolic acid biosynthetic pathway (MD-OA15). This 
strain would be expected to produce β-amyrin, erythrodiol, and oleanolic acid, as well 
as oleanolic aldehyde, for which an authentic standard is not available. Cells were 
initially grown for 24 h in glucose-supplemented media, diluted into galactose-
supplemented media to induce gene expression, and grown for 96 h. The cultures 
were washed, resuspended in ethanolic KOH containing 80 nmol/ml coprostanol (the 
internal standard), and lysed by incubating at 100 °C for 10 min. The total lysates 
were extracted twice in 500 μl hexane then twice in 500 μl ethyl acetate to obtain 2 
ml of organic extract. 600 μl of the metabolite extract was vacuum evaporated to 
dryness, derivatised and analysed as described for the standards. This method was 
based on one provided by Thomas Louveau (Anne Osbourn lab, John Innes Centre). 
The expected analytes were observed in the TICs, at the same retention times as the 
corresponding standards (Figure 3.5 B). By contrast, an empty vector control strain 
(MD-N1) produced ergosterol but no detectable triterpenoids (Figure 3.5 B). 
As stated above, an internal standard (IS) was added to the samples at the cell lysis 
step. Using an appropriate IS helps to account for extraction efficiency across 
samples and possible manual errors introduced after its addition to the sample, 
because sample handling variation should affect the peak areas of the IS and analytes 
equally. Internal standardisation is performed by adding a fixed concentration of IS to 
each sample and dividing analyte peak areas by that of the IS, giving normalised peak 
areas. The choice of IS is important, as it should have a similar structure and 
physicochemical properties to the analytes of interest, to ensure that they are 
extracted at similar efficiencies in the solvents used. In this way, any sample handling 
variation should affect the IS and analytes similarly. In addition, the IS should not be 
present naturally in the sample, so that the IS peak area corresponds only to what 
was added to the sample. Coprostanol meets these criteria and has a distinct 
retention time (Figure 3.5 B). By adding coprostanol at the cell lysis step, error 
introduced during metabolite extraction, derivatisation, and GC-MS analysis can be 
accounted for. 
  




Figure 3.5. Initial analysis of triterpenoids by GC-MS. (A) Overlay of total ion 
chromatograms (TICs) of the standards mix used to generate the standard curve, alongside 
individual triterpenoid standards (coprostanol, ergosterol, β-amyrin, erythrodiol and oleanolic 
acid). (B) TIC of MD-OA15 alongside MD-N1 and the standards mix, showing that the 
expected triterpenoids can be detected using the chosen GC-MS method. 
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The combination of solvents used for extraction (hexane and ethyl acetate) was 
chosen to maximise the extraction efficiency for the analytes of interest. In order to 
compare the levels of different triterpenoids in the sample, it is important that they are 
extracted at similar efficiencies. Hexane favours the extraction of more hydrophobic 
compounds, such as β-amyrin, ergosterol and coprostanol, while ethyl acetate 
efficiently extracts oxidised triterpenoids such as erythrodiol, oleanolic aldehyde and 
oleanolic acid. 
3.5 Quantifying triterpenoid production 
GC-MS analysis returns peak areas that are proportional to the concentration of 
analyte in the sample, but do not represent the actual concentration. To calculate the 
concentration of an analyte, a standard curve can be constructed by injecting various 
concentrations of an authentic standard and plotting the resulting peak areas against 
these known concentrations. The concentration of analyte in the sample is then 
calculated by reading the analyte peak area off the linear region of the standard curve. 
Quantification using this method can only be done for analytes for which a standard 
of known concentration can be obtained. The standard does not have to be pure, but 
the peaks of any impurities should not overlap with that of the analyte, and the 
concentration of the standard itself must be known. Nevertheless, high purities are 
desirable to facilitate analysis. If an IS has been added to the samples, it can be 
included in the quantification. In this case, normalised peak areas for the samples are 
calculated by dividing the analyte peak area by that of the IS. The standard curve is 
constructed by mixing a fixed concentration of IS with various concentrations of the 
authentic standard and calculating the normalised peak areas. The normalised peak 
areas from the samples are then read off this standard curve. 
Triterpenoid titres were calculated using the internal standard coprostanol and 
standard curves of authentic standards. A mixture of β-amyrin, erythrodiol, oleanolic 
acid and ergosterol standards was prepared with each standard at the same 
concentration (in ng/μl). Various dilutions of this standard mixture were made and 
coprostanol was added to each to a final concentration of 0.18 mM. The final 
concentrations of analytes ranged from 0 to 120 ng/μl (increasing in increments of 10 
ng/μl). These were made up such that the concentration remained the same after 
evaporation of the solvent and derivatisation in 50 μl MSTFA:pyridine. The 
concentration of coprostanol was lower than that added to samples. During sample 
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preparation, 40 nmol coprostanol is added at the cell lysis step, resulting in a 
concentration of 0.24 mM coprostanol after derivatisation (assuming 100 % extraction 
efficiency and complete derivatisation). However, injection of 0.24 mM coprostanol 
standard resulted in a saturated peak (Figure 3.6), which would cause inaccuracies if 
used for quantification. By contrast, the coprostanol peak in the samples is not 
saturated (Figure 3.6). This can be explained by losses of coprostanol during sample 
extraction, leading to less coprostanol being injected onto the column than would 
otherwise be expected. Therefore, 0.18 mM coprostanol was used in the standard 
curve. This gave a similar peak area to the coprostanol in the samples and was not 
saturated (Figure 3.6). 
The standards were derivatised and GC-MS analysis was performed by injecting 1 μl 
with a 10:1 split. Because the concentration of coprostanol in the standard curve was 
lower than in the samples, the coprostanol peak areas in the standard curve were 
multiplied by 4/3 (equal to 0.24 mM / 0.18 mM) to account for this difference, giving a 
corrected coprostanol peak area. For each concentration of standard, the peak area 
from the TIC was normalised to the corrected coprostanol peak area and used to 
construct a standard curve of normalised peak areas against the amount of standard 
on the column (ng). The amount of standard on the column can be calculated as: 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑜𝑛 𝑐𝑜𝑙𝑢𝑚𝑛 (𝑛𝑔) =
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑛𝑔/𝜇𝑙) × 𝐼𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 (𝜇𝑙)
𝑆𝑝𝑙𝑖𝑡 𝑓𝑎𝑐𝑡𝑜𝑟
 
where concentration refers to the concentration of analyte injected, and the split factor 
is simply the dilution factor due to the split. For a split ratio of A:B, the split factor is A 
+ B. Thus, for a split ratio of 10:1, the split factor is 11. A straight line was fit to the 
linear region of each standard curve (Figure 3.7), and used to calculate titres. For β-
amyrin and erythrodiol, the linear region ranged from 0.91 to 10.9 ng on the column, 
which would correspond to sample titres of 1.7 to 20.0 mg/L. The linear region for 
ergosterol and oleanolic acid ranged from 1.82 to 9.09 ng, corresponding to sample 
titres of 3.3 to 16.7 mg/L. 
  




Figure 3.6. Injection of 0.24 mM coprostanol gives a saturated peak. Analysis of TICs 
shows that injection of 0.24 mM coprostanol (1 μl, 10:1 split) gives a saturated peak, while 
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To calculate sample titres, derivatised samples are injected at 1 μl volume with a 10:1 
split and normalised peak areas for each analyte are calculated. These are converted 
to the amount of analyte on the column using the following equation for the 
appropriate standard curve: 




where 𝑃𝐴𝑠𝑎𝑚𝑝 is the peak area of the analyte in the sample, and 𝑐 and 𝑚 are the 
intercept and slope of the straight line from the standard curve. The amount of analyte 
on the column can be converted to a titre (expressed as milligram of analyte per litre 
of culture, or mg/L) using the following equation: 




Multiplying the amount of analyte on the column by the split factor gives the amount 
of analyte injected, and because the injection volume was 1 μl, multiplying by 50 gives 
the amount of analyte in the 50 μl of derivatisation mixture. This is equal to the amount 
of analyte in 600 μl crude extract, which is the volume of extract that was evaporated 
and derivatised. Because a total of 2 ml crude extract was obtained for each sample, 
we then multiply by 2000/600 to obtain the amount of analyte in the total extract. This 
is equal to the amount of analyte (ng) extracted from 1 ml of culture, i.e. the titre in 
ng/ml. Dividing by 1000 converts this to mg/L. 
It is important that the sample peak area falls within the linear region of the standard 
curve, otherwise titres cannot be reliably calculated. For peak areas that fall outside 
of this range, the sample can be injected at a different split to ensure that the peak 
area falls within the linear region. In this case, the peak area of the analyte from the 
new split is normalised to the coprostanol peak area from the same sample injected 
at the 10:1 split. This is equivalent to changing the concentration of the analyte in the 
sample while keeping the concentration of coprostanol the same. A sample analyte 
that falls above the linear region should be injected at a higher split (greater dilution), 
and an analyte that falls below this region is injected at a lower split. 
  




Figure 3.7. Standard curves of ergosterol (A), β-amyrin (B), erythrodiol (C) and 
oleanolic acid (D). Standard curves were generated by injecting various concentrations of a 
triterpenoid standards mix (ergosterol, β-amyrin, erythrodiol and oleanolic acid), each with the 
same concentration of the internal standard coprostanol (0.18 mM). Injections were 1 μl 
volume at a 10:1 split. Triterpenoid concentrations were from 0 to 120 ng/μl (increasing in 
increments of 10 ng/μl). The amount of triterpenoid on the column is equal to the concentration 
divided by 11 (the split factor), so ranges from 0 to 10.9 ng. Each concentration of standards 
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3.6 Discussion 
A GC-MS method to monitor the production of triterpenoids in engineered yeast has 
been presented. This method is similar to previous methods for measuring 
triterpenoid production reported in the literature (Fukushima et al., 2013; Moses et al., 
2014b; Moses et al., 2014c; Arendt et al., 2017; Miettinen et al., 2017; Zhang et al., 
2015; Seki et al., 2011; Zhao et al., 2018; Zhu et al., 2018; Dai et al., 2014; Kirby et 
al., 2008). Metabolites were extracted using hexane and ethyl acetate, which are both 
commonly used to extract triterpenoids (Fukushima et al., 2013; Moses et al., 2014b; 
Moses et al., 2014c; Arendt et al., 2017; Miettinen et al., 2017; Zhang et al., 2015; 
Seki et al., 2011; Zhao et al., 2018; Zhu et al., 2018) and, based on their chemical 
structures, should favour the extraction of the non-polar triterpenoids. The crude 
extracts were derivatised by trimethylsilylation using a mixture of MSTFA and pyridine 
and incubating for 30 min at 37 °C. Previous studies have typically derivatised 
triterpenoid extracts by trimethylsilylation, using either MSTFA alone or a mixture of 
MSTFA and pyridine (Fukushima et al., 2013; Moses et al., 2014b; Moses et al., 
2014c; Arendt et al., 2017; Miettinen et al., 2017; Zhang et al. 2015; Seki et al., 2011; 
Zhao et al., 2018); where reported, incubations were either at room temperature for 
15 min or at 80 °C for 30 min (Moses et al., 2014b; Zhang et al, 2015; Seki et al., 
2011). 
In addition, GC-MS analysis was performed similarly to that reported in the literature. 
The column used was the non-polar DB-5ms column, which uses a phenyl arylene 
polymer stationary phase – equivalent to (5%-phenyl)-methylpolysiloxane – and has 
been used previously for the analysis of triterpenoids (Kirby et al., 2008; Zhang et al., 
2015). Other studies have used similar non-polar columns, for example the HP-5 and 
HP-5ms columns which use a (5%-phenyl)-methylpolysiloxane stationary phase (Dai 
et al., 2014; Seki et al., 2011), the DB-1 and DB-1ms columns which have a 100% 
dimethylpolysiloxane stationary phase (Fukushima et al., 2013; Seki et al., 2011), and 
the VF-5ms column which has a 5% phenylmethyl stationary phase (Moses et al., 
2014b; Moses et al., 2014c; Arendt et al., 2017; Miettinen et al., 2017). As with 
previous studies (Moses et al., 2014b; Moses et al., 2014c; Arendt et al., 2017; 
Miettinen et al., 2017; Zhao et al., 2018; Dai et al., 2014), electron ionisation (EI) was 
used to ionise the metabolites, and the injection temperature was 250 °C (compared 
with 250-300 °C used in previous studies) (Fukushima et al., 2013; Moses et al., 
2014b; Moses et al., 2014c; Arendt et al., 2017; Miettinen et al., 2017; Zhang et al., 
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2015; Seki et al., 2011; Zhao et al., 2018; Dai et al., 2014; Zhu et al., 2018). The oven 
temperatures were also similar to those described previously, starting at 100 °C for 2 
min before being ramped to 300 °C at a rate of 25 °C/min then being held at 300 °C 
for 25 min. Previous studies have used an 80 °C starting temperature for 1 min, 
followed by a ramp to 290-300 °C at a rate of 20 °C/min then holding at that 
temperature for 15-30 min (Fukushima et al., 2013; Seki et al., 2011; Zhao et al., 
2018; Dai et al., 2014; Zhu et al., 2018). 
It is difficult to compare the quantification method described here with those used in 
previous studies, as the precise method of quantification is often not described in 
detail (Moses et al., 2014b; Arendt et al., 2017; Kirby et al., 2008; Zhao et al., 2018). 
In the present method, sample peak areas were first normalised to that of the internal 
standard (IS) coprostanol before being compared to a standard curve of an authentic 
triterpenoid standard (also normalised to coprostanol) to calculate titres. As described 
earlier, use of an IS can account for variation introduced after its addition to the 
sample, facilitating comparison between different samples. Dai et al. (2014), Zhang 
et al. (2015), and Zhu et al. (2018) did not used an IS to quantify triterpenoid 
production, instead using only authentic standards. However, it was not clear if a 
standard curve was used or whether sample peak areas were compared to that of a 
single concentration of the standard.  
While Kirby et al. (2008) used an IS, it was unclear if this was used as part of the 
quantification procedure, which involved the use of a standard curve to quantify β-
amyrin production. The IS used was cholesterol rather than coprostanol, which is 
structurally similar to coprostanol and is also not produced by yeast, making it a 
suitable IS. Due to their similar structures, both cholesterol and coprostanol are likely 
to perform similarly as internal standards, although this was not tested in the present 
study. Several other studies also used cholesterol as an IS (Moses et al., 2014c; 
Arendt et al., 2017; Miettinen et al., 2017). Moses et al. (2014c) and Miettinen et al. 
(2017) normalised triterpenoids to the IS to allow comparison between different 
strains, but neither quantified production. Meanwhile, Arendt et al. (2017) used a 
standard curve of hederagenin to quantify medicagenic acid titres, however, it was 
unclear if the IS was used in these calculations. In addition, the use of a hederagenin 
standard to quantifiy medicagenic acid production may cause inaccuracies; it was 
observed above (Figure 3.5 A) that different triterpenoids can give different peak 
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areas when run at the same concentration. Thus, the standard used for quantification 
should ideally match the metabolite being quantified. 
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Chapter 4: Comparison of β-amyrin Synthases 
4.1 Introduction 
Beta-amyrin is one of the most widespread triterpenes and is produced by many 
plants (Hoshino, 2017; Vincken et al., 2007). Numerous enzymes that act on β-amyrin 
and its derivatives have been identified, and the biosynthesis of β-amyrin-derived 
triterpenoids (oleanane triterpenoids) is relatively well characterised. The oleanane 
triterpenoids contain numerous bioactive molecules that are of commercial and 
medical interest. These include triterpenoids that act as feeding deterrents towards 
plant pests (e.g. hederagenin cellobioside) (Nielsen et al., 2010; Augustin et al., 
2012), serve as vaccine adjuvants (QS-21) (Ragupathi et al., 2011; Didierlaurent et 
al., 2017) or have anti-cancer activities (hederacolchiside A) (Bang et al., 2005). 
Indeed, oleanane triterpenoids and their derivatives have been evaluated in clinical 
trials for leukaemia, chronic kidney disease, Friedreich’s ataxia, and in a vaccine 
against malaria (Tsao et al., 2010; Moses et al., 2013; Strawser et al., 2017; Gosling 
and von Seidlein, 2016; Mahmoudi and Keshavarz, 2017). For more information, see 
section 1.2 and Figure 1.6. 
Although oleanane triterpenoids are of great industrial and medical interest, their 
commercial exploitation is currently hindered due to the difficulty in obtaining them in 
sufficiently high quantities. Plants typically produce low quantities of triterpenoids and 
are often not amenable to large-scale cultivation, making this method of production 
uneconomical. Furthermore, although chemical synthesis has proved effective for the 
production of a range of molecules, the complex structures of triterpenoids precludes 
their effective chemical synthesis. By contrast, the microbial production of 
triterpenoids, in which the plant biosynthetic pathways are expressed in a selected 
microorganism, has potential for the industrial production of triterpenoids. The yeast 
Saccharomyces cerevisiae is a particularly promising host, as it naturally produces 
the triterpene precursor 2,3-oxidosqualene, can functionally express plant 
cytochromes P450, and has been successfully employed to produce triterpenoids 
(Moses et al., 2014b; Fukushima et al., 2013; Arendt et al., 2017; Miettinen et al., 
2017). 
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The relatively well characterised pathways and the numerous bioactive molecules 
makes the oleananes excellent candidate triterpenoids for production in yeast. The 
monofunctional OSC responsible for β-amyrin biosynthesis (Figure 4.1) is β-amyrin 
synthase (BAS), many homologues of which have been identified from diverse plant 
species (Thimmappa et al., 2014); several multifunctional OSCs are also known to 
produce β-amyrin (Ghosh, 2016). When engineering yeast to produce oleanane 
triterpenoids, no studies have systemically compared the productivities of BASs when 
expressed in yeast. Instead, an arbitrary BAS variant is usually chosen (Fukushima 
et al., 2013; Kirby et al., 2008; Madsen, 2011; Seki et al., 2011; Miettinen et al., 2017). 
However, the choice of homologue can have a large impact on productivity. Indeed, 
Moses et al. compared GgBAS (from Glycyrrhiza glabra) and MtBAS (from Medicago 
truncatula) in yeast and obtained ~ 2-fold higher β-amyrin titres from the strain 
expressing GgBAS (Moses et al., 2014b). Similarly, Dai et al. observed ~ 50-fold 
higher titres for GgBAS compared with PgBAS1 (from Panax ginseng) when 
expressed in yeast (Dai et al., 2014).  
To optimise this critical step in triterpenoid biosynthesis, twelve BAS homologues 
(Table 4.1) were compared for β-amyrin production in the haploid S. cerevisiae strain 
BY4741. The chosen BASs represent those most commonly used in metabolic 
engineering studies as well as several others. These included MtBAS, GgBAS, 
PgBAS1 and AaBAS, for which β-amyrin titres have previously been reported in yeast 
expressing these BASs. Moses et al. reported β-amyrin titres of 19 mg/L and 36 mg/L 
for MtBAS and GgBAS, respectively (Moses et al., 2014b), while Dai et al. reported 
β-amyrin titres of 107 mg/L when using GgBAS (Dai et al., 2014). PgBAS1 showed 
lower productivity, producing only 1.9 mg/L in the system used by Dai et al., 2014. 
 
Figure 4.1. Cyclisation of 2,3-oxidosqualene to β-amyrin by a β-amyrin synthase (BAS). 
 
Chapter 4: Comparison of β-amyrin Synthases 
 91 
AaBAS was used in the first reported production of β-amyrin in yeast, with titres of 6 
mg/L being reported (Kirby et al., 2008). Notably, these yeast strains were 
metabolically engineered to enhance triterpenoid production, so the titres achieved 
by expressing a BAS alone may be lower. In addition to these BASs, seven other 
characterised BASs for which β-amyrin titres had not been reported (AsBAS, BvBAS, 
CqBAS1, EtBAS, LjBAS, PtBAS and SlBAS) were also chosen to ensure good 
coverage across species. Finally, an additional BAS was newly identified from 
Gossypium hirsutum (upland cotton) and functionally characterised. 
Beta-amyrin production was quantified using GC-MS, and growth curves were 
recorded using a microplate assay to determine if BAS expression caused any 
detrimental effects on cell growth rate. The enzyme sequences were then analysed 
to investigate if the observed differences in activity could be explained by amino acid 
variants. 
4.2 Discovery and characterisation of a specific β-
amyrin synthase from Gossypium hirsutum 
An initial investigation was undertaken to identify additional monofunctional β-amyrin 
synthase (BAS) homologues. A BLASTp search was performed on NCBI with default 
parameters against the non-redundant database, using a previously characterised 
monofunctional BAS from Glycyrrhiza glabra (GgBAS) as the query sequence. This 
returned 100 hits with amino acid sequence identities to GgBAS > 80 %, the majority 
of which were annotated as predicted BASs, but some predicted multifunctional OSCs 
and other triterpene synthases were also present. Two predicted monofunctional 
BASs were selected for analysis: GhBAS from Gossypium hirsutum (upland cotton) 
(XP_016749748) and TcBAS from Theobroma cacao (cocoa tree) (XP_017979420). 
Both had high sequence identities to previously characterised BASs (> 79 % identity 
to AaBAS, GgBAS, MtBAS and EtBAS) and contained the expected conserved 
residues for a monofunctional BAS (Figure 4.2) (Hoshino, 2017). These included the 
highly conserved DCTAE motif involved in initiation of the cyclisation reaction (Ito et 
al., 2013; Hoshino, 2017), the MWCYCR motif important for product specificity 
(Kushiro et al., 2000), and the QW motifs that are characteristic of OSCs and may be 
important for the stability of the protein (Poralla, 1994; Wendt et al., 1997; Salmon et 
al., 2016). 
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Figure 4.2. Multiple sequence alignment of GhBAS and TcBAS showing selected 
conserved residues. GhBAS and TcBAS were aligned with the previously characterised β-
amyrin synthases AaBAS, GgBAS, MtBAS and EtBAS to determine if they contained the 
conserved residues expected for a β-amyrin synthase. The QW motifs (blue), MWCYCR motif 
(green) and DCTAE motif (red) are highlighted. The concensus is shown under the alignment: 
identical residues are marked by ‘*’, conservative substitutions by ‘.’, and semi-conservative 
substitutions by ‘:’. Protein sequences were aligned using Clustal Omega 
(www.ebi.ac.uk/Tools/msa/clustalo/) with default parameters. AaBAS: Artemisia annua β-
amyrin synthase (BAS) (ACA13386); GgBAS: Glycyrrhiza glabra BAS (BAA89815); MtBAS: 
Medicago truncatula BAS (CAD23247); EtBAS: Euphorbia tirucalli BAS (BAE43642); GhBAS: 
putative Gossypium hirsutum BAS (XP_016749748); TcBAS: putative Theobroma cacao BAS 
(XP_017979420). 
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Triterpenoid biosynthetic pathways have not been reported for either G. hirsutum or 
T. cacao. However, β-amyrin has been reported in Gossypium spp. (Shakhidoyatov 
et al., 1997), suggesting that G. hirsutum may encode a BAS (although it is also 
possible that it instead encodes a multifunctional triterpene synthase that produces 
multiple triterpenes including β-amyrin). While T. cacao has been reported to contain 
triterpenoids and saponins, their identities were not determined (Falade et al., 2005; 
Zainal et al., 2014; Komlaga and Cojean, 2015). Nevertheless, due to the widespread 
occurrence of β-amyrin, it is likely that T. cacao produces this triterpene. 
The GhBAS and TcBAS genes were codon-optimised for S. cerevisiae, synthesised, 
and assembled into a low copy yeast plasmid (CEN6/ARS4) for expression from the 
GAL1 galactose-inducible promoter (pGAL1) (see materials and methods). 
Unfortunately, TcBAS could not be cloned into the MoClo-YTK entry vector; all 
obtained clones contained missense mutations or deletions and TcBAS was therefore 
not analysed. The GhBAS expression plasmid was transformed into S. cerevisiae 
BY4741 (strain MD-BA9; see Chapter 2, List of Yeast Strains) and analysed for β-
amyrin production by thin layer chromatography (TLC). Cells were grown in SC-URA 
+ 2 % D-Glc media for 24 h, then diluted into SC-URA + 2 % D-Gal media to induce 
gene expression and cultured for 96 h. Metabolites were extracted twice with hexane 
and loaded onto a TLC plate for analysis. An authentic β-amyrin standard and an 
extract from a strain carrying an empty vector (MD-N1) were also run as controls. The 
metabolite extraction and TLC methods were based on protocols provided by Thomas 
Louveau (Anne Osbourn lab, John Innes Centre). Several distinct bands were 
observed for MD-BA9, one of which had a similar retention time to the band observed 
for the β-amyrin standard (Figure 4.3). While a band with a similar retention time was 
observed for the control strain, it was much fainter compared with MD-BA9 and the 
intensities of the other bands were similar for both strains, indicating that the amount 
of total metabolite loaded was similar for each strain. Thus, the faint band for MD-N1 
may correspond to a native yeast metabolite. The TLC results therefore indicate that 
MD-BA9 produces β-amyrin. 
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Figure 4.3. Thin layer chromatography (TLC) suggests that GhBAS produces β-amyrin. 
Thin layer chromatography was performed on extracts of MD-BA9 (expressing GhBAS) and 
MD-N1 (empty vector control) and on 0.6 µg β-amyrin standard. A band of the expected size 
for β-amyrin was observed for the strain expressing GhBAS, while MD-N1 had a fainter band 
of this size, suggesting that GhBAS may produce β-amyrin. Control: MD-N1; Standard: 
authentic β-amyrin standard. 
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To confirm β-amyrin production, an extract of MD-BA9 was analysed by GC-MS. By 
comparing the retention time and mass spectrum of the putative β-amyrin peak with 
an authentic standard, this should further verify the presence of β-amyrin in the 
sample. As a positive control, extract from a strain expressing a previously verified 
BAS (GgBAS; strain MD-BA3) was also analysed by GC-MS, together with the 
negative control strain MD-N1 that expressed no BAS. In addition, a mixture of 
authentic triterpenoid standards was analysed. The standards mixture was as 
described before, containing coprostanol, ergosterol, β-amyrin, erythrodiol and 
oleanolic acid (see Chapter 3, section 3.4). Analysis of the total ion chromatograms 
(TICs) showed that MD-BA9 had distinct peaks that corresponded in retention time to 
ergosterol and β-amyrin from the standards mix (Figure 4.4 A). As expected, these 
peaks were also present for MD-BA3, while only the ergosterol peak was observed 
for MD-N1. The putative β-amyrin peak for MD-BA9 was confirmed to be β-amyrin by 
comparison of its mass spectrum with the standard (Figure 4.4 B). As expected, the 
characteristic fragment ions derived from the retro Diels-Alder fragmentation of the 
parent ion (with m/z values of 218, 203 and 189) were present in high abundance, 
while the parent ion and those fragment ions deriving from the loss of TMSOH and/or 
a methyl group from it (with m/z values of 498, 483, 408 and 393) were in low 
abundance. 
All three strains had an additional peak at ~ 21.5 min, as well as some minor peaks 
that were not present in the standards mix (Figure 4.4 A). These likely correspond to 
native yeast metabolites. As expected, no erythrodiol or oleanolic acid were observed 
from the yeast strain extracts. While MD-N1 showed a small peak with a similar 
retention time as the oleanolic acid standard, its mass spectrum was not consistent 
with this triterpenoid. Because this peak was not observed for MD-BA9 or MD-BA3, it 
may derive from carryover of the aqueous phase or emulsion during metabolite 
extraction, which would contain metabolites not present in the organic phase, or from 
uneven extraction or loading across the yeast samples. In summary, the GC-MS 
results confirm that GhBAS is a genuine β-amyrin synthase that specifically produces 
β-amyrin when expressed in yeast. 




Figure 4.4. GC-MS confirming β-amyrin production by GhBAS. (A) Total ion 
chromatograms (TICs) zoomed between 15-22 min from GC-MS analysis of MD-BA9 
(GhBAS), MD-BA3 (GgBAS), MD-N1 (empty vector control) and a mixture of triterpenoid 
standards containing β-amyrin, erythrodiol and oleanolic acid at 50 µg/ml concentration. MD-
BA3 is a positive control that expresses GgBAS, a previously characterised β-amyrin 
synthase. (B) Mass spectra of the β-amyrin peaks for GhBAS and the β-amyrin standard, with 
the m/z values of key ions labelled. Analysis of the TICs and mass spectra confirmed that 
GhBAS produces β-amyrin. Emily Johnston set up the galactose cultures and Tessa Moses 
performed the extractions. 
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4.3 Comparison of β-amyrin synthase homologues 
for β-amyrin production 
A total of twelve BASs were selected for comparison in yeast (Table 4.1). These 
included those previously used in metabolic engineering and yeast expression studies 
(e.g. AaBAS, GgBAS, MtBAS and PgBAS1) (Kirby et al., 2008; Moses et al., 2014b, 
2015b; Dai et al., 2014; Arendt et al., 2017), the newly discovered GhBAS, and seven 
others to ensure good coverage across species. A protein sequence alignment of the 
BASs and other OSCs is shown in Figure 4.5. All BASs shared ≥ 70 % amino acid 
sequence identity except for AsBAS, which had ~ 50 % sequence identity to the other 
BASs (Figure 4.6). Phylogenetic analysis indicated that AsBAS was less closely 
related to the other BASs (Figure 4.7), which is consistent with previous phylogenetic 
analyses (Thimmappa et al., 2014). All of the chosen BASs except AsBAS are from 
dicotyledonous plants, with AsBAS being from the monocotyledon Avena strigosa. 
AsBAS is the only characterised monocot BAS, and is believed to have evolved 
separately from the dicot BASs (Thimmappa et al., 2014; Haralampidis et al., 2001; 
Qi et al., 2004). 
Table 4.1. β-amyrin synthase homologues tested in this study 
BAS Species Accession 
number* 
Reference 
AsBAS Avena strigosa CAC84558.1 Haralampidis et al., 2001 
PgBAS1 Panax ginseng BAA33461.1 Kushiro, Shibuya and 
Ebizuka, 1998 
GgBAS Glycyrrhiza glabra BAA89815.1 Hayashi et al., 2001 
LjBAS Lotus japonicus BAE53429.1 Iturbe-Ormaetxe et al., 
2003 
EtBAS Euphorbium tirucalli BAE43642.1 Kajikawa et al., 2005 
PtBAS Polygala tenuifolia ABL07607.1 Jin et al., 2014 
GhBAS Gossypium hirsutum XP_016749748.1 The present study 
AaBAS Artemisia annua ACA13386.1 Kirby et al., 2008 
BvBAS Barbarea vulgaris AFF27505.1 Wei et al., 2012 
CqBAS1 Chenopodium quinoa ANY30852.1 Fiallos-Jurado et al., 2016 
MtBAS Medicago truncatula CAD23247.1 Suzuki et al., 2002 
SlBAS Solanum lycopersicum ADU52574.1 Wang et al., 2011 
* Note that AaBAS, BvBAS, CqBAS1, MtBAS and SlBAS had an additional ‘GS’ sequence 
at the C-terminus, and CqBAS1 also contained a D196Y mutation. Sequences were 
otherwise identical to those from GenBank. 
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Figure 4.5. Multiple sequence alignment of β-amyrin synthases and other OSCs. Protein 
sequences were aligned using Clustal Omega (www.ebi.ac.uk/Tools/msa/clustalo/) (Sievers and 
Higgins, 2018) with default parameters. Conserved sequences are highlighted. Red: DCTAE motif and 
hydrogen-bonded Cys; green: MWCYCR motif; blue: QW motifs; orange: other conserved residues 
(numbered relative to EtBAS). The concensus is shown under the alignment: identical residues are 
marked by ‘*’, conservative substitutions by ‘.’, and semi-conservative substitutions by ‘:’. The BASs 
tested in the present study are highlighted (see Table 4.1 for accession numbers). ScErg7: S. cerevisiae 
lanosterol synthase (NP_011939); HsLAS: Homo sapiens lanosterol synthase (AAC50184); AtCAS1: 
Arabidopsis thaliana cycloartenol synthase (NP_178722); OEW: Olea europaea lupeol synthase 
(BAA86930); LjAMY2: Lotus japonicus multifunctional lupeol/β-amyrin synthase. The sequences of 
AaBAS, BvBAS, MtBAS and SlBAS contained an additional ‘GS’ sequence at the C-terminus due to the 
modular DNA assembly platform used (MoClo-YTK) (Lee et al., 2015) but were otherwise identical to 
those from GenBank. The CqBAS1 sequence included this C-terminal ‘GS’ and had a D196Y mutation 
(highlighted dark red; see main text). 
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Figure 4.6. Percent identity matrix of BAS sequence identities. Protein sequences were 
aligned using ClustalOmega (www.ebi.ac.uk/Tools/msa/clustalo/) (Sievers and Higgins, 
2018) with default parameters to obtain a percent identity matrix (PIM). All proteins except 
BvBAS and AsBAS had sequence identities > 75 %. For accession numbers see Table 4.1.  
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Figure 4.7. Phylogenetic analysis of β-amyrin synthases (BASs) and other 
oxidosqualene cyclases (OSCs). The phylogenetic tree was generated from protein 
sequences by using the maximum likelihood method and bootstrapping for 1000 replicates. 
Bootstrap values (%) are displayed at each node. The BASs tested in the present study are 
highlighted green (see Table 4.1 for accession numbers), and the function of each OSC is 
annotated. The scale bar represents the number of substitutions per site. AtBAS (LUP4): 
Arabidopsis thaliana β-amyrin synthase (NP_178016.2); AeBAS: Aralia elata β-amyrin 
synthase (ADK12003.1); AseBAS (OXA1): Aster sedifolius β-amyrin synthase (AAX14716.1); 
BcBAS: Bupleurum chinense β-amyrin synthase (ABY90140.2); BgBAS: Bruguiera 
gymnorrhiza β-amyrin synthase (BAF80443.1); BpBAS (BPY): Betula platyphylla β-amyrin 
synthase (BAB83088.1); GsBAS1: Gentiana straminea β-amyrin synthase (ACO24697.1); 
GsBAS2: G. straminea β-amyrin synthase (AHX97777.1); MlBAS: Maesa lanceolata β-amyrin 
synthase (AHF49822.1); NsBAS: Nigella sativa β-amyrin synthase (ACH88048.1); PgBAS2 
(PNY2): Panax ginseng β-amyrin synthase (BAA33722.1); PsBAS (PSY): Pisum sativum β-
amyrin synthase (BAA97558.1); VhBAS: Vaccaria hispanica β-amyrin synthase 
(ABK76265.1); AtLUP1: A. thaliana Multifunctional triterpene synthase (NP_178018.1); 
LjAMY2: Lotus japonicus Multifunctional β-amyrin/lupeol synthase (AAO33580.1); CrAS: 
Catharanthus roseus Multifunctional a/β-amyrin synthase (AFJ19235.1); OEA: Olea 
europaea Multifunctional triterpene synthase (BAF63702.1); AtLUS1: A. thaliana Lupeol 
synthase (AAD05032.1); BpLUS (BPW): Betula platyphylla Lupeol synthase (BAB83087.1); 
ToLUS (TRW): Taraxacum officinale Lupeol synthase (BAA86932.1); OeLUS (OEW): Olea 
europaea Lupeol synthase (BAA86930.1); WsLUS: Withania somnifera Lupeol synthase 
(AGA17939.1); PNA: P. ginseng Dammarenediol-II synthase (BAF33291.1); BARS1: A. 
thaliana Baruol synthase (NP_193272.1); AtPEN1: A. thaliana Arabidiol synthase 
(NP_567462.1); AtMRN1: A. thaliana Marneral synthase (NP_199074.1); THAS: A. thaliana 
Thalianol synthase (NP_001078733.1); AtCAS1: A. thaliana Cycloartenol synthase 
(NP_178722.1); PsCAS: Pisum sativum Cycloartenol synthase (BAA23533.1); PgCAS: P. 
ginseng Cycloartenol synthase (BAA33460.1); GgCAS: Glycyrrhiza glabra Cycloartenol 
synthase (BAA76902.1); WsCAS: Withania somnifera Cycloartenol synthase (ADG60271.1); 
AtLAS1: A. thaliana Lanosterol synthase (NP_001327790.1); LjLAS: L. japonicus Lanosterol 
synthase (BAE95410.1); PNZ1: P. ginseng Lanosterol synthase (BAA33462.1); HsLAS: 
Homo sapiens Lanosterol synthase (AAC50184.1); ScErg7: Saccharomyces cerevisiae 
Lanosterol synthase (NP_011939.2). 
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The BASs were codon-optimised for S. cerevisiae, synthesised, assembled into a low 
copy plasmid (CEN6/ARS4) under the control of the GAL1 promoter, and transformed 
into S. cerevisiae BY4741 (MD-BAX series, see Table 4.1). For clarity, the strains will 
be referred to by the name of the BAS, and not by their strain code. All BASs were 
codon-optimised for S. cerevisiae except AsBAS, which failed gene synthesis and a 
wild-type sequence was used instead (provided by Thomas Louveau, Anne Osbourn 
Lab, John Innes Centre). Initially, correct clones of CqBAS1 could not be obtained, 
and sequencing revealed that the E. coli Tn5 transposon had been inserted into the 
open reading frame. The transposon was removed by PCR and silent mutations were 
introduced to prevent its reinsertion, but all resulting clones contained unintended 
missense mutations. A clone with a D196Y mutation was selected for analysis, as this 
residue is not predicted to be involved in catalysis and has little sequence 
conservation (Figure 4.5). 
The resulting strains and MD-N1 were analysed for β-amyrin production by GC-MS 
as described before. Ergosterol titres and the OD600 at the end of the production run 
(the “final OD600”) were also measured, as they may be affected by BAS expression. 
In addition, growth in both glucose- and galactose-supplemented media was 
monitored using a 96-well microplate assay to determine the effects of BAS 
expression on growth rate. The glucose precultures used for the production runs were 
used to inoculate media in the 96-well plate, and OD595 was read every 15 min for 96 
h in a Tecan Sunrise plate reader. The experiment was repeated three times, each 
with three biological replicates, for a total of nine replicates. 
β-amyrin production varied (Figure 4.8 A). The AaBAS and CqBAS1 strains had the 
highest β-amyrin titres at 10.6 mg/L, while SlBAS and GhBAS produced less at 3.7 
mg/L and 5.9 mg/L, respectively. Notably, PgBAS1 produced very low quantities of β-
amyrin that fell below the linear region of the standard curve, preventing reliable 
calculation of titres. The standard curve can be used to calculate β-amyrin titres down 
to 1.7 mg/L (see Chapter 3), indicating that PgBAS1 produced < 1.7 mg/L β-amyrin. 
Furthermore, the normalised β-amyrin peak area for PgBAS1 was 97-fold lower than 
for AaBAS and CqBAS1 (see Figure 4.14 for the TICs). The final OD600 also varied, 
and negatively correlated with the β-amyrin titre (Figure 4.8 C, Figure 4.9 A). The high 
β-amyrin producers AaBAS and CqBAS1 reached an OD600 of 4.7 and 4.4, 
respectively, while the low producers PgBAS1, GhBAS and SlBAS reached an  
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Figure 4.8. Comparison of β-amyrin synthase productivity in yeast. (A-B) β-amyrin and 
ergosterol titres as measured by GC-MS. (C) OD600 measured at the end of the production 
run (96 h). Titres were divided by the final OD600 to obtain specific titres (mg/L/OD600) for β-
amyrin (D) and ergosterol (E). Strains produced varying amounts of β-amyrin and ergosterol 
and reached different cell densities dependent on the BAS. Specific ergosterol titres were 
fairly consistent across all strains, while specific β-amyrin titres showed large variations. 
Control: MD-N1 (empty vector). *, titre could not be calculated as the peak area fell below the 
linear region of the standard curve. Shown is the mean ± 1 standard deviation for 3 biological 
replicates repeated across three experiments (n = 9). 
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OD600 of 6.7 - 7.6. By comparison, MD-N1 reached an OD600 of 9.0. A striking 
exception to this correlation was AsBAS, which reached an OD600 of 9.2 yet produced 
a relatively large amount of β-amyrin (8.2 mg/L) (Figure 4.9 A). 
Specific β-amyrin titres were calculated by dividing the titre by the final OD600 
(mg/L/OD600). These showed a similar overall pattern to the total β-amyrin titres 
(Figure 4.8 D), although specific titres for AsBAS, GhBAS, BvBAS and SlBAS were 
particularly low because of their high OD600. Thus, while total β-amyrin production was 
relatively high for AsBAS (8.2 mg/L), specific production was low (0.88 mg/L/OD600). 
Similar to total β-amyrin titres, there was also a negative correlation between specific 
β-amyrin titres and final OD600 (Figure 4.9 B) with AsBAS having a higher specific β-
amyrin titre than would be expected for its OD600 (Figure 4.9 B). Overall, it appears 
that BAS expression slows growth, and that the magnitude of this effect increases 
with β-amyrin production. 
Ergosterol titres also varied (Figure 4.8 B), showing a positive correlation with the final 
OD600 (Figure 4.9 C) and a negative correlation with β-amyrin titre (Figure 4.9 E). 
PgBAS1, GhBAS and SlBAS, which produced relatively low amounts of β-amyrin (≤ 
5.9 mg/L), had the highest ergosterol titres of the BAS strains, ranging from 10.7 mg/L 
to 11.8 mg/L. AaBAS and CqBAS1, which had the highest β-amyrin titres, 
accumulated less ergosterol at 7.0 mg/L and 6.8 mg/L, respectively. The ergosterol 
titre could not be accurately calculated for MD-N1 because three replicates lied above 
the linear region of the standard curve. When excluding these replicates the titre was 
calculated as 14.7 mg/L, however this is an underestimate due to the exclusion of the 
replicates with greater peak areas. In addition to reaching a similar OD600 to MD-N1, 
AsBAS had a high ergosterol titre (11.9 mg/L) despite producing a relatively high 
amount of β-amyrin (8.2 mg/L) (Figure 4.9 E). In general, strains expressing BASs 
reached a lower OD600 and accumulated less total ergosterol than MD-N1, with the 
poorer β-amyrin producers (PgBAS1, GhBAS and SlBAS) reaching higher OD600 and 
accumulating more total ergosterol. 
Specific ergosterol titres were similar for all strains (Figure 4.8 E) and did not vary with 
final OD600 or specific β-amyrin titre (Figure 4.9 D, F). Because both ergosterol and β-
amyrin are derived from oxidosqualene, it might be expected that β-amyrin production 
would redirect metabolic flux from ergosterol to β-amyrin biosynthesis, reducing 
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Figure 4.9. Correlations between total and specific titres and the final OD600. Correlations 
between total (A) or specific (B) β-amyrin titres and OD600, total (C) or specific (D) ergosterol 
titres and OD600, β-amyrin and ergosterol titres (E), and specific β-amyrin and ergosterol titres 
(F). Shown is the mean ± 1 standard deviation for 3 biological replicates repeated across 
three experiments (n=9). Lines were fit using R and AsBAS was treated as an outlier for plots 
A, B and E. 
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cellular ergosterol levels. However, the lack of variation in specific ergosterol titres 
indicates that cellular ergosterol levels were similar for all strains, and that BAS 
expression had little or no effect on ergosterol biosynthesis. If flux was being 
redirected to β-amyrin, we would expect an inverse correlation between specific 
ergosterol titres and specific β-amyrin titres, as increased β-amyrin production would 
reduce ergosterol levels. The fact that this was not observed could be because β-
amyrin production was relatively low and that Erg7p, the yeast enzyme that cyclises 
oxidosqualene to lanosterol as part of ergosterol biosynthesis, is known to be highly 
active (Veen et al., 2003). In addition, the ergosterol biosynthetic pathway is tightly 
regulated, which may allow cells to maintain stable amounts of ergosterol under a 
range of conditions (Klug and Daum, 2014; Hu et al., 2017). 
The lack of variation in specific ergosterol titres, combined with the positive correlation 
between total ergosterol and OD600, indicate that the observed variations in ergosterol 
titre are due to differences in growth, rather than depletion of cellular ergosterol levels 
caused by BAS expression. It therefore appears that BAS expression reduces growth 
rate and this in turn reduces total ergosterol titres, explaining the observed 
correlations between β-amyrin titres, ergosterol titres and OD600. 
In general, the growth curves in galactose-supplemented media corroborated the 
OD600 measurements from the production runs (Figure 4.10 A). It should be noted that 
the plate reader gives different OD values to the spectrophotometer that was used to 
measure the OD600 of the production run cultures. As such, relative strain growth can 
be compared but the absolute OD values cannot. When grown in galactose, most 
BAS strains showed a considerable reduction in growth rate and an increased lag 
phase compared with MD-N1, while AsBAS grew at almost the same rate, indicating 
that its expression had little effect on cell growth (Figure 4.10 A). This is particularly 
striking compared to the slow growth rates of most of the other BAS strains, and is in 
agreement with the OD600 data from the production runs. In addition to AsBAS, the 
strains expressing PgBAS1 and BvBAS grew noticeably faster than the others, 
although not as fast as AsBAS. While the growth curves generally agreed with the 
OD600 measurements from the production runs, this was not the case for SlBAS. This 
strain grew very slowly in the plate reader assay and reached the lowest OD595 of the 
strains tested, while in the production run it reached a relatively high OD600. However, 
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Figure 4.10. Growth of BAS strains in a 96-well plate reader assay. Cells were grown in 
media supplemented with either galactose (A) or glucose (B). OD595 was monitored using a 
Tecan Sunrise plate reader, reading every 15 min for 96 h. A variety of growth rates were 
observed in the galactose-supplemented media, while all strains grew similarly in glucose, 
with the empty vector control strain (MD-N1) growing slightly faster. Shown is the mean ± 1 
standard deviation for 3 biological replicates from one experiment. 
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for the remaining strains, the relative OD reached by the end of the growth curve 
agreed well with those from the production run. 
In contrast with the galactose growth curves, all strains grew similarly in glucose-
supplemented media (Figure 4.10 B). MD-N1 had a long lag phase of approximately 
10 h when grown in galactose, whereas this lag phase was much shorter (~ 4 h) when 
grown in glucose. The cells are first grown in glucose-supplemented media before 
being diluted into fresh glucose- or galactose-supplemented media for the plate 
reader assay. This sudden change in carbon source could explain the longer lag 
phase in galactose media, together with the fact that galactose is a poorer carbon 
source for yeast than glucose and that galactose metabolism is repressed in the 
presence of glucose and is activated only upon glucose depletion and in the presence 
of galactose (Timson, 2007). The fact that all strains grew similarly in glucose media 
might be explained by there being little BAS expression under these conditions. 
Indeed, western blots of selected BASs could detect protein after growth in galactose 
but not glucose (Figure 4.11 A). The exception was AsBAS, which was not detected 
after growth in galactose, although RT-PCR confirmed that the AsBAS gene was 
being expressed (Figure 4.11 B). The inability to detect AsBAS by western blot could 
be because the His-tag used for detection was inaccessible, or because it was 
expressed at low levels and was below the limit of detection. 
The reduced growth rates of most BAS strains is quite striking. Some possible 
reasons are expression of the BAS, potential toxicity of β-amyrin, depletion of native 
metabolites such as ergosterol, the formation of toxic side-products by the BAS, or 
misfolding of the BAS leading to a burden on the unfolded protein response in yeast, 
thus affecting growth. As reasoned above, BAS expression does not appear to have 
depleted cellular ergosterol levels. However, depletion of other metabolites and 
cofactors were not monitored and so cannot be ruled out. Differences in BAS 
expression could account for the variation in β-amyrin production as well as the 
differences in growth. Lower expression would be expected to favour growth and 
decrease β-amyrin titres, and would be consistent with the negative correlation 
between β-amyrin titres and OD600. Furthermore, the GAL1 promoter from which the 
BASs are expressed gives very high expression levels, comparable to the constitutive 
TDH3 promoter, which is among the strongest yeast promoters (Lee et al., 2015), and 
expression from this promoter would be expected to cause burden. It is possible that 
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AsBAS is expressed at very low levels, resulting in very similar growth to MD-N1 and 
the inability to detect the protein by western blot. Although it was also expressed from 
the strong GAL1 promoter, poor translation efficiency could nevertheless cause it to 
be expressed poorly. If this were the case, AsBAS would be a highly active enzyme, 
as it produced a relatively large amount of β-amyrin. However, expression levels of 
the BASs would need to be determined to test this hypothesis. 
4.4 BvBAS is a multifunctional OSC 
The total ion chromatogram of BvBAS revealed two additional peaks to β-amyrin, 
eluting at ~ 17.7 min (peak U1) and 19.1 min (U2), which from their mass spectra 
appeared to be triterpenes (Figure 4.12). Although the BASs tested here were 
supposedly monofunctional (producing only β-amyrin), there are numerous 
multifunctional OSCs that produce multiple triterpenes, often including β-amyrin, α-
amyrin, and/or lupeol (Ghosh, 2016). Alpha-amyrin has a very similar structure to β-
amyrin, differing only in the position of a methyl group, while lupeol is a pentacyclic 
triterpene like β-amyrin but with a five-membered E-ring instead of a six-membered 
E-ring (Figure 4.13) (Thimmappa et al., 2014). These three triterpenes are derived 
from sequentially-formed carbocation intermediates during the cyclisation reaction 
Figure 4.11. Analysis of BAS expression by western blot and RT-PCR. Western blots (A) 
and RT-PCR (B) were performed on strains expressing 6xHis-tagged AsBAS, PgBAS1, 
GgBAS, LjBAS, EtBAS and PtBAS. For the western blots, strains were grown in galactose 
(left) or glucose (right), while RT-PCR was performed on strains grown in galactose. All BASs 
but AsBAS were detected by the western blot, while mRNA was detected for all six BASs by 
RT-PCR. The expected molecular weights of the BASs were ~ 87 kDa. Molecular weights for 
the protein and DNA ladders are shown in kDa and bp, respectively. 
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Figure 4.12. BvBAS is a multifunctional OSC producing multiple triterpenes. (A) Total 
ion chromatogram (TIC) overlay of the strains expressing AaBAS, BvBAS and of the MD-N1 
control strain, showing two additional peaks (U1 and U2) observed for BvBAS. Mass spectra 
of peaks U1 (B) and U2 (C), with background spectra (corresponding to 18.104 - 18.398 min 
of each sample) subtracted. Peak U1 may correspond to lupeol based on comparison with a 
published mass spectrum of this triterpene (see Fig. S3 from Khakimov et al., 2015). The 
identity of U2 is unknown but its mass spectrum is consistent with it being a triterpene. 
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(the lupanyl, germanicyl and oleanyl cations for lupeol, α-amyrin and β-amyrin, 
respectively; see Figure 1.3) (Thimmappa et al., 2014). It is therefore possible that 
these additional peaks could correspond to α-amyrin and/or lupeol. 
The mass spectrum of U1 is consistent with lupeol mass spectra reported in the 
literature (e.g. see Fig. S3 from Khakimov et al., 2015). In addition, the sequence of 
BvBAS is consistent with it producing a mixture of triterpenes. Mutational studies of 
PgBAS1 have shown that a W259L mutation in the MWCYCR motif, which is highly 
conserved among BASs, converts it into a multifunctional OSC that produces a 
mixture of lupeol, β-amyrin, and small quantities of other triterpenes (Kushiro et al., 
2000). BvBAS contains this mutation, having TLCYCR instead of MWCYCR (Figure 
4.5). Lupeol synthases (LUSs) have MLCYCR instead of MWCYCR, and a L256W 
mutation in the MLCYCR motif of a LUS from Olea europaea caused it to produce 
mainly β-amyrin, with only small amounts of lupeol observed (Kushiro et al., 2000). 
Thus, the second residue of the MWCYCR motif is critical for product specificity, and 
the presence of a leucine at this position in BvBAS indicates that it is likely to produce 
lupeol. Although BvBAS also differs in the first residue of the MWCYCR motif, having 
Thr instead of Met, this may not be important for product specificity. A PgBAS1 mutant 
containing an MW258IL mutation (having ILCYCR) had a very similar product profile 
to the W259L mutant (having MLCYCR) (Kushiro et al., 2000). 
The identity of peak U2 is unknown, but its mass spectrum is consistent with it being 
a triterpene. It contains ions with m/z values of 498, 483, 408 and 393, which would 
Figure 4.13. Chemical structures of β-amyrin, α-amyrin and lupeol. The rings are labelled 
A through E. β-amyrin and α-amyrin have a 6 membered E-ring while lupeol has a five 
membered E-ring, and β-amyrin and α-amyrin differ in the position of a methyl group at the 
E-ring. 
 
Chapter 4: Comparison of β-amyrin Synthases 
 116 
be consistent with a triterpene parent ion with a single TMS group (m/z 498) and 
fragment ions resulting from the loss of a methyl and/or a TMSOH group from this 
parent ion. Furthermore, the presence of peaks with m/z values of 189 and 203 are 
consistent with rDA fragmentation of a triterpene. Indeed, these peaks are seen in the 
mass spectra of both β-amyrin (e.g. see Figure 4.4 B) and lupeol (see Fig. S3 of 
Khakimov et al., 2015 and the putative lupeol mass spectrum in Figure 4.12 B). 
Kushiro et al. also reported small amounts of butyrospermol and germanicol for the 
PgBAS1 W269L mutant, in addition to β-amyrin and lupeol (Kushiro et al., 2000). 
These are therefore possible candidate identities for U2. Thus, BvBAS is a 
multifunctional triterpene synthase, mainly producing β-amyrin, low amounts of most 
likely lupeol, and an unknown triterpene. 
Because BvBAS produced additional triterpenes, the other BASs were reanalysed to 
determine if they also produced additional products. AsBAS and EtBAS had clear yet 
small peaks with a similar retention time to peak U1 of BvBAS, at ~ 17.7 min (Figure 
4.14). The other BASs also had very small putative peaks with similar retention times, 
but the signal was too weak to determine whether they were genuine peaks or due to 
noise. PgBAS1 had no peak at this position, which might be explained by its low 
activity, preventing any trace products from being detected. Due to the low intensity 
of the peaks, background spectra (~18.6-19.0 min of each sample) were subtracted 
to facilitate analysis of the mass spectra. In general, the mass spectra appeared 
consistent with lupeol, but the low abundance made some difficult to interpret (Figure 
4.14). To confirm lupeol production, a splitless injection would be required to generate 
enough signal to reliably interpret the mass spectra. Lupeol has been reported as a 
co-product of β-amyrin for several OSCs (Ghosh, 2016), and as discussed above, a 
single mutation is enough to convert a BAS into a mixed β-amyrin/lupeol synthase 
(Kushiro et al., 2000). 
It is not surprising that the other BASs may produce additional triterpenes, despite 
most being previously characterised as monofunctional. The cyclisation reaction that 
converts oxidosqualene to a triterpene occurs through many intermediates, and 
termination of the reaction at any one intermediate results in the generation of a 
corresponding triterpene (see section 1.1.2 and Figure 1.3). There are therefore many 
possible triterpenes that can be produced through this reaction. Indeed, 
approximately 150 OSC cyclisation products have been reported to date (Hoshino, 
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Figure 4.14. Additional triterpenes produced by the BASs. Analysis of TICs revealed that 
some BASs also had peaks corresponding to U1 from BvBAS in low abundance. Peaks 
corresponding to U2 were not observed. Inset: mass spectrum of peak U1 from AsBAS, with 
a background spectrum (corresponding to 18.104 – 18.398 min of the sample) subtracted. 
Peak U1 may correspond to lupeol. 
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2017). After cyclisation is initiated by the OSC (through protonation of the epoxide of 
oxidosqualene), the reaction occurs spontaneously, with the OSC acting to block 
unwanted cyclisation pathways to favour the production of the desired triterpene(s) 
(Thimmappa et al., 2014). Thus, the cyclisation reaction intrinsically acts to generate 
a diverse range of triterpenes, and the OSC ensures that one or a few products are 
favoured (Thimmappa et al., 2014). We would therefore expect monofunctional 
OSCs, such as the BASs tested here, to produce small amounts of other triterpenes 
in addition to the favoured one(s). 
4.5 Effect of a catalytically inactive β-amyrin 
synthase on cell burden 
The BAS strains displayed a variety of growth rates, with many growing slowly 
compared to MD-N1, indicating that BAS expression caused significant burden on the 
cells. AaBAS conferred high β-amyrin production and a slow growth rate, while 
AsBAS interestingly had little effect on growth rate yet still produced a relatively large 
amount of β-amyrin. To investigate the cause of this burden, a strain expressing a 
catalytically inactive variant of AaBAS was generated. It was previously reported that 
the D485N mutation in the DCTAE motif of EtBAS completely eliminated catalytic 
activity (Ito et al., 2013). This motif is highly conserved across all OSCs, and the Asp 
residue is responsible for initiating the cyclisation reaction by protonating the epoxide 
group of oxidosqualene (Hoshino, 2017). The equivalent mutation (D484N) was 
introduced into AaBAS to generate the catalytically inactive variant dAaBAS, which 
was transformed into yeast to generate strain MD-dBA14. This strain was cultured for 
GC-MS analysis and growth curves were generated as before. AaBAS, AsBAS and 
MD-N1 (the empty vector control) were also analysed for comparison. 
No β-amyrin or other triterpenoids were observed for dAaBAS in the GC-MS profile, 
indicating that it was indeed catalytically inactive (Figure 4.15 C). Its TIC was very 
similar to MD-N1. By contrast, AaBAS had a distinct peak corresponding to β-amyrin. 
The growth curves showed that in galactose-supplemented media, dAaBAS grew at 
an intermediate rate between AaBAS and MD-N1, and that AsBAS grew similarly to 
MD-N1 as before (Figure 4.15 A). This indicates that the catalytic activity of AaBAS 
may indeed contribute to burden, but the fact that it grew slower than MD-N1 indicates 
that this is not the only cause. As with previous results, all strains grew similarly in 
glucose-supplemented media (Figure 4.15 B). 
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Figure 4.15. Effect on growth of a catalytically inactivated BAS. Strains expressing 
AsBAS, AaBAS, a catalytically inactive AaBAS (dAaBAS) and the control strain MD-N1 were 
grown in galactose (A) or glucose (B) supplemented media. Cells were grown in 96-well 
plates and OD595 was measured every 15 min for 96 h using a Tecan Sunrise plate reader. 
While all strains grew similarly in glucose, a variety of growth rates were observed in 
galactose, with dAaBAS growing at an intermediate rate between AsBAS/MD-N1 and AaBAS. 
Shown are the means of three biological replicates ± 1 standard deviation, except for 
dAaBAS, for which the mean of two biological replicates is shown. (C) Total ion chromatogram 
from GC-MS analysis showing that dAaBAS does not produce β-amyrin. 
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It is possible that the D484N mutation affected the expression level of dAaBAS. A 
reduced expression level would be expected to improve strain growth, and could 
explain the growth phenotype observed here. Indeed, Hoshino et al. report that the 
expression levels of EtBAS mutants were often lower than the wild-type enzyme 
(Hoshino, 2017). They recommended normalising the activity of each enzyme to its 
expression level to account for these differences, which can be done by simply 
dividing the amount of triterpene by the amount of enzyme (Hoshino, 2017). 
Unfortunately, it was not possible to accurately determine the expression levels of the 
BASs. Further work is therefore necessary to thoroughly investigate the burden 
caused by BAS expression. 
4.6 In silico analysis of BASs to explain differences in 
activity 
To further understand the differences in activity and burden caused by the BASs, in 
silico analyses were performed. The multiple sequence alignment (Figure 4.5) 
showed no obvious amino acid variants that might explain the differences in activity. 
The MWCYCR motif was highly conserved amongst all BASs except for BvBAS (see 
above) and AsBAS, which instead had FWCFTR. Kushiro et al. found that mutations 
in the MWCYCR affected the product profile of PgBAS1 (Kushiro et al., 2000). The 
W259L mutation caused PgBAS1 to produce significant amounts of lupeol, while the 
Y261H mutation caused it to produce predominantly dammaranes (tetracyclic 
triterpenes). Kushiro et al. did not measure the expression level of PgBAS1 and so 
their work does not provide information on the overall catalytic activity (in terms of 
total triterpenes produced) of the mutants (Kushiro et al., 2000). AsBAS was 
monofunctional, so of greater interest here are the amino acid variants that may affect 
its overall activity, rather than its product profile.  Nevertheless, it is reasonable that 
the mutations identified by Kushiro et al. might affect the overall activity, so it is worth 
taking this data into account. 
AsBAS has a Phe instead of a Tyr (FWCFTR instead of MWCYCR), however, these 
amino acids are very similar in structure, differing in only a hydroxyl group, and 
therefore may not have a significant effect on activity. Similarly, AsBAS has a Phe 
instead of a Met, both of which are hydrophobic. The MW258IL PgBAS1 mutant had 
a very similar product profile to the W259L mutant, indicating that a mutation at this 
position (at least to a similar amino acid) has little effect on the product ratio (Kushiro 
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et al., 2000). Lastly, AsBAS differs from the MWCYCR consensus at the fifth position, 
having a Thr instead of a Cys. However, a C262S mutation in PgBAS1 had no effect 
on the product ratio, and given the similarity of Ser to Thr, this suggests that the 
presence of a Thr in AsBAS may not affect activity.  
As expected, the DCTAE motif was highly conserved amongst all BASs. As discussed 
above, the Asp initiates the cyclisation reaction by protonating the epoxide of 
oxidosqualene (Hoshino, 2017). This Asp is conserved across all OSCs and 
represents a common mechanism to initiate cyclisation. Two highly conserved Cys 
residues, one in the DCTAE motif and the other corresponding to C564 of EtBAS, are 
believed to hydrogen-bond with this Asp, increasing its acidity to allow it to protonate 
oxidosqualene (Thoma et al., 2004; Ito et al., 2013). Indeed, mutation of these 
residues to Ala in EtBAS (C486A and C564A mutants) reduced catalytic activity to 50 
% and 2 % of the wild-type (Ito et al., 2013), indicating that C564 is the more important 
interaction partner. 
F413 (EtBAS numbering) is highly conserved amongst the BASs and mutational 
studies on EtBAS suggest that its role is to provide steric bulk to prevent premature 
termination of the cyclisation cascade (Ito et al., 2017). AsBAS has a Tyr at this 
position, which due to its similar structure to Phe may fulfil a similar role. Similarly, 
F474 of EtBAS also provides steric bulk (Ito et al., 2014) and is present in all the BASs 
except AsBAS and BvBAS, which have a Leu instead. Like Phe, Leu is a hydrophobic 
amino acid but would not provide quite as much steric bulk as Phe. Nevertheless, 
AsBAS is monofunctional, indicating that premature cyclisation does not occur. F728 
of EtBAS is believed to stabilise the baccarenyl and oleanyl carbocation intermediates 
of the cyclisation reaction (Hoshino, 2017), and is present in all of the BASs. 
Notably, AsBAS has a Tyr at position 533, while the other BASs have a Trp at this 
position. Mutations of the equivalent residue in EtBAS (W534) considerably reduced 
β-amyrin production (< 10 % of wild-type activity). This included a W534Y mutation 
(Hoshino et al., 2017). Thus, it is possible that the presence of a Tyr instead of a Trp 
in AsBAS may lower its activity, and that a Y533W mutation in AsBAS could boost β-
amyrin production. V483 of EtBAS is located close to W534, and mutations in V483 
caused EtBAS to produce monocyclic triterpenes (Hoshino et al., 2017). However, 
V483 is conserved amongst all the BASs tested here. Mutants of EtBAS at W612 and 
L734 produced aberrant cyclisation products and had reduced activities (Aiba et al., 
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2018). However, all BASs had this Trp and all but AsBAS had the Leu; AsBAS instead 
had a Phe. The purpose of L734 may be to provide steric bulk (Aiba et al., 2018) and 
Phe may be able to provide a similar role in AsBAS, although it is a slightly larger 
amino acid. 
All of the BASs had a conserved Asn at position 731 (EtBAS numbering) except for 
AsBAS, which had a Ser (S728). It was previously shown that an S728F AsBAS 
mutant produced the tetracyclic triterpene dammarenediol-II when expressed in oat 
(Avena strigosa) (Salmon et al., 2016). When expressed in S. cerevisiae GIL77, this 
mutant produced mainly epoxydammara-3,25-diol, which is derived from the 
cyclisation of dioxidosqualene (Salmon et al., 2016). Oxidosqualene is produced by 
the epoxidation of squalene by squalene epoxidase (e.g. Erg9p in S. cerevisiae), and 
squalene epoxidase can oxidise oxidosqualene again to produce dioxidosqualene, 
which has two epoxide groups. Thus, the S728F AsBAS mutant preferentially utilises 
dioxidosqualene as a substrate to produce a tetracyclic triterpene when expressed in 
yeast. It would be interesting to introduce N731F and N731S mutations (EtBAS 
numbering) into the dicot BASs, and an S728N mutation into AsBAS, to determine 
whether these mutations alter their substrate or product specificities. However, it 
should be noted that S. cerevisiae GIL77 accumulates both 2-3-oxidosqualene and 
dioxidosqualene, as it lacks the ERG7 gene that encodes lanosterol synthase enzyme 
which converts 2,3-oxidosqualene to lanosterol (Kushiro et al., 1998). By contrast, 
dioxidosqualene is not detectable in yeast that are wild-type for ERG7 (e.g. BY4741 
used in the present study) (Milla et al., 2002; Field and Holmlund, 1977).  
AsBAS also differs from the other BASs at Y561 and N611 (EtBAS numbering), which 
are conserved amongst the BASs, having a Ser at each position instead (S560 and 
S610). Homology models and substrate docking of GsBAS1 and GsBAS2 (Gentiana 
straminea) indicated the hydroxyl of Y560 in GsBAS2 may interact with the hydroxyl 
of Y259 (in the MYCYCR motif) and the amido group of N610 (GsBAS2 numbering) 
(Liu et al., 2016). This would provide a hydrophilic environment around position C-13 
of the oleanyl cation, which could facilitate deprotonation and thus β-amyrin formation 
(Liu et al., 2016). By contrast, GsBAS1 had a H560 instead which might not interact 
with Y269. Y560H and Y560F mutations (lacking hydroxyl groups) in GsBAS2 
substantially reduced β-amyrin production, while the H560Y mutation in GsBAS1 
(introducing a hydroxyl group) increased production (Liu et al., 2016). Thus, the 
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presence of a hydroxyl group at this position may be important for activity. AsBAS has 
S560 and therefore possess such a hydroxyl, but differences in steric bulk and side-
chain length between Ser and Tyr may still affect activity. Furthermore, the presence 
of a Ser, which lacks an amido group, instead of Asn at position 610 likely also affects 
this interaction network. Thus, S560 and S610 are potential candidates that affect 
AsBAS activity. 
Although there were numerous differences in amino acid sequence for AsBAS 
compared with the other BASs, most of the BASs had little variation in the residues 
known to be involved in catalysis. Importantly, protein levels will need to be 
determined to properly assess the differences in BAS activity. Western blots were 
unable to detect AsBAS, suggesting it may be expressed at very low levels or not at 
all, while differences in expression between the other BASs may not have been 
detectable using this method (Figure 4.11; see above). Thus, analysis of the protein 
sequences alone does not explain the observed variation in activity for the dicot BASs, 
but does suggest possible candidate residues for AsBAS. 
4.7 Discussion 
A total of twelve BASs were expressed in yeast and compared for their ability to 
produce β-amyrin in S. cerevisiae. They showed a range of β-amyrin titres, with 
PgBAS1 producing very small quantities of β-amyrin (titre undetermined because the 
peak area was below the linear region of the standard curve) and the most active 
homologues (AaBAS and CqBAS1) producing 10.6 mg/L β-amyrin. The lowest point 
of the standard curve represents a β-amyrin titre of 1.7 mg/L, so PgBAS1 produces 
less than this amount. The β-amyrin titres in the strains ranged at least 10-fold 
(between 10.6 mg/L and < 1.7 mg/L). Notably, these strains had not been 
metabolically engineered to enhance triterpenoid production, and expressed only the 
BAS from a low copy plasmid. 
Interestingly, the β-amyrin titre for AaBAS was higher than that reported by Kirby et 
al., who achieved a titre of 6 mg/L β-amyrin in S. cerevisiae BY4742, a haploid strain 
similar to BY4741 used in the present study (Kirby et al., 2008). Notably, this strain 
was metabolically engineered to boost triterpenoid production, overexpressing the 
tHMG1 and ERG1 genes that are rate-limiting steps in 2,3-oxidosqualene production, 
and repressing the ERG7 gene which converts 2,3-oxidosqulaene to lanosterol, 
diverting flux from β-amyrin biosynthesis. By contrast, the non-optimised strain 
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expressing only AaBAS produced only 4 mg/L β-amyrin, ~ 2.5-fold lower than reported 
in the present study. Similar to the present study, Kirby et al. cultured cells in synthetic 
media supplemented with 2 % D-galactose, however the starting OD600 was much 
lower (0.02-0.03 instead of 0.2) and the culture time was longer (240 h instead of 96 
h) (Kirby et al., 2008). Furthermore, they expressed AaBAS from the GAL1 promoter 
but on a high copy plasmid instead of a low copy plasmid. These differences could 
explain the higher titre in the present study, as a higher copy plasmid might be 
expected to cause more burden, slowing cell growth, and this combined with the lower 
starting OD600 may resulted in a low cell density that limited β-amyrin production. 
By contrast, Moses et al. and especially Dai et al. reported substantially higher β-
amyrin titres than the current work for MtBAS and GgBAS (Moses et al., 2014b; Dai 
et al., 2014). Moses et al. expressed MtBAS or GgBAS in S. cerevisiae BY4742, 
combined with overexpression of tHMG1 and repression of ERG7, and achieved β-
amyrin titres of 19 mg/L or 36 mg/L, respectively (Moses et al., 2014b). By contrast, 
only 7.4 mg/L and 9.2 mg/L β-amyrin were produced in the MtBAS and GgBAS strains 
in the present study, respectively. Dai et al. reported a much higher β-amyrin titre of 
107 mg/L in S. cerevisiae BY4742, using GgBAS and with tHMG1, ERG9 and ERG1 
overexpressed (Dai et al., 2014). ERG9 and ERG1 are squalene synthase and 
squalene epoxidase and are responsible for the production squalene and is oxidation 
to 2,3-oxidosqulane; ERG1 may be rate-limiting (M’Baya et al., 1989; Veen et al., 
2003; Leber et al., 2001). Dai et al. integrated these genes and expressed them from 
constitutive promoters, which allowed them to grow the cells in YPD, a rich media 
containing glucose (Dai et al., 2014). By contrast, Moses et al. expressed the BAS 
and tHMG1 from galactose-inducible promoters on a plasmid with an auxotrophic 
marker, requiring the use of synthetic media supplemented with galactose, which 
would be expected to reduce growth compared with YPD (Moses et al., 2014b). This 
could explain the much higher titres reported by Dai et al. Similar to the present work, 
Dai et al. also reported low titres of β-amyrin for PgBAS1, producing 1.9 mg/L β-
amyrin in a strain overexpressing tHMG1, ERG9 and ERG1, ~ 50-fold lower than for 
GgBAS (Dai et al., 2014). 
Zhang et al. were also able to achieve a relatively high titre of β-amyrin (49 mg/L) with 
GgBAS (Zhang et al., 2015). To increase the supply of 2,3-oxidosqualene, they 
overexpressed E. coli IDI, S. cerevisiae ERG20 and ERG9, and Candida albicans 
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ERG1, which together are responsible for the conversion of isopentenyl 
pyrophosphate (IPP), the terpene precursor produced from the MEV pathway, into 
2,3-oxidosqualene. The genes were integrated and expressed from constitutive 
promoters engineered to contain the binding site of the S. cerevisiae Upc2p 
transcription activator, and the cultures were performed in YPD. Expression from low 
or high copy plasmids resulted in reduced β-amyrin titres, and plasmid loss was 
observed over a 48 h cultivation period (Zhang et al., 2015). Thus, integrating the 
pathway appears to be a promising strategy for boosting triterpenoid production. 
Strain growth was also assessed, as this is an important consideration when scaling 
up production. The strain expressing AsBAS unexpectedly grew much faster than 
those expressing the other BASs, having a similar growth rate to the empty vector 
control MD-N1. Strains expressing PgBAS1, which produced little β-amyrin, and 
BvBAS, a multifunctional OSC that produced additional products to β-amyrin, also 
displayed relatively fast growth. The other grew very slowly, indicating that there was 
significant metabolic burden caused by BAS expression.  
The growth curves of some strains (expressing LjBAS, GhBAS and SlBAS) showed 
large errors starting in exponential phase (Figure 4.10 A). This could be due to small 
differences in the starting OD600 introduced by manual error, causing some replicates 
to enter exponential phase earlier than others. Indeed, such differences have been 
shown to affect growth kinetics in microplate fermentations (Huber et al., 2009). These 
effects were not observed in the glucose cultures, where the strains grew much more 
quickly, or for the faster growing strains (AsBAS and MD-N1) in galactose media. It 
makes sense that such effects might be exacerbated in slow growing strains with 
longer lag phases. 
BvBAS produced two additional triterpenes (U1 and U2), and U1 was detected for all 
BASs but PgBAS1. Analysis of the mass spectrum of U1 for BvBAS suggests that it 
corresponds to lupeol, and the sequence of BvBAS was consistent with this, having 
a Leu instead of a Trp in the MWCYCR motif. Nevertheless, to confirm the identity of 
U1, GC-MS analysis of BvBAS and an authentic lupeol standard must be performed. 
It would be interesting to perform mutational studies on BvBAS to confirm that the Leu 
in the MWCYCR motif is causing the shift in product specificity. In this case, a Leu to 
Trp mutation should shift the product specificity of BvBAS to β-amyrin. 
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The observed differences in productivity and growth rate could be due to variation in 
BAS expression levels. Increased expression would be expected to increase β-amyrin 
production and increase metabolic burden, reducing growth rate. Indeed, the BASs 
were expressed from the strong GAL1 promoter, which could cause burden. Western 
blots of six BASs (AsBAS, PgBAS1, GgBAS, LjBAS, EtBAS and PtBAS) showed 
similar band intensities for all but AsBAS, indicating that they may be expressed at 
similar levels (Figure 4.11 A). AsBAS was not detected, possibly due to low 
expression levels or because the His-tag was inaccessible. AsBAS was the only BAS 
that was not codon-optimised, which could have resulted in lower expression levels 
than the other BASs. Low expression of AsBAS would be consistent with its minimal 
metabolic burden, and would indicate that it is a highly active enzyme given the 
relatively high β-amyrin titre (8.88 mg/L compared with 10.6 mg/L for the most 
productive BASs). However, this western blot did not provide quantitative information 
as it lacked a loading control, and so conclusions about the relative expression levels 
of the BASs could not be made. 
To properly explain the differences in activity and investigate the causes of burden, it 
will be necessary to determine the relative expression levels of the BASs. Performing 
western blots with a suitable loading control (e.g. an anti-actin antibody) should allow 
for such a comparison. However, because this approach can include a significant 
amount of experimental error, repeated experiments would be required to obtain 
reliable data (Hoshino, 2017). A perhaps more accurate approach would be to perform 
untargeted proteomics, where proteins are extracted, digested into peptides, and 
analysed by LC-MS/MS. Peptides can be identified based on their mass spectra and 
matched to their parent protein, and the relative abundance can be measured by 
comparing their peak areas (label-free quantification). Such an approach could detect 
very low quantities of protein, possibly allowing the detection of AsBAS. Following the 
determination of relative expression levels, β-amyrin titres could be normalised to 
BAS expression and this “specific activity” used to better compare their activities. 
In silico analysis of the BASs identified several amino acid variants in AsBAS that may 
affect its activity. First, AsBAS had a Tyr at position 533 instead of the Trp that was 
present in the other BASs. An EtBAS W534Y mutant was reported to have greatly 
reduced activity (Hoshino et al., 2017), indicating that this variant could affect AsBAS 
activity. Second, AsBAS had a Ser at position 728, whereas the other BASs had Asn. 
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An AsBAS S728F mutant showed altered substrate and product specificity when 
expressed in yeast (Salmon et al., 2016), and it is possible that mutating this residue 
to Asn would affect activity. Equally, mutants of the dicot BASs at this position, 
replacing Asn with Ser or Phe, might also show different activities. Finally, Y259, Y561 
and N611 (EtBAS numbering) may form an interaction network that is important for 
activity in the dicot BAS GsBAS2 (Liu et al., 2016), and these residues are conserved 
across the dicot BASs tested here. AsBAS instead has S560 and S610, which would 
be expected to alter the interaction network and potentially catalytic activity. By 
contrast with AsBAS, there were no obvious amino acid variants between the other 
BASs that might explain the differences in activity. 
Knowledge of expression levels is essential for properly interpreting the in silico 
analyses, as any differences in activity could be due to expression rather than 
sequence variations. It would thus be important to compare BASs with different 
specific activities to identify residues important for high activity. Generating homology 
models and performing substrate docking may provide additional information not 
obvious from the alignments, potentially allowing the identification of residues 
important for high catalytic activity in the dicot BASs. Mutational studies could then be 
performed to test the importance of these residues. The AsBAS amino acid variants 
highlighted above should also be considered with expression levels in mind and 
subjected to mutational studies to investigate their function. If residues that correlate 
with activity can be identified, this might enable protein engineering of the BASs to 
improve their catalytic activity. 
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Chapter 5: Comparison of CYP716As for 
oleanolic acid production 
5.1 Introduction 
Following the cyclisation of 2,3-oxidosqualene, the resulting triterpenes are typically 
subject to a range of modifications by tailoring enzymes. The most common 
modifications are oxygenations performed by cytochromes P450, producing 
triterpenoids, and glycosylations performed by UDP glycosyltransferases (UGTs), 
producing triterpenoid saponins. Such modifications are important for functionalising 
triterpenes and are responsible for the varied bioactivities observed in this family 
(Thimmappa et al., 2014; Moses et al., 2014a). Glycosylations occur at oxidised 
positions (the hydroxyl and carboxyl groups) but triterpenes such as β-amyrin have 
only one such group, the C-3 hydroxyl, which is derived from the epoxide of 
oxidosqualene. The P450-mediated oxygenations introduce additional moieties that 
can be glycosylated, increasing saponin diversity (Moses et al., 2014a). Especially 
important are the C-3 hydroxyl and C-28 carboxyl groups (Figure 5.1), which are the 
most common sites of glycosylation (Thimmappa et al., 2014). 
Oleanolic acid is derived from β-amyrin through the oxidation of the C-28 methyl group 
to a carboxyl, a reaction performed by P450s of the CYP716A subfamily. This is a 
three-step reaction that occurs through the hydroxyl and aldehyde intermediates 
erythrodiol and oleanolic aldehyde (Figure 5.1). Oleanolic acid thus contains both a 
C-3 hydroxyl and a C-28 carboxyl group. 
Like β-amyrin, oleanolic acid occurs widely in plants and is a precursor to many 
bioactive triterpenoids. For example, QS-21, a mixture of two saponins with a quillaic 
acid aglycone (containing a C-28 carboxyl), is being evaluated as an adjuvant in 
vaccines for a number of diseases, most notably in the anti-malarial vaccine RTS,S 
(Didierlaurent et al., 2017; Mahmoudi and Keshavarz, 2017). It is also used in a 
commercially available veterinary vaccine against feline leukaemia virus (Sun et al., 
2009). Furthermore, several oleanolic acid derivatives are under investigation for 
various indications, and some have undergone clinical trials (Moses et al., 2013). For 
example, the synthetic derivative bardoxolone methyl has been investigated in clinical 
trials as an anti-cancer agent and for the treatment of chronic kidney disease (Moses 
et al., 2013). Meanwhile, the synthetic derivative RTA 408 (omaveloxolone) is 
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Figure 5.1. Oxidation of β-amyrin to oleanolic acid by cytochromes P450 of the 
CYP716A subfamily. Oxidation takes place at the C-28 methyl group and occurs through 
hydroxyl and aldehyde intermediates (erythrodiol and oleanolic aldehyde) to generate a 
carboxyl group (oleanolic acid). Carbon 3, which contains the hydroxyl group derived from 
2,3-oxidosqualene, and carbon 28 are labelled. 
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currently undergoing a phase II clinical trial for the treatment of the neurodegenerative 
disease Friedreich's ataxia, and has shown promising results (ClinicalTrials.gov, 
Identifier NCT02255435, 2014; Strawser et al., 2017). Saponins derived from 
oleanolic acid and hederagenin (an oleanolic acid derivative) have been reported as 
having anti-feedant and insecticidal activities (Shinoda et al., 2002; Nielsen et al., 
2010; Augustin et al., 2012), potentially lending themselves to agricultural 
applications. Oleanolic acid itself is reported to have hepatoprotective properties and 
is used in China to treat liver disorders such as viral hepatitis (Pollier and Goossens, 
2012). For more information, see section 1.2 and Figure 1.6. 
The CYP716A subfamily comprises many characterised P450s involved in 
triterpenoid biosynthesis (Miettinen et al., 2017). Most catalyse the C-28 oxidation of 
β-amyrin and related triterpenes (often α-amyrin and lupeol), however, some catalyse 
other reactions (Miettinen et al., 2017; Ghosh, 2017). For example, CYP716A2 from 
Arabidopsis thaliana catalyses the C-22α hydroxylation of β-amyrin (Yasumoto et al., 
2016), while CYP716A14v2 (Artemisia annua) oxidises the C-3 hydroxyl group of β-
amyrin and α-amyrin to a ketone (Moses et al., 2015a). CYP716A141 from 
Playocodon grandiflorus catalyses the C-16β hydroxylation of β-amyrin and oleanolic 
acid, but also has a weaker C-28 oxidation activity against β-amyrin (Tamura et al., 
2017; Miettinen et al., 2017). Nevertheless, the majority of CYP716As discovered to 
date are C-28 oxidases. 
Due to the importance of the C-28 oxidation reaction in triterpenoid biosynthesis, I 
sought to compare members of this subfamily for their ability to oxidise β-amyrin to 
oleanolic acid when expressed in yeast. Although a large number of CYP716As have 
been characterised, many were discovered relatively recently and metabolic 
engineering studies have typically utilised the same subfamily member (CYP716A12 
from Medicago truncatula) for the production of oleanolic acid and its derivatives 
(Moses et al., 2014b; Dai et al., 2014; Fukushima et al., 2013; Arendt et al., 2017). 
However, as shown earlier for the comparative analysis of β-amyrin synthases (see 
Chapter 4), the choice of homologue can have a large impact on strain productivity. 
This is especially true of the CYP716As, which also produce the intermediate 
compounds erythrodiol and oleanolic aldehyde, meaning that not only catalytic activity 
but also product ratios might differ between homologues. 
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Sixteen CYP716As from a range of plants were compared for their ability to oxidise 
β-amyrin to oleanolic acid when expressed in yeast. They were co-expressed with 
AaBAS, the most productive BAS identified in the BAS comparative analysis (see 
Chapter 4), and the cytochrome P450 reductase ATR2 from Arabidopsis thaliana. The 
CYP716As spanned the majority of identified CYP716As, including the commonly 
used CYP716A12. In addition, two new CYP716As, from Theobroma cacao (cocoa 
tree) and Olea europaea (olive), were functionally characterised by expression in 
yeast and included in the comparative analysis. Triterpenoid production was 
monitored by GC-MS and microplate growth assays were performed to assess 
burden.  
5.2 Characterisation of two new cytochromes P450 of 
the CYP716A subfamily 
An initial investigation was untaken to identify additional C-28 oxidises from the 
CYP716A subfamily. A BLASTp search on NCBI against the non-redundant database 
with default parameters was performed using CYP716A12, a characterised β-amyrin 
C-28 oxidise, as the query sequence. This returned 100 hits with sequence identities 
to CYP716A12 > 70 %, many of which were annotated as predicted β-amyrin C-28 
oxidases, and two genes were selected for analysis. The first was CYP716A48 from 
Olea europaea (olive; BAP59949), which had 78 % amino acid identity to 
CYP716A12. O. europaea is known to produce oleanolic acid and is used as a source 
of this triterpenoid for commercial purposes (Pollier and Goossens, 2012). It encodes 
a multifunctional triterpene synthase that produces mainly α-amyrin and β-amyrin 
(Saimaru et al., 2007) (no monofunctional BAS has been reported), but the gene 
responsible for oleanolic acid biosynthesis was yet to be identified. The high sequence 
identity of CYP716A48 with characterised C-28 oxidases (> 70 %) (Figure 5.4), and 
the known oleanolic acid production capacity of O. europaea, suggest that 
CYP716A48 may indeed be a β-amyrin C-28 oxidase. Furthermore, it contains the 
expected conserved residues for a P450, notably the proton transfer groove, ExxR 
motif, PERF motif and haem binding loop, as well as a predicted N-terminal 
transmembrane anchor (Figure 5.4). 
A predicted β-amyrin C-28 oxidase from Theobroma cacao (cocoa tree; 
XP_017978138.1) with 74 % amino acid identity to CYP716A12 was located in close 
proximity with another predicted β-amyrin C-28 oxidase (CYP716A147; 
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XP_007023618), the putative β-amyrin synthase identified earlier (TcBAS; see 
Chapter 4), a predicted P450 of the CYP705A subfamily, and a predicted cycloartenol 
synthase on the T. cacao genome, in what appeared to be a possible gene cluster 
(within a 270 kb region). Cycloartenol synthases cyclise oxidosqualene to the plant 
sterol cycloartenol, and triterpene synthases such as BASs are believed to have 
evolved from cycloartenol synthases via gene duplication (Augustin et al., 2011). 
Gene clusters have been described for triterpenoid and other plant secondary 
metabolic pathways before (Qi et al., 2004; Field and Osbourn, 2008; Field et al., 
2011; Osbourn and Field, 2009), and contain genes involved in the same biosynthetic 
pathway. The presence of this putative gene cluster suggests that these predicted 
enzymes may be genuine. CYP716A147 had been simultaneously identified (but not 
characterised) by Miettinen et al. (Miettinen et al., 2017) and was selected for 
analysis. It had a high amino acid identity (> 70 %) to CYP716A12 and other 
characterised CYP716As, and contained the expected conserved residues that were 
also observed for CYP716A48 (Figure 5.4, Figure 5.5). 
The CYP716A48 and CYP816A147 genes were synthesised with codon-optimisation 
for S. cerevisiae (see materials and methods), and were cloned into a centromeric 
plasmid with the Euphorbia tirucalli BAS (EtBAS) and ATR2, a cytochrome P450 
reductase (CPR) from Arabidopsis thaliana that is required for P450 activity. Each 
gene was expressed from a galactose-inducible promoter. Most plant P450s, 
including those involved in triterpenoid biosynthesis, require a plant CPR for activity 
in yeast. The CPR oxidises NADPH and transfers the electrons to the P450 active 
site, where they are used to activate molecular oxygen to oxidise the substrate 
(Werck-Reichhart and Feyereisen, 2000; Jensen and Møller, 2010; Bak et al., 2011). 
While yeast encodes its own native CPR (NCP1), it is less effective at transferring 
electrons to heterologously expressed plant P450s, resulting in lower catalytic activity 
(Dejong et al., 2005). Instead, a plant CPR is often co-expressed with the P450, and 
the A. thaliana CPRs ATR1 and ATR2 are commonly used for this purpose (Urban et 
al., 1997; Zhao et al., 2016; Dai et al., 2013, 2014; Moses et al., 2014b; Arendt et al., 
2017; Gavira et al., 2013; Wang et al., 2015); ATR2 was reported to have a higher 
catalytic activity than ATR1 (Schückel et al., 2012; Zhu et al., 2018). 
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The plasmids expressing GgBAS, P450 (CYP716A147 or CYP716A48) and ATR2 
were transformed into S. cerevisiae BY4741, and the resulting strains (MD-OA5 and 
MD-OA6) were cultured and prepared for TLC analysis as before (see Chapter 4). 
Strains expressing EtBAS (MD-BA5), an oleanolic acid pathway containing 
CYP716A12, GgBAS and ATR2 (MD-OA1), and an empty vector control (MD-N1) 
were run as controls. Extracts of each strain, as well as authentic β-amyrin and 
oleanolic acid standards, were loaded onto the TLC plate. As expected, EtBAS and 
MD-N1 had multiple bands, one of which was much stronger for EtBAS and migrated 
a similar distance to the β-amyrin standard (Figure 5.2). The CYP716A12 strain had 
two additional bands that migrated slower than β-amyrin, and likely corresponded to 
products of the β-amyrin C-28 oxidation reaction (erythrodiol, oleanolic aldehyde, or 
oleanolic acid). Accordingly, the oleanolic acid standard migrated more slowly than 
the β-amyrin standard. Unfortunately, this standard gave a very diffuse band, possibly 
Figure 5.2. Thin layer chromatography (TLC) indicates that CYP716A147 and 
CYP716A48 are functional in yeast. TLC was performed on extracts of cells expressing 
oleanolic acid pathways containing either CYP716A147, CYP716A48 or CYP716A12 (a 
previously characterised P450). A strain expressing EtBAS only, the control strain MD-N1, 
and 0.6 µg of β-amyrin and oleanolic acid standards were also analysed. The boxes indicate 
additional bands present in the oleanolic acid strains that were not present for EtBAS and the 
control strain. These could represent erythrodiol, oleanolic aldehyde and/or oleanolic acid.
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due to manual error when loading it onto the plate, making it difficult to identify a 
putative oleanolic acid band in the samples. Both CYP716A147 and CYP716A48 
gave a similar pattern of bands to CYP716A12, containing the putative β-amyrin band 
as well as those possibly corresponding to β-amyrin derivatives (Figure 5.2). The data 
thus indicate that both P450s are active in yeast. 
To confirm the TLC results and identify the products of CYP716A147 and 
CYP716A48, these strains were analysed by GC-MS. Cells were cultured and GC-
MS analysis was performed as before (see Chapter 4). The MD-N1 control strain was 
also analysed, as was a standards mixture containing β-amyrin, erythrodiol, oleanolic 
acid, ergosterol and coprostanol (an oleanolic aldehyde standard is not available). 
Peaks with the same retention times as the erythrodiol and oleanolic acid standards 
were observed for both CYP716A147 and CYP716A48 (Figure 5.3 A), and their 
identities were confirmed by comparison of their mass spectra with the authentic 
standards (Figure 5.3 B-E). An additional peak that was not present in MD-N1 was 
also observed (Figure 5.3 A), and its mass spectrum was consistent with that reported 
for an authentic oleanolic aldehyde standard (Figure 5.3 F-G and see Fig. S3 of 
(Khakimov et al., 2015)). A peak that eluted shortly after oleanolic aldehyde was also 
observed (Figure 5.3 A), but this was present in MD-N1 and probably corresponds to 
a native yeast metabolite. Thus, CYP716A147 and CYP716A48 are genuine β-amyrin 




Figure 5.3. GC-MS confirms that CYP716A147 and CYP716A48 are functional in yeast. 
(A) Total ion chromatograms of strains expressing CYP716A147 and CYP716A48, the control 
strain MD-N1, and a mixture of ergosterol, β-amyrin, erythrodiol and oleanolic acid standards 
(each at 50 µg/ml). Peaks corresponding to erythrodiol and oleanolic acid were observed for 
both P450s, as was an additional peak not present in the control strain that may correspond 
to oleanolic aldehyde. (B-E) Mass spectra of the erythrodiol and oleanolic acid peaks from 
the CYP716A strains, showing that they match the mass spectra of the standards. (F-G) Mass 
spectra of the putative oleanolic aldehyde peaks. These are consistent with what would be 
expected for oleanolic aldehyde (e.g. see Fig. S3 of Khakimov et al. for the mass spectrum of 
an authentic oleanolic aldehyde standard (Khakimov et al., 2015)). 
 
Chapter 5: Comparison of CYP716As for oleanolic acid production 
 135 
 
Figure 5.3. GC-MS confirms that CYP716A147 and CYP716A48 are functional in yeast. 
See previous page for full legend 
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5.3 Comparison of CYP716A homologues for the 
production of oleanolic acid 
Sixteen CYP716As (Table 5.1) were compared in yeast for their ability to oxidise β-
amyrin to oleanolic acid. These represented many of the CYP716As characterised to 
date, including CYP716A12 and the newly discovered CYP716A147 and 
CYP716A48. A multiple sequence alignment of the protein sequences was performed 
(Figure 5.4), and most had sequence identities of 65 % or greater (Figure 5.5). The 
exceptions to this were CYP716A1 and CYP716A80, which had lower sequence 
identities to the other CYP716As but an 80 % sequence identity to each other. 
Phylogenetic analysis of the CYP716As and numerous other P450s involved in 
triterpenoid biosynthesis showed that the CYP716As clustered together (Figure 5.6). 
CYP716A1 and CYP716A80 formed a separate clade with CYP716A2, which has C-
16α, C-22α and C-28 hydroxylation activity, while CYP716A110 was slightly more 
distantly related. 
The CYP716As were synthesised with codon-optimisation for S. cerevisiae and 
cloned into centromeric plasmids together with AaBAS and ATR2; AaBAS was the 
most productive BAS identified in Chapter 4 (together with CqBAS1). AaBAS and the 
CYP716As were expressed from the strong pGAL1 and pGAL10 galactose-inducible 
promoters, while ATR2 was expressed from pGAL3, which was reported to be weaker 
(Paddon et al., 2013). Previous studies have indicated that the ratio of P450 to CPR 
is important for activity. Moses et al. compared different ATR1 expression levels for 
triterpenoid production, integrating it into the chromosome and expressing it from low 
and high copy plasmids, while the P450 (CYP716Y1) was expressed from a high copy 
plasmid. The strain expressing ATR1 from the low copy plasmid gave the highest 
titres (Moses et al., 2014b). Paddon et al. found that reducing CPR expression 
improved the growth and viability of an artemisinic acid production strain, but also 
reduced titres (Paddon et al., 2013). Indeed, when the CPR is present in excess over 
the P450 uncoupling in electron transfer can occur, and the resulting electron leakage 
generates reactive oxygen species that are toxic to the cells (Renault et al., 2014). 
Consistent with this, studies of natural systems have shown the P450 to be present 
in greater abundance than the CPR (Peterson et al., 1976; Reed and Backes, 2012; 
Renault et al., 2014). 




Table 5.1. CYP716A homologues tested in this study. The cytochrome P450 
reductase ATR2 is also shown. 
CYP716A Species Accession 
number 
Reference 
CYP716A12 Medicago truncatula CBN88269.1 Fukushima (2011) 
CYP716A15 Vitis vinifera BAJ84106 Fukushima (2011) 
CYP716AL1 Catharanthus roseus AEX07773 Huang (2012) 
CYP716A52v2 Panax ginseng AFO63032 Han (2012, 2013) 
CYP716A147 Theobroma cacao XP_007023618 The present study 
CYP716A48 Olea europaea  BAP59949.1 The present study 
CYP716A44 Solanum lycopersicum AK329870.1 Yasumoto (2017) 
CYP716A75 Maesa lanceolata AHF22088.1 Moses (2015a) 
CYP716A79 Chenopodium quinoa ANY30854.1 Fiallos-Jurado 
(2016) 
CYP716A80 Barbarea vulgaris ALR73782.1 Khakimov (2015) 
CYP716A83 Centella asiatica AOG74832.1 Miettinen (2017), 
Kim (2018) 
CYP716A110 Aquilegia coerulea AOG74847.1 Miettinen (2017) 
CYP716A140 Platycodon grandiflorus AOG74836.1 Miettinen (2017) 
CYP716A179 Glycyrrhiza uralensis BAW34647.1 Tamura (2017b) 
CYP716A244 Eleutherococcus 
senticosus 
APZ88353.1 Jo (2017) 
CYP716A1 Arabidopsis thaliana NP_198460.1 Yasumoto (2016) 
ATR2 Arabidopsis thaliana NP_849472.2 Urban (1997) 
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Figure 5.4. Multiple sequence alignment of CYP716As. See next page for full legend. 
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The plasmids were transformed into S. cerevisiae BY4741, and the resulting strains 
(MD-OAX series) were analysed for triterpenoid production by GC-MS. The OD600 at 
the end of the production run (final OD600) was measured, and growth curves were 
generated using the same microplate assay as before (see Chapter 4). A strain 
expressing AaBAS alone (MD-BA14) and the MD-N1 control strain were also 
analysed. The experiment was performed twice and both repeats were in good 
agreement. In the first experiment, the GC-MS analysis was performed with a 10:1 
split ratio for all samples but titres could not be calculated for some samples because 
the peak areas fell outside of the linear region of the standard curve. The second 
experiment was therefore performed with additional split ratios (5:1 or 25:1) to allow 
titres to be calculated. Therefore, only the data from the second experiment is 
presented here. Nevertheless, some peaks were so small that titres still could not be 
calculated. 
Titres were calculated for ergosterol, β-amyrin, erythrodiol and oleanolic acid, but 
could not be calculated for oleanolic aldehyde due to the lack of a standard. Instead, 
normalised peak areas were used to compare oleanolic aldehyde abundance 
between different strains. Notably, these cannot be used to compare the levels of 
oleanolic aldehyde with the other triterpenoids. Different analytes can give different 
signal intensities when analysed by GC-MS, so unless two analytes are known to give 
very similar signals, their relative abundances cannot be determined using peak areas 
alone. This was observed when analysing erythrodiol and oleanolic acid standards, 
where injecting the same amount of each gave noticeably different peak areas (see 
section 3.4, Figure 3.5 A). Calculating titres from standard curves accounts for such 
differences in signal intensity, allowing the abundances of different analytes to be 
 
Figure 5.4. Multiple sequence alignment of CYP716As. Protein sequences were aligned 
using Clustal Omega (www.ebi.ac.uk/Tools/msa/clustalo/) with default parameters. 
Conserved sequences are highlighted. Green: transmembrane domain predicted by the 
TMHMM server (http://www.cbs.dtu.dk/services/TMHMM); purple: proline cluster that forms a 
hinge between the transmembrane and cytoplasmic domains (P450 consensus PPxP); light 
blue: A/G-G-X-D/E-T-T/S motif (proton transfer groove); blue: ExxR motif; red: PERF motif; 
orange: FxxGxRxCxG motif (haem binding loop). See Table 5.1 for accession numbers. The 
sequences contained an additional ‘GS’ at the C-terminus but were otherwise identical to the 
GenBank sequences. 
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Figure 5.5. Percent identity matrix of BAS sequence identities. Protein sequences were 
aligned using ClustalOmega (www.ebi.ac.uk/Tools/msa/clustalo/) with default parameters to 
obtain a percent identity matrix (PIM). All proteins except CYP716A80 and CYP716A1 had 
sequence identities > 65 %. For accession numbers see Table 5.1. 
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Figure 5.6. Phylogenetic analysis of CYP716As and other P450s involved in triterpenoid 
and sterol biosynthesis. The phylogenetic tree was generated from protein sequences by 
using the maximum likelihood method and bootstrapping for 1000 replicates. Bootstrap values 
(%) are displayed at each node. The CYP716As tested in the present study are highlighted 
green (see Table 5.1 for accession numbers), and the function of each enzyme is annotated. 
The scale bar represents the number of substitutions per site. Red bar: CYP716 family; yellow 
bar: CYP716A subfamily; * multifunctional CYP716A; ** putative activity. CYP716A2: 
Arabidopsis thaliana a/ß-amyrin oxidase (BAU61505); CYP716A14v2: Artemisia annua C-3 
oxidase (AHF22083); CYP716A17: Vitis vinifera C-28 oxidase (BAJ84107); CYP716A46: 
Solanum lycopersicum C-28 oxidase (XP_004243906.1); CYP716A78: Chenopodium quinoa 
C-28 oxidase (ANY30853.1); CYP716A86: Centella asiatica C-28 oxidase (AOG74831.1); 
CYP716A111: Aquilegia coerulea C-16β hydroxylase (APG38190.1); CYP716A141: 
Platycodon grandiflorus C-16β hydroxylase (AOG74838.1); CYP716A113v1: Aquilegia 
coerulea putative cycloartenol hydroxylase (AOG74849.1); CYP716A252: Ocimum basilicum 
C-28 oxidase (AFZ40057); CYP716A253: Ocimum basilicum C-28 oxidase (AFZ40058); 
CYP716A180: Betula platyphylla C-28 oxidase (AHL46848); CYP716A94: Kalopanax 
septemlobus C-28 oxidase (ALO23117.1); CYP716C11: C. asiatica C-2α hydroxylase 
(AOG74835.1); CYP716E26: S. lycopersicum C-6β hydroxylase (XP_004241821.1); 
CYP716E41: S. asiatica C-6β hydroxylase (AOG74834.1); CYP716S5: Platycodon 
grandiflorus C-12,13α-epoxidase (AOG74839.1); CYP716Y1: Bupleurum falcatum C-16α 
hydroxylase (AHF45909.1); CYP93E1: Glycine max C-24 hydroxylase (BAE94181.1); 
CYP93E2: Medicago truncatula C-24 hydroxylase (ABC59085.1); CYP93E9: Phaseolus 
vulgaris C-24 hydroxylase (AIN25421); CYP51H10: Avena strigosa multifunctional oxidase 
(ABG88961.1); CYP72A61v2: M. truncatula C-22 hydroxylase (BAL45199); CYP72A69: G. 
max C-21 hydroxylase (BAW35010.1); CYP72A154: Glycyrrhiza uralensis C-30 oxidase 
(BAL45207); CYP87D16: Maesa lanceolata C-16α hydroxylase (AHF22090.1); CYP88D6: G. 
uralensis C-11 oxidase (BAG68929); CYP716U1: Panax ginseng C-12 hydroxylase (DM-II) 
(AEY75212); CYP716S1: P. ginseng C-6 hydroxylase (PPD) (AFO63031); CYP705A1: 
Arabidopsis thaliana, arabidiol side-chain cleavage (NP_193268); CYP708A2: A. thaliana C-
7 hydroxylase (Q8L7D5); CYP71A16: A. thaliana C-23 hydroxylase (NP_199073); 
CYP71D353: Lotus japonicus C-20 hydroxylase, C-28 oxidation (AHB62239.1).
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compared (see Chapter 3 for more information). The “total triterpenoid titre” was also 
calculated, and is the sum of the titres of ergosterol, β-amyrin, erythrodiol and 
oleanolic acid; oleanolic aldehyde was not included in this metric because its titres 
could not be calculated.  
Ergosterol and β-amyrin titres were similar for all strains, ranging from 5.6 to 7.5 mg/L 
for ergosterol (Figure D) and 7.1 to 10.4 mg/L for β-amyrin (Figure 5.7 C). The 
exception was MD-N1, which accumulated 15 mg/L ergosterol and, as expected, 
produced no β-amyrin. Similarly, the final OD600 was similar across all strains except 
MD-N1, which reached a considerably higher OD600 (Figure 5.7 E). The increased 
OD600 and ergosterol titre of MD-N1 compared with the CYP716A strains is similar to 
what was observed in Chapter 4, where MD-N1 grew faster and accumulated more 
ergosterol than the strains expressing a BAS. Notably, β-amyrin titres, ergosterol titres 
and growth rates were very similar between the CYP716A strains and the strain 
expressing AaBAS alone (Figure 5.7 C-E). 
In contrast with the β-amyrin and ergosterol titres, there were large differences in 
levels of erythrodiol, oleanolic aldehyde and oleanolic acid between the strains 
(Figure 5.7 A-B). Oleanolic acid titres ranged from 14.1 mg/L to 2.08 mg/L (a 6.8-fold 
difference), while erythrodiol titres ranged from 20.9 mg/L to 1.12 mg/L (an 18.7-fold 
difference). However, for a number of strains the oleanolic acid and erythrodiol peak 
areas fell below the linear regions of the respective standard curves, preventing titres 
from being calculated. As such, the actual fold difference in titres is expected to be 
much greater. Oleanolic aldehyde levels also varied and for some strains, erythrodiol, 
oleanolic aldehyde and/or oleanolic acid were not observed. Together, this reveals 
the variation that can occur across homologues that catalyse the same reaction, and 
highlights the importance of the choice of homologue. 
CYP716AL1 accumulated the most oleanolic acid at 14.1 mg/L, and also produced 
6.7 mg/L erythrodiol (2.1-fold lower than oleanolic acid) (Figure 5.7 A), representing 
41 % and 19 % of total triterpenoids, respectively (Table 5.2). CYP716A12 produced 
10.9 mg/L oleanolic acid and 4.6 mg/L erythrodiol (2.4-fold lower), corresponding to 
36 % and 15 % of the total triterpenoids. Both accumulated significant amounts of 
oleanolic aldehyde compared with the other homologues, with CYP716A12 producing 
slightly less than CYP716AL1 (Figure 5.7 B). As such, both had similar product 
profiles, favouring the production of oleanolic acid over erythrodiol, with CYP716AL1 
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Figure 5.7. Comparison of CYP716As. (A) Erythrodiol and oleanolic acid titres. (B) Oleanolic aldehyde 
normalised peak areas. (C) β-amyrin titres. (D) Ergosterol titres. (E) OD600. Metabolites were measured 
by GC-MS, and OD600 was measured at the end of the production run (96 h). Normalised peak areas 
are shown for oleanolic aldehyde because a standard was not available, preventing titres from being 
calculated. While all strains except MD-N1 produced similar amounts of β-amyrin and ergosterol and 
reached a similar OD600, erythrodiol, oleanolic aldehyde and oleanolic acid levels varied widely. Control: 
MD-N1 (empty vector). *, titre could not be calculated as the peak area fell below the linear region of the 
standard curve; **, no peak observed. Shown is the mean ± 1 standard deviation for 3 biological 
replicates. P-values calculated using a Welch (unequal variances) two-sample t-test in R. 
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having an overall higher activity. Thus, the comparative analysis immediately 
identified a CYP716A with greater activity than the homologue commonly used in 
metabolic engineering projects. 
Similar to CYP716AL1 and CYP716A12, CYP716A83 and CYP716A244 also 
accumulated oleanolic acid in greater abundance than erythrodiol (Figure 5.7 A). 
CYP716A83 produced 8.1 mg/L oleanolic acid and 4.4 mg/L erythrodiol (a 1.8-fold 
difference), and accumulated a moderate amount of oleanolic aldehyde compared 
with the other homologues. Meanwhile, CYP716A244 produced 9.3 mg/L oleanolic 
acid and 6.2 mg/L erythrodiol (a 1.5-fold difference), and accumulated higher amounts 
of oleanolic aldehyde compared to the other CYP716As. Oleanolic acid represented 
31 % and 32 % of total triterpenoids for CYP716A83 and CYP716A244. 
The newly identified P450s (CYP716A147 and CYP716A48) produced similar 
amounts of oleanolic acid at 7.1 mg/L and 7.6 mg/L, respectively (Figure 5.7 A). 
However, CYP716A147 produced two-fold more erythrodiol than oleanolic acid at 
 
 
Table 5.2. Percentage accumulation of triterpenoids 
 
Enzyme Ergosterol β-amyrin Erythrodiol Oleanolic acid 
CYP716A12 22.3 ± 0.9 27.2 ± 0.7 15 ± 0.3 35.5 ± 0.1 
CYP716A15 20.6 ± 0.4 23.3 ± 1.2 33.5 ± 1 22.6 ± 0.8 
CYP716AL1 19.6 ± 0.6 20.5 ± 0.6 19.4 ± 0.4 40.5 ± 0.9 
CYP716A52v2 30.9 ± 1.5 43.2 ± 1 25.9 ± 0.5 0 
CYP716A147 18.4 ± 1 21.9 ± 1.1 40.2 ± 1.7 19.5 ± 0.4 
CYP716A48 20 ± 0.3 24.6 ± 0.6 31.9 ± 0.3 23.4 ± 0.6 
CYP716A44 21.7 ± 1.5 25.6 ± 0.4 36.6 ± 3.4 16.1 ± 1.6 
CYP716A75 21.1 ± 0.6 21.4 ± 0.3 57.5 ± 0.4 0 
CYP716A79 44.8 ± 2.4 55.2 ± 2.4 0 0 
CYP716A80 31.7 ± 1.4 40.1 ± 0.3 28.2 ± 1.2 0 
CYP716A83 24.7 ± 0.3 28.2 ± 0.9 16.5 ± 0.5 30.6 ± 0.8 
CYP716A110 39 ± 0.5 55.1 ± 0.6 6 ± 0.6 0 
CYP716A140 42 ± 1.3 58 ± 1.3 0 0 
CYP716A179 40.6 ± 10.3 48.8 ± 1.3 0 0 
CYP716A244 22.7 ± 0.5 23.5 ± 0.2 21.5 ± 0.6 32.3 ± 0.4 
CYP716A1 35.8 ± 1.6 42.3 ± 1.5 21.8 ± 1.1 0 
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14.6 mg/L, the second highest erythrodiol titre overall, while CYP716A48 produced 
less at 10.3 mg/L. For CYP716A147, erythrodiol and oleanolic acid represented 40 % 
and 20 % of total triterpenoids, while for CYP716A48 they represented 32 % and 23 
% (Table 5.2). In addition, CYP716A147 produced slightly more oleanolic aldehyde 
(1.6-fold higher) than CYP716A48. Thus, CYP716A147 clearly favours erythrodiol 
over oleanolic acid production, and CYP716A48 has a more balanced product profile. 
In addition to CYP716A147 and CYP716A48, a number of other enzymes also 
accumulated more erythrodiol than oleanolic acid. Strikingly, CYP716A75 produced 
20.9 mg/L erythrodiol, representing 58 % of total triterpenoids, yet accumulated very 
little oleanolic aldehyde compared with the other strains and no detectable oleanolic 
acid (Figure 5.7 A-B). CYP716A75 therefore appears to be highly specific for the C-
28 hydroxylation of β-amyrin. This was the highest triterpenoid titre observed in this 
study, and more than two-fold greater than the β-amyrin titre of AaBAS alone, 
indicating that there is a significant amount of metabolic “pull-through” occurring. 
Similarly, CYP716A52v2 produced 5.9 mg/L erythrodiol (26 % of total triterpenoids) 
and low quantities of oleanolic aldehyde and oleanolic acid compared with the other 
homologues. CYP716A15 produced 1.5-fold more erythrodiol than oleanolic acid, with 
titres of 11.3 and 7.6 mg/L, respectively, while CYP716A44 produced 11.4 mg/L 
erythrodiol and only 4.8 mg/L oleanolic acid (2.4-fold lower than erythrodiol). 
Erythrodiol thus represented 34 % and 37 % of total triterpenoids for CYP716A15 and 
CYP716A44, respectively. Both enzymes produced similar amounts of oleanolic 
aldehyde. 
CYP716A1 only produced erythrodiol (4.6 mg/L); oleanolic aldehyde and oleanolic 
acid were not observed (Figure 5.7 A-B). This observation contrasts with the results 
of Yasumoto et al., who observed significant amounts of both erythrodiol and oleanolic 
acid when expressing CYP716A1 in yeast (Yasumoto et al., 2017). Yasumoto et al. 
observed similar peak areas for erythrodiol and oleanolic acid, while in the present 
study the erythrodiol peak was of considerable size yet no oleanolic acid peak was 
visible. Thus, differences in the sensitivities of the analytical methods used are 
unlikely to explain this discrepancy, as such differences would be unlikely to affect the 
detection of oleanolic acid but not erythrodiol. However, Yasumoto et al. used a CPR 
from Lotus japonicus (LjCPR1), whereas the present study used ATR2 (from A. 
thaliana). As such, differences in electron transfer efficiencies between the CPR and 
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CYP716A1 might explain the differences in product ratios between these two studies. 
Interestingly, Yasumoto et al. (2016) reported that CYP716A1 was only capable of 
performing C-28 hydroxylation on lupeol, producing betulin, which is equivalent to the 
hydroxylation of β-amyrin to erythrodiol. They used a diploid yeast strain (INVSc1), 
expressed three copies of CYP716A1, used LjCPR1 and cultured cells for two days 
in galactose-supplemented media (Yasumoto et al., 2016). By contrast, the present 
study used a haploid yeast strain expressing a single copy of CYP716A1 and the CPR 
ATR2, and cultures were performed for 4 days. These differences could explain the 
discrepancies between our results.  
CYP716A79 and CYP716A110 did not produce any detectable oleanolic aldehyde or 
oleanolic acid, and accumulated very low quantities of erythrodiol (Figure 5.7 A-B). 
CYP716A110 produced 1.12 mg/L erythrodiol, while the titre could not be calculated 
for CYP716A79 because it fell below the linear region of the standard curve. However, 
both enzymes were previously reported to oxidise β-amyrin to oleanolic acid (Fiallos-
Jurado et al., 2016; Miettinen et al., 2017). These studies used S. cerevisiae BY4742, 
a haploid yeast strain similar to strain BY4741 used in the present study, but 
overexpressed the tHMG1 gene, repressed the ERG7 gene using a methionine-
repressible promoter, and added methyl-β-cyclodextrin to the growth medium, which 
sequestered triterpenoids in the growth medium. These are strategies that have been 
shown to boost triterpenoid production (Moses et al., 2014b; Fiallos-Jurado et al., 
2016; Miettinen et al., 2017). Furthermore, Miettinen et al. used a different CPR 
(MTR1 from Medicago truncatula instead of ATR2), which could have affected P450 
activity (Miettinen et al., 2017). These differences could explain why oleanolic acid 
was detected in those studies yet was not detected here. 
CYP716A80 also accumulated significantly more erythrodiol than oleanolic acid, 
producing 5 mg/L erythrodiol, while the oleanolic acid peak was too small for titres to 
be calculated (Figure 5.7 A). It also produced a relatively small amount of oleanolic 
aldehyde compared with the other CYP716As (Figure 5.7 B). However, two additional 
products (U3 and U4) were also observed (Figure 5.8 A). These had retention times 
of 18.48 min (U3) and 18.88 min (U4), and had slightly larger peaks than oleanolic 
acid. Khakimov et al. also reported additional products with similar retention times for 
this enzyme, and reasoned that both were β-amyrin derivatives, the first containing 
two hydroxyl groups and the other being similar but containing an additional double 
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Figure 5.8. CYP716A80 produces additional products. (A) Total ion chromatogram overlay 
of the strains expressing the oleanolic acid pathways containing CYP716A80 and 
CYP716AL1, AaBAS alone, or the empty vector control (MD-N1). The two additional peaks 
observed for CYP716A80 (U3 and U4) are labelled. (B-C) Mass spectra of peaks U3 and U4, 
with background mass spectra (corresponding to 19.049 - 19.545 min of each sample) 
subtracted. Both are consistent with them being β-amyrin derivatives. 
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bond (Khakimov et al., 2015). Indeed, the mass spectrum of U3 contains a fragment 
ion with an m/z of 216 (Figure 5.8 B), which is characteristic of β-amyrin derivatives 
that contain a hydroxyl group in their diene fragment (see Chapter 3). Furthermore, a 
low abundance peak with an m/z of 496 could result from the loss of a TMSOH (90 
Da) from the parent ion, and a low abundance peak with an m/z of 586 is indeed 
visible in the mass spectrum (Figure 5.8 B). In this case, the parent ion of U3 would 
have the same m/z as the erythrodiol parent ion (586). This would indicate that U3 
and erythrodiol are structural isomers, with U3 being derived from β-amyrin by a single 
hydroxylation, supporting the hypothesis that U3 contains two hydroxyl groups. 
The mass spectrum of U4 contained peaks with m/z values of 584, 569, 494 and 479, 
which could represent the parent ion, the loss of a TMSOH (90 Da) from the parent, 
and/or the loss of a methyl group (15 Da) (Figure 5.8 C). This indicates that U4 also 
contains a hydroxyl group. Furthermore, the mass spectrum contains ions with m/z 
values of two lower than the corresponding ions for U3 (e.g. 584 vs. 586, 569 vs. 571, 
494 vs. 496 and 479 vs. 481). This is consistent with it containing an additional double 
bond as proposed by Khakimov et al. (Khakimov et al., 2015), because the addition 
of a double bond is accompanied by the loss of two hydrogen atoms, decreasing the 
m/z by two. Comparison with the mass spectrum of erythrodiol (see Figure 3.4 B and 
Table 3.1 in Chapter 3) shows that the erythrodiol parent ion (m/z 586) has an m/z of 
two higher than the U4 parent ion, and erythrodiol has fragment ions with m/z values 
of 496 and 481, while U4 has fragments ions with m/z values of 494 and 479 (two m/z 
values lower). This is consistent with U4 having two hydroxyl groups (like erythrodiol) 
but an additional double bond. U4 does not contain the fragment ion with an m/z of 
216, which is characteristic of β-amyrin derivatives containing a hydroxyl in their diene 
fragment. However, this would make sense if the additional double bond was present 
in the diene fragment. In this case, a fragment ion with m/z 214 would be expected, 
and a peak with this m/z value is indeed observed (Figure 5.8 C). 
No oxidised products were observed for CYP716A140 (Figure 5.7 A-B). However, it 
was previously reported to oxidise β-amyrin, as well as 12,13α-epoxy-β-amyrin and 
16β-hydroxy-β-amyrin, with the latter being the favoured substrate (Miettinen et al., 
2017). It is likely that this enzyme simply showed low activity in this study, and its 
products could not be detected using the current method. Finally, while erythrodiol, 
oleanolic aldehyde and oleanolic acid were all observed for CYP716A179, these were 
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in low abundance (Figure 5.7 A-B), with erythrodiol and oleanolic acid titres of only 
1.13 mg/L and 2.08 mg/L, respectively. These represent the joint lowest erythrodiol 
titres (with CYP716A110, which produced 1.12 mg/L) and the lowest oleanolic acid 
titre of the CYP716As. 
In addition to the expected products, two further peaks were observed for all 
CYP716As, the first eluting ~ 0.6 min after β-amyrin and the second ~ 0.4 min after 
erythrodiol (Figure 5.9 A). Most of the BASs tested in the BAS comparative analysis, 
including AaBAS, had an additional small peak that also eluted ~ 0.6 min after β-
amyrin, and appeared to be lupeol based on their mass spectra (see Figure 4.14 of 
Chapter 4). For BvBAS, this peak was much larger and was suggested to be lupeol 
based on comparison of its mass spectrum with those reported in the literature. For 
the current experiment, the strain expressing AaBAS alone had a small putative peak 
at this position (Figure 5.9 A), although it was smaller than the corresponding peak 
observed for AaBAS in Chapter 4 (Figure 4.14). The corresponding peak in the 
CYP716A strains was larger, perhaps suggestive of metabolic pull-through. However, 
in both cases the signal was weak enough to make interpretation of the mass spectra 
difficult (Figure 5.9 B-C). Therefore, the first additional peak potentially corresponds 
to lupeol, but further analysis is required to confirm this. If the first peak is indeed 
lupeol, then the second additional peak may be betulin, the C-28 hydroxy derivative 
of lupeol. Betulin is the lupane equivalent of erythrodiol, which is the C-28 hydroxy 
derivative of β-amyrin, and this is therefore consistent with it having a similar retention 
time to erythrodiol. However, as with the putative lupeol peak, it was in low abundance 
and the mass spectrum was difficult to interpret. As such, the identities of these peaks 
cannot be confirmed. 
Interestingly, there was no noticeable substrate depletion in the CYP716A strains. All 
accumulated similar amounts of β-amyrin to the strain expressing AaBAS alone, 
despite many producing significant amounts of erythrodiol and oleanolic acid (Figure 
5.7 C). Indeed, CYP716A75 produced 7.8 mg/L β-amyrin and 20.9 mg/L erythrodiol, 
for a total triterpenoid content of 28.7 mg/L. By contrast, the AaBAS strain produced 
9 mg/L β-amyrin, a > 3-fold lower total triterpenoid titre than CYP716A75. Thus, 
expression of the CYP716A enzymes did not deplete the cellular β-amyrin pool. This 
may be indicative of a metabolic “pull-through” effect, where expression of 
downstream enzymes increases the flux through the upstream parts of the pathway. 
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Figure 5.9 Additional triterpenoid produced by the other CYP716As. (A) Overlay of total 
ion chromatograms showing the two additional peaks (U1 and U2) observed for many 
CYP716As. Peaks U3 and U4, which were only observed for CYP716A80, are also labelled. 
(B-C) Mass spectra of peaks U1 and U2 from CYP716AL1, with the background spectra 
(corresponding to 18.601 - 19.000 min of each sample) subtracted. Peak U1 was also 
observed for AaBAS, while U2 was unique to the strains expressing a CYP716A.
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In strains expressing only a BAS, β-amyrin titres may be constrained by toxicity or 
inhibition of the BAS when cellular β-amyrin levels reach a certain threshold, 
preventing it from accumulating further. Utilisation of β-amyrin by the CYP716As 
might relieve this inhibition and allow more β-amyrin to be produced by the BAS, the 
result being that β-amyrin is not depleted by CYP716A expression but instead 
remains at a constant level. 
5.4 Growth of CYP716A strains 
The growth curves showed that all CYP716A strains grew more slowly in galactose-
supplemented media than the empty vector control (MD-N1) (Figure 5.10 A). By 
contrast, all grew similarly in glucose-supplemented media (Figure 5.10 B), which was 
also seen in the BAS comparative analysis (see Chapter 4). The relative final cell 
densities from the growth curves generally agreed with the relative final OD600 values 
from the production runs. The strains can be divided into two groups based on the 
shape of their growth curves in galactose-supplemented media. The first group grew 
similarly to the strain expressing AaBAS alone, having a relatively short lag phase 
similar to MD-N1 (~ 10 h) and slow exponential growth (Figure 5.10 A). It included 
CYP716A52v2, CYP716A79, CYP716A110, CYP716A140, CYP716A179 and 
CYP716A1. The second group, containing the remaining strains, had a longer lag 
phase of ~ 30 h but a fast exponential phase. 
All CYP716As in the first group produced little or no oleanolic aldehyde and oleanolic 
acid, and most produced little or no erythrodiol (Figure 5.7 A-B). In fact, the first group 
contained all the CYP716As that produced little of any oxidised product (CYP716A79, 
CYP716A110, CYP716A140, and CYP716A179). The exceptions were 
CYP716A52v2 and CYP716A1, which produced significant amounts of erythrodiol 
(5.8 mg/L and 4.6 mg/L, respectively). However, CYP716A52v2 accumulated very 
little oleanolic aldehyde and oleanolic acid, and CYP716A1 produced only erythrodiol. 
Thus, these P450s produced low levels of oxidised triterpenoids. 
Most enzymes in the second group produced significantly more oleanolic aldehyde 
and oleanolic acid than those in the first group, and generally had higher activities, 
producing more oxidised triterpenoids (Figure 5.7 A-B). The exceptions to this were 
CYP716A75 and CYP716A80. The latter accumulated similar amounts of erythrodiol, 
oleanolic aldehyde and oleanolic acid to CYP716A52v2. However, it also produced 
two additional products in significant amounts (Figure 5.8 A), and the amount of total 
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Figure 5.10. Growth of CYP716A strains in a 96-well plate assay. Cells were grown in 96-
well plates in media supplemented with either galactose (A) or glucose (B). OD595 was 
measured every 15 min for 96 h using a Tecan Sunrise plate reader. All triterpenoid-producing 
strains grew considerably slower than the empty vector control (MD-N1) in galactose, while 
growth was similar in glucose. Shown is the mean ± 1 standard deviation for 3 biological 
replicates. 
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oxidised triterpenoids is therefore probably higher. CYP716A75 produced very low 
levels of oleanolic aldehyde and no detectable oleanolic acid, similar to the group one 
P450s (Figure 5.7 A-B). However, it had a high erythrodiol titre and therefore 
accumulated a large amount of oxidised triterpenoid (Figure 5.7 A, Table 5.2). 
CYP716A75 grew faster than the other P450s in the second group, entering stationary 
phase slightly earlier and reaching a higher OD595, and also reached a slightly higher 
final OD600 in the production runs compared with the other strains (Figure 5.8 A). 
It was interesting that some CYP716A strains (group one) had similar growth profiles 
to the strain expressing AaBAS alone, while for others (group two) the shape of the 
growth curve was markedly different (Figure 5.8 A). The group one strains grew 
slightly faster than AaBAS, having a faster exponential phase, entering stationary 
phase earlier, and reaching a higher final OD595. This suggests that there was little 
additional burden to expressing these enzymes, and that there may be a small growth 
benefit to expressing them. The different shapes of the growth curves between the 
group 2 strains and the AaBAS strain indicate that these CYP716As also have an 
impact on cell burden. However, it is unclear from the present data what is causing 
these differences. Overall, the growth curves, combined with the similar ergosterol 
titres and final OD600 of the CYP716A strains and the AaBAS strain, indicate that there 
is relatively little additional burden caused by CYP716A expression, and that BAS 
expression may cause the majority of the cellular burden. 
The differences in growth cannot be explained by differences in β-amyrin or ergosterol 
levels, as these are similar across all strains except MD-N1, as is the final OD600 
(Figure 5.7 C-E). It is possible that the total amount of oxidised triterpenoids has an 
impact, as the group one strains all accumulated less oxidised triterpenoids than the 
group two strains. It is also possible that β-amyrin accumulation in the cells is toxic, 
and therefore reduces cell growth, while the accumulation of oxidised triterpenoids 
works to offset this by some unknown mechanism. Triterpenoids are structurally 
similar to sterols and may therefore insert into cell membranes, which could disrupt 
their integrity and cause the observed reductions in growth rate. Indeed, analysis of a 
strain expressing a catalytically inactive AaBAS suggested that the burden observed 
in the AaBAS strain might be partly due to β-amyrin production, although it remained 
possible that differences in expression levels between the wild-type and inactive 
AaBAS variants could have explained the data (see section 4.5).  
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Another possible explanation for the observed differences in growth rate could be 
differences in the expression levels of the enzymes. It is possible that the group one 
P450s were expressed at low levels, while those in group two were expressed more 
highly. This could explain why the group one P450s produced lower amounts of 
oxidised triterpenoids compared with the group two P450s. In addition, it might explain 
the similar growth profiles of the group one strains to the AaBAS strain, as they could 
be expressed at such low levels as to not cause any burden, while higher expression 
of the group two P450s could explain their more substantial effect on growth. 
However, the group one strains did grow slightly faster than AaBAS, and in fact all 
strains reached slightly higher ODs than AaBAS (Figure 5.7 E, Figure 5.8 A), which 
is unlikely to be explained by differences in expression levels alone. Differences in 
stability of the P450s could also contribute to the differences in growth rate, as 
misfolding of the P450s (or indeed ATR2) could cause burden on the unfolded protein 
response, affecting growth. 
Figure 5.11. Analysis of CYP716A and ATR2 expression by western blot and RT-PCR. 
Western blots (A) and RT-PCR (B) were performed on strains expressing 6xHis-tagged 
CYP716A12, CYP716A15, CYP716AL1, CYP716A52v2 and ATR2. For the western blots, 
each strain co-expressed a CYP716A and ATR2. A strain expressing His-tagged EtBAS was 
also analysed as a positive control. No CYP716A or ATR2 protein was detected by western 
blot, whereas mRNA was detected by RT-PCR, indicating that the genes were expressed. 
The expected molecular weights of the CYP716As and ATR2 were 54 kDa and 79 kDa, 
respectively. Molecular weights for the protein and DNA ladders are in kDa and bp, 
respectively. 
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Western blot analysis of four P450s (CYP716A12, CYP716A15, CYP716AL1 and 
CYP716A52v2) and ATR2 was unable to detect these enzymes (Figure 5.11 A), while 
mRNA was detected by RT-PCR (Figure 5.11 B). Furthermore, five of six selected 
BASs were detected by western blot (see Chapter 4, Figure 4.11 A); AsBAS was not 
detected. This might be consistent with the P450s and ATR2 being expressed at lower 
levels than the BASs. However, further work will be necessary to successfully detect 
the P450s and ATR2 and confirm the relative protein levels of the BASs, P450s and 
ATR2. 
Although variations in expression level could explain some of the differences in activity 
between the CYP716As, it would not explain differences in product profiles. These 
would instead be best explained by differences in the enzymes themselves. 
Therefore, to properly understand why the CYP716A homologues vary in terms of 
their product profiles, overall activities and burden, expression levels must be 
determined and in silico analyses performed to assess these differences. While 
expression levels unfortunately could not be determined, in silico analyses were 
nevertheless performed to investigate the possible causes of the differences in 
product profiles. 
5.5 In silico analyses of CYP716A homologues 
The CYP716As had a range of activities and product profiles, with CYP716A75 
producing almost exclusively erythrodiol and others, such as CYP716AL1, producing 
significant amounts of oleanolic acid. Furthermore, CYP716A80 accumulated two 
additional triterpenoids in notable abundance. As such, the multiple sequence 
alignments generated earlier (Figure 5.4) were analysed to investigate the cause of 
this variation. 
Most of the CYP716As had 64 % to 90 % sequence identities (Figure 5.5) and only 
displayed β-amyrin C-28 oxidase activity, accumulating erythrodiol, oleanolic 
aldehyde and oleanolic acid (Figure 5.7 A-B). However, CYP716A80 and CYP716A1 
had relatively low sequence identities (< 63 %) to the other CYP716As and 81 % 
identity to each other. Both displayed β-amyrin C-28 oxidise activity but CYP716A80 
also produced two additional products. Although CYP716A1 only produced 
erythrodiol, a previous study reported it to have weak C-22α hydroxylation activity 
against α-amyrin, and to oxidise lupeol to an unknown product (Yasumoto et al., 
2016). All other CYP716As tested here have only been reported to have C-28 oxidase 
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activity. Thus, these differences in activities appear to correlate well with sequence 
identities. 
The P450 superfamily has very low sequence conservation, and sequence identities 
can be < 20 %. However, they have a highly conserved tertiary structure, particularly 
around the catalytic core (Werck-Reichhart and Feyereisen, 2000). The active site 
contains a haem group, with the iron coordinated by a cysteine residue that is 
conserved across all P450s (Bak et al., 2011). Important sequence motifs in the core 
include: the haem binding loop containing the highly conserved FxxGxRxCxG motif, 
which contains the conserved cysteine; the ERR triad, which is important in stabilising 
the core structure, and corresponds to the Glu and Arg residues of the EXXR motif 
and the Arg residue of the PERF motif; and the proton transfer groove 
(A/GCxD/ETT/S motif) (Werck-Reichhart and Feyereisen, 2000; Bak et al., 2011). 
Plant P450s are membrane bound, typically localising to the endoplasmic reticulum 
(ER) (Bak et al., 2011). Such P450s have an N-terminal membrane anchor rich in 
hydrophobic sequences, often followed by a cluster of basic residues called the halt 
transfer signal and a cluster of prolines (the PPXP motif) that acts as a hinge between 
the membrane and cytoplasmic domains of the protein (Werck-Reichhart and 
Feyereisen, 2000). The N-terminal anchor and the substrate binding regions show the 
highest sequence variability (Werck-Reichhart and Feyereisen, 2000). 
Analysis of the multiple sequence alignment identified the highly conserved haem 
binding loop (FxxGxRxCxG motif), with all tested CYP716As sharing the sequence 
FGGGPRMCPG (Figure 5.4). The CYP716As had the consensus sequences E-V-
M/L-R and P-S/T/N-R-F/Y, which correspond to the ExxR and PERF motifs that make 
up the ERR triad. The proton transfer groove had the sequence GGHDTA for all 
CYP716As, differing from the P450 consensus (A/G-G-X-D/E-T-T/S) only in the final 
residue (A instead of T/S). The position of the membrane anchors were predicted 
using the TMHMM server (http://www.cbs.dtu.dk/services/TMHMM), and were 
located at the N-terminus as expected (Figure 5.4). In addition, a cluster of three 
proline residues was located just C-terminal to the membrane anchor (sequence 
PPGxxGxP), which may correspond to the hinge region. The CYP716As typically 
contained two to three Lys or Arg residues between the membrane anchor and proline 
cluster, corresponding to the cluster of basic residues that has been reported for 
P450s (Werck-Reichhart and Feyereisen, 2000). Unfortunately, the low sequence 
Chapter 5: Comparison of CYP716As for oleanolic acid production 
 160 
conservation outside of these regions makes it difficult to identify amino acid variants 
responsible for the observed differences in product specificity and activity. 
5.6 Comparing BASs and CYP716As with different 
productivities for oleanolic acid production 
The CYP716As were co-expressed with AaBAS, which was identified as the most 
productive BAS homologue from the comparative analysis. CYP716AL1 was found to 
produce the most oleanolic acid in the CYP716A comparative analysis. Thus, the 
CYP716AL1 strain (MD-OA15) should represent an optimal strain for oleanolic acid 
production in terms of the BAS and CYP716A homologue expressed. This strain was 
compared with strains expressing less productive BAS and CYP716A homologues, 
to determine whether combining the optimal homologues of each enzyme class did 
indeed boost production. The following strains were analysed: MD-OA15 (expressing 
AaBAS and CYP716AL1), MD-OA16 (AaBAS, CYP716A52v2), MD-OA30 (SlBAS, 
CYP716AL1) and MD-OA31 (SlBAS, CYP716A52v2). SlBAS gave the lowest β-
amyrin titres after PgBAS1, while CYP716A52v2 produced low but detectable levels 
of oleanolic aldehyde and oleanolic acid. Co-expression of these enzymes is therefore 
expected to result in the production of low but detectable amounts of triterpenoids. By 
contrast, use of poor performing homologues such as PgBAS1 or CYP716A179 are 
less likely to result in detectable peaks in the total ion chromatograms, which would 
prevent comparison of titres with the strains expressing AaBAS and CYP716AL1. 
The strains were analysed by GC-MS, and growth curves were generated using a 
microplate assay as before. For the GC-MS analysis, strains were grown in shake 
flasks, which may improve growth and possibly production by providing better 
agitation and aeration. MD-OA31 (SlBAS, CYP716A52v2) produced very low levels 
of erythrodiol (1.2 mg/L), oleanolic aldehyde and oleanolic acid, however titres for the 
latter could not be calculated due to the small peak area (Figure 5.12 A-B). By 
contrast, MD-OA16, which expressed AaBAS and CYP716A52v2, produced 5.4-fold 
more erythrodiol (6.4 mg/L), more oleanolic aldehyde, and small amount of oleanolic 
acid, which again was not abundant enough for titres to be calculated. It also 
accumulated substantially more β-amyrin (9.6 mg/L) than MD-OA31 (3.0 mg/L), 
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Figure 5.12. Comparison of “optimal” and “suboptimal” oleanolic acid pathways. 
Strains expressing combinations of BASs and CYP716As with high (AaBAS, CYP716AL1) or 
low (SlBAS, CYP716A52v2) productivities were analysed for triterpenoid production by GC-
MS. Control strains expressing the BAS alone or carrying an empty vector (MD-N1) were also 
analysed. (A) β-amyrin, erythrodiol and oleanolic acid titres. (B) Oleanolic aldehyde 
normalised peak areas. (C) Ergosterol titres. (D) OD600 at the end of the production run. The 
strain expressing the best performing BAS and CYP716A homologues (MD-OA15; AaBAS 
and CYP716AL1) produced considerably more triterpenoids than that expressing the poor 
performing homologues (MD-OA31; SlBAS and CYP716A52v2). *, titre could not be 
calculated as the peak area fell below the linear region of the standard curve; **, no peak 
observed in the TIC. Shown is the mean ± 1 standard deviation for 3 biological replicates. 
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indicating that the choice of BAS had a significant effect on triterpenoid titres and 
product ratios by providing a greater β-amyrin substrate pool for the P450. 
Commensurate with this, the strain expressing AaBAS alone produced substantially 
more β-amyrin than that expressing SlBAS, and these strains both produced slightly 
more β-amyrin than the corresponding oleanolic acid strains expressing the same 
BAS (Figure 5.12 A). 
MD-OA30 (SlBAS, CYP716AL1) produced a similar amount of erythrodiol (1.7 mg/L), 
more oleanolic aldehyde and considerably more oleanolic acid (2.9 mg/L) than MD-
OA31, while accumulating similar amounts of β-amyrin (2.5 mg/L) (Figure 5.12 A-B). 
This strain also accumulated significantly less β-amyrin, erythrodiol, oleanolic 
aldehyde and oleanolic acid than MD-OA15 (AaBAS, CYP716AL1). Comparison of 
MD-OA31 with MD-OA15, which represent the “suboptimal” and “optimal” strains in 
terms of BAS and CYP716A homologue, respectively, showed that MD-OA15 
produced 2.8-fold more β-amyrin and 6.1-fold more erythrodiol. The fold difference in 
oleanolic acid titres could not be calculated because low productivity of MD-OA31 
prevented oleanolic acid titres from being determined. However, MD-OA15 
accumulated 3-fold more oleanolic acid than MD-OA30. Thus, combining the most 
productive BAS with the most productive CYP716A greatly improved triterpenoid 
titres. 
The final OD600 was similar for all oleanolic acid strains, indicating that changing the 
BAS and P450 had little effect on the final cell density (Figure 5.12 D). By contrast, 
the strain expressing SlBAS alone reached a higher OD600 than AaBAS. Ergosterol 
titres were a little higher in the oleanolic acid strains expressing SlBAS compared with 
AaBAS, and were similar to the strains expressing a BAS only (Figure 5.12 C). 
The growth in galactose-supplemented media varied depending on the strain (Figure 
5.13 A), while all strains grew similarly in glucose-supplemented media (Figure 5.13 
B). Notably, the strains expressing AaBAS grew faster than those expressing SlBAS 
(Figure 5.13 A). SlBAS grew very slowly, as did the corresponding oleanolic acid 
strains expressing this BAS (MD-OA30 and 31). MD-OA16, which expressed AaBAS 
and CYP716A52v2, grew faster than the AaBAS-only strain, while MD-OA15 (AaBAS, 
CYP716AL1) had a longer lag phase but a much faster exponential phase than MD-
OA16 and the AaBAS-only strain (Figure 5.13 A). However, due to relatively large 
error bounds in the MD-OA16 growth curve, it cannot be determined whether the 
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Figure 5.13. Growth of strains expressing “optimal” and “suboptimal” oleanolic acid 
pathways. The growth of strains expressing combinations of BASs and CYP716As with high 
(AaBAS, CYP716AL1) or low (SlBAS, CYP716A52v2) productivities were monitored using a 
96-well plate assay. Cells were grown in galactose (A) or glucose (B) supplemented media 
and OD595 was measured every 15 min for 96 h in a Tecan Sunrise plate reader. Strains 
expressing SlBAS grew more slowly than those expressing AaBAS, indicating that the BAS 
homologue is the primary determinant of strain growth. 
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growth dynamics of MD-OA15 and 16 are genuinely different. Nevertheless, both 
display different growth curves to the AaBAS-only strain, indicating that the additional 
expression of the P450 and ATR2 affects growth. It is interesting that expressing the 
P450 and ATR2 did not have an observable effect on the growth rate of the SlBAS 
strain. This might be because the SlBAS-only strain already grew very slow, meaning 
that any additional effect of P450 and ATR2 expression could not be observed. As 
expected, MD-N1 grew considerably faster than the other strains in galactose-
supplemented media (Figure 5.13 A). Together, the data suggest that while the 
additional expression of the P450 and ATR2 can affect growth, the choice of BAS is 
the primary determinant of growth rate. 
Triterpenoid and ergosterol titres for the shake flask cultures were similar to those 
observed for the comparative analysis, which was performed in glass culture vials 
(Figure 5.18). One notable exception was the oleanolic acid titre of MD-OA15, which 
was 8.5 mg/L in the shake flask experiment compared with 14.1 mg/L in the culture 
vials. The cause of this is unknown, but could possibly be explained by differences in 
aeration (the P450-catalysed reaction is oxygen-dependent). The final OD600 was also 
similar for both shake flask and glass vial cultures. Thus, in general, culturing in shake 
flasks had a negligible impact on growth and productivity. 
5.7 Comparing AaBAS and AsBAS for oleanolic acid 
production 
The BAS comparative analysis showed that AsBAS expression had little effect on 
growth rate compared with an empty vector control strain (MD-N1), yet still produced 
a considerable amount of β-amyrin (Figure 5.8 A, Figure 5.7 C). By contrast, the strain 
expressing AaBAS grew much slower compared with AsBAS and MD-N1, and was 
used in the CYP716A comparative analysis due to its superior β-amyrin titres. The 
CYP716A strains grew much more slowly compared with MD-N1, probably due to 
burden caused by expression of the triterpenoid biosynthetic pathway, and it is 
possible that this may limit productivity. The use of AsBAS instead of AaBAS may 
afford a faster growth rate, which could affect triterpenoid titres. A strain expressing 
AsBAS and CYP716AL1 (MD-OA29) was therefore analysed for triterpenoid 
production by GC-MS, culturing in shake flasks as above. Growth was also monitored 
using the microplate assay. MD-OA15 (AaBAS, CYP716AL1) and MD-N1, as well as 
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strains expressing AaBAS or AsBAS alone (MD-BA14 and MD-BA1), were also 
analysed as controls. 
There was a considerable difference in triterpenoid titres and product ratios between 
the two strains (Figure 5.14 A-B). While MD-OA15 produced substantial amounts of 
β-amyrin, erythrodiol, oleanolic aldehyde and oleanolic acid, MD-OA29 accumulated 
predominantly oleanolic acid. β-amyrin and erythrodiol titres could not be calculated 
for MD-OA29 as the peak areas were too low, while the oleanolic acid titres were 
similar to MD-OA15 (7.1 mg/L for MD-OA29 and 8.5 mg/L for MD-OA15). MD-OA29 
reached a slightly higher OD600 than MD-OA15 (7.8 vs. 6.1) and produced more 
ergosterol (Figure 5.14 C-D). 
The growth curves showed that MD-OA15 and MD-OA29 also grew at considerably 
different rates in galactose-supplemented media, with MD-OA29 growing much faster 
than MD-OA15 (Figure 5.15 A). Interestingly, MD-OA29 grew at a similar rate to MD-
BA1 (AsBAS alone), while MD-OA15 grew more similarly to MD-BA14 (AaBAS alone). 
The growth of MD-OA15 was a little different to MD-BA14, having a longer lag phase 
followed by a fast exponential, whereas MD-BA14 had a long exponential phase 
characterised by slow growth. Thus, the additional expression of CYP716AL1 and 
ATR2 had little effect on growth rate in the AsBAS strain, while it adjusted the growth 
dynamics in the AaBAS strain but still had much slower growth compared with MD-
N1. As expected, all strains grew similarly in glucose-supplemented media, although 
the strains expressing BAS alone reached a slightly lower OD595 than the other strains 
(Figure 5.15 B). 
The data thus suggest that much of the observed burden is caused by the BAS rather 
than the P450 and ATR2. This is consistent with the growth curves from the CYP716A 
comparative analysis, where none of the strains grew slower than MD-BA14 (Figure 
5.8 A). It is also consistent with the growth curves in the previous section, where the 
oleanolic acid strains grew similarly to the strains expressing only the corresponding 
BAS (Figure 5.13 A). 
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Figure 5.14. Comparison of strains expressing AaBAS and AsBAS for oleanolic acid 
production. Strains expressing either AaBAS or AsBAS in an oleanolic acid pathway (BAS, 
CYP716AL1 and ATR2) were analysed for triterpenoid production by GC-MS. Control strains 
expressing the BAS alone or carrying an empty vector (MD-N1) were also analysed. (A) β-
amyrin, erythrodiol and oleanolic acid titres. (B) Oleanolic aldehyde normalised peak areas. 
(C) Ergosterol titres. (D) OD600 at the end of the production run. MD-OA29, which expressed 
AsBAS, produced predominantly oleanolic acid, with little β-amyrin, erythrodiol and oleanolic 
aldehyde detected. By contrast, MD-OA15, which expressed AaBAS, produced a more even 
mixture of these triterpenoids. *, titre could not be calculated as the peak area fell below the 
linear region of the standard curve; **, no peak observed in the TIC. Shown is the mean ± 1 
standard deviation for 3 biological replicates. P-values calculated using a Welch (unequal 
variances) two-sample t-test in R. 
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Figure 5.15. Growth of strains expressing oleanolic acid pathways containing either 
AaBAS or AsBAS. The growth of strains MD-OA15 (AaBAS, CYP716AL1, ATR2) and MD-
OA29 (AsBAS, CYP716AL1, ATR2) were monitored using a 96-well plate assay. Strains 
expressing the BAS alone or carrying an empty vector (MD-N1) were also analysed. Cells 
were grown in galactose (A) or glucose (B) supplemented media and OD595 was measured 
every 15 min for 96 h in a Tecan Sunrise plate reader. MD-OA29 grew at similar rate to AsBAS 
and MD-N1 in galactose, while MD-OA15 and AaBAS grew much more slowly. 
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5.8 BioLector fermentations of oleanolic acid and β-
amyrin strains 
To assess strain growth during an actual fermentation run, cells were cultured using 
a BioLector micro fermentation system (m2p-labs GmbH, Baesweiler, Germany). This 
allows biomass to be measured throughout the fermentation run, and cultures can be 
harvested at the end of culturing for GC-MS analysis. During the 96-well plate assays 
performed earlier, it was noticed that cells had settled to the bottom of the wells by 
the end of the culture period, which may have affected strain growth. Indeed, plate 
readers generally have low shaking speeds and stop shaking during measurements, 
which contributes to the settling of cells. Furthermore, oxygen transfer is known to be 
poor when growing cells in 96-well plates due to the poor shaking regime, and the 
lack of humidity control can result in evaporation from the wells, which can have an 
impact on results (Kensy et al., 2009). The BioLector uses 48-well plates with baffled 
wells and continuous shaking that continues during measurements. This gives a 
similar agitation to that seen in conventional bioreactors and should prevent cells from 
settling and improve oxygen transfer (Kensy et al., 2009; Back et al., 2016). In 
addition, humidity can be maintained to prevent evaporation. The BioLector uses 
scattered light to measure cell biomass, which allows measurements of higher 
biomass concentrations to be made compared with OD600 readings, which are known 
to be inaccurate at high biomass concentrations (Back et al., 2016). Thus, growth 
curves generated using the BioLector should be more representative of strain growth 
during a fermentation run. 
Strains MD-OA15 and MD-OA29, as well strains expressing only a BAS (either 
AaBAS or AsBAS) and MD-N1, were cultured in the BioLector for 96 h. Biomass was 
measured every 15 min, and the OD600 was measured and cellular metabolites were 
analysed by GC-MS at the end of the fermentation. The results were similar to the 
shake flask experiments above, with MD-OA29 producing mainly oleanolic acid, and 
reaching a higher OD600 and producing more ergosterol than MD-OA15 (Figure 5.16). 
However, MD-OA29 produced more oleanolic acid than MD-OA15, and the strain 
expressing only AsBAS produced a similar amount of β-amyrin to AaBAS (Figure 5.16 
A). This contrasted with the results from the shake flask experiment, where MD-OA15 
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Figure 5.16. BioLector fermentations for oleanolic acid production. Strains MD-OA15 
and MD-OA29, which expressed oleanolic acid pathways containing AaBAS or AsBAS, 
respectively, were grown in a BioLector for 96 h and triterpenoid production was measured 
by GC-MS. Control strains expressing the BAS alone or carrying an empty vector (MD-N1) 
were also analysed. (A) β-amyrin, erythrodiol and oleanolic acid titres. (B) Oleanolic aldehyde 
normalised peak areas. (C) Ergosterol titres. (D) OD600 at the end of the production run. *, 
titre could not be calculated as the peak area fell below the linear region of the standard curve; 
**, no peak observed in the TIC. Shown is the mean ± 1 standard deviation for 3 biological 
replicates. P-values calculated using a Welch (unequal variances) two-sample t-test in R. 
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produced more oleanolic acid than MD-OA29, and AaBAS gave higher β-amyrin titres 
than AsBAS (Figure 5.14 A). 
Similar to the growth curves generated using the plate reader assay above, MD-OA15 
grew similarly to the strain expressing AaBAS alone, while MD-OA29 grew at a similar 
rate to the strain expressing AsBAS alone (Figure 5.17, Figure 5.15 A). However, the 
shapes of the growth curves were a little different than in the plate reader assay. 
Notably, MD-OA15 had a shorter lag phase and a much longer and slower exponential 
phase in the BioLector fermentation, similar to AaBAS. By contrast, in the plate reader 
assay it had a long lag phase followed by a relatively fast exponential phase (Figure 
5.15 A). This difference may be due to the improved agitation and oxygenation 
provided by the BioLector, which could allow cells to start growing sooner after 
inoculation, contributing to a shorter lag phase.  
Furthermore, in the plate reader assay growth slowed considerably following the 
exponential phase and appeared to approach a stationary phase by the end of the 
culture (Figure 5.15 A). By contrast, growth in the BioLector slowed by a much smaller 
degree following the exponential phase and did not appear to be approaching a 
stationary phase by the end of the fermentation (Figure 5.17). Yeast growth is typically 
characterised by a lag phase, an exponential phase where fermentation and 
respiration of sugars occurs, a diauxic shift, a post-diauxic growth phase where cells 
perform only respiration, and finally a stationary phase (Teste et al., 2009). This was 
the pattern observed for MD-OA29, MD-N1 and AsBAS when grown in the BioLector, 
although it was less apparent for MD-OA15 and AaBAS, perhaps because of their 
slow growth (Figure 5.17). In the plate reader assay, the growth period following the 
exponential phase likely corresponds to this post-diauxic growth phase (Figure 5.15 
A). The fact that growth appears to be much slower here compared with the BioLector 
fermentations could be due to poor mixing and oxygenation in the 96-well plate, or 
due to issues with measuring OD595 at high cell densities. The fact that MD-OA15, 
which reached a lower OD595 than MD-OA29, MD-N1 and AsBAS, also showed slow 
post-exponential growth in the plate reader assay indicates that the former is the case. 
A comparison of selected strains grown in culture vials (from the CYP716A 
comparative analysis), shake flasks and the BioLector is presented in Figure 5.18. 
Titres and the final OD600 were generally similar across all three experiments. 
However, the oleanolic acid titre for MD-OA15 was only 8.5 mg/L in the shake flask  
Chapter 5: Comparison of CYP716As for oleanolic acid production 
 171 
experiment and 4.1 mg/L for the BioLector fermentation, compared with 14.1 mg/L for 
the culture vials (Figure 5.18 D). Erythrodiol titres for MD-OA15 were similar between 
the culture vials and shake flasks (6.7 mg/L and 7.3 mg/L, respectively), but only 3.0 
mg/L for the BioLector (Figure 5.18 B). It is unclear why oleanolic acid and erythrodiol 
titres for MD-OA15 were lower in the BioLector fermentation compared with the 
culture vials and shake flasks, especially considering that β-amyrin titres, ergosterol 
titres and the final OD600 were similar across all experiments for this strain, and that 




Figure 5.17. Growth of strains in the BioLector. Biomass was measured every 15 min for 
the duration of the fermentation (96 h) with continuous shaking and humidity maintained at 
85 % relative humidity. MD-OA29, AsBAS and MD-N1 grew similarly, while MD-OA15 and 
AaBAS grew more slowly. This corroborates the data from the 96-well plate assays, 
suggesting that the choice of BAS is the most important determinant for growth. Shown is the 
mean ± 1 standard deviation for 3 biological replicates. 
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Figure 5.18. Comparison of culture vials, shake flasks and the BioLector for 
triterpenoid production. Titres of β-amyrin (A), erythrodiol (B), ergosterol (C) and oleanolic 
acid (D), and the OD600 at the end of the production runs (E), are shown. Data for the culture 
vials are from the CYP716A comparative analysis. Titres and OD600 were similar for all 
methods of culture, with the exception of MD-OA15 erythrodiol and oleanolic acid titres, which 
were lower in the BioLector experiment (erythrodiol) or in both the shake flask and BioLector 
experiments (oleanolic acid). *, titre could not be calculated as the peak area fell below the 
linear region of the standard curve; na, strain not analysed in this experiment. Shown is the 
mean ± 1 standard deviation for 3 biological replicates. 
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5.9 Discussion 
Sixteen CYP716As were compared for their ability to oxidise β-amyrin to oleanolic 
acid when expressed in yeast. A range of activities and product ratios were observed, 
with calculated oleanolic acid titres ranging from 14.1 mg/L (for CYP716AL1) to 2.08 
mg/L (for CYP716A179), a 6.8-fold difference (Figure 5.7 A). Interestingly, 
CYP716A75 produced 20.9 mg/L erythrodiol, representing the highest triterpenoid 
titre in the present study, and accumulated very little oleanolic aldehyde or oleanolic 
acid (Figure 5.7 A-B). By contrast, CYP716A110 produced only 1.12 mg/L erythrodiol, 
an 18.7-fold difference than CYP716A75. Growth assays showed that all strains 
generally grew similarly, although they could be divided into two groups based on the 
shape of their growth curves (Figure 5.10 A). 
Notably, these titres were reported in strains that expressed only the oleanolic acid 
biosynthetic pathway and were otherwise unoptimised for triterpenoid production. 
Higher oleanolic acid titres have been reported in strains that were metabolically 
engineered to boost flux towards triterpenoid biosynthesis. Dai et al. reported an 
oleanolic acid titre of 71 mg/L in a strain expressing two copies of GgBAS, 
CYP716A12, ATR1 and overexpressing the MEV and early sterol pathway genes 
tHMG1, ERG9 and ERG1, which should increase flux towards 2,3-oxidosqualene (Dai 
et al., 2014). These genes were integrated and expressed from constitutive 
promoters, allowing the strains to be cultured in rich media containing glucose as the 
carbon source (YPD media). This should allow for improved growth and possibly 
higher triterpenoid production compared with the present study, which used a 
plasmid-based expression system that required the use of synthetic media with 
galactose as the carbon source, because glucose is the favoured carbon source for 
yeast (Timson, 2007). 
The highest oleanolic acid titre reported to date was 186 mg/L (in shake flasks) and 
607 mg/L (in a fermenter) (Zhao et al., 2018). This was achieved through several 
strategies. First, four CPRs were compared in a strain expressing GgBAS and 
CYP716A12 (all expressed from the galactose-inducible GAL promoters), with 
MtCPR (Medicago truncatula) being identified as the optimal CPR, and this pathway 
was then integrated. Second, the GAL1 and GAL80 genes were knocked out. They 
are responsible for the metabolism of galactose and the repression of the GAL 
promoters in the absence of galactose, respectively, and their knockout was therefore 
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be expected to increase expression from the GAL promoters. Finally, flux towards 
2,3-oxidosqualene was increased through overexpression of tHMG1, ERG9 and 
ERG1 (Zhao et al., 2018). Thus, there is great promise to scale-up oleanolic acid 
production towards industrially relevant levels. 
A comparative analysis of P450s of the CYP93E subfamily, which catalyse the C-24 
hydroxylation of β-amyrin, was previously reported by Moses et al. (Moses et al., 
2014c). Similar to the results obtained in the present study, the CYP93Es showed a 
range of activities and product ratios. Together with the results presented here, this 
highlights the importance of screening homologues for metabolic engineering 
applications. The CYP716As were co-expressed with AaBAS and ATR2 for the 
comparative analysis; AaBAS is one of the most productive BASs (together with 
CqBAS1) identified from the BAS comparative analysis (see Chapter 4). By 
comparing strains expressing combinations of genes with high (AaBAS, CYP716AL1) 
and low (SlBAS, CYP716A52v2) oleanolic acid productivities, it was shown that 
combining the most productive homologues resulted in considerably higher oleanolic 
acid production (Figure 5.12). MD-OA15, which expressed AaBAS and CYP716AL1, 
produced 8.5 mg/L oleanolic acid, while oleanolic acid titres could not be calculated 
for MD-OA31 (expressing SlBAS and CYP716A52v2) due to its low abundance. 
Further to this, strains expressing AaBAS and AsBAS (co-expressed with 
CYP716AL1 and ATR2) were compared for oleanolic acid production. In Chapter 4 it 
was observed that the strain expressing AsBAS grew much faster than the other 
BASs, having a very similar growth rate to the empty vector control strain, and this 
might be advantageous for oleanolic acid production. The strain expressing AsBAS 
(MD-OA29) produced nearly as much oleanolic acid as MD-OA15 (expressing 
AaBAS) (7.1 mg/L compared with 8.5 mg/L), yet accumulated minimal quantities of β-
amyrin, erythrodiol and oleanolic aldehyde (titres undetermined) (Figure 5.14). This 
further highlights the impact that the choice of homologue has on strain performance. 
It is unclear why MD-OA29 accumulated mainly oleanolic acid, but it is possible that 
the lower burden caused by AsBAS expression is responsible. Comparison with 
characterised OSCs (notably human and yeast lanosterol synthases) suggests that 
BASs may be monotopic membrane proteins localised to the ER or lipid particles 
(which are closely associated with the ER) (Milla et al., 2002; Thoma et al., 2004; 
Thimmappa et al., 2014; Jacquier et al., 2013; Liang et al., 2012). Furthermore, most 
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plant P450s and CPRs localise to the ER via an N-terminal membrane anchor, and 
may also localise here in yeast (Bak et al., 2011; Renault et al., 2014; Urban et al., 
1994). Overexpression of the BASs from the strong GAL1 promoter may saturate the 
ER, which could disrupt CYP716A activity. Western blots were unable to detect 
AsBAS protein (Figure 4.11 A), possibly indicating that it is expressed at a lower level 
compared to the other BASs. However, further work to detect AsBAS and compare 
its protein level with the other BASs would be required to confirm this. 
An interesting observation from the growth assays performed in conjunction with the 
above experiments was that strain growth appeared to largely depend on the choice 
of BAS. The additional expression of a CYP716A and ATR2 had little impact on 
growth rate compared with a strain expressing only a BAS (Figure 5.10 A, Figure 5.13 
A, Figure 5.15 A). Furthermore, the choice of CYP716A had only a small effect on 
growth rate, while changing the BAS altered growth considerably. Specifically, MD-
OA15 and MD-OA16 (expressing AaBAS, ATR2 and either CYP716AL1 or 
CYP716A52v2) grew similarly to the strain expressing only AaBAS (Figure 5.13 A); 
MD-OA30 and MD-OA31 (expressing SlBAS, ATR2 and CYP716AL1 or 
CYP716A52v2) grew similarly to the strain expressing only SlBAS (Figure 5.13 A); 
and MD-OA29 (expressing AsBAS, ATR2 and CYP716AL1) grew similarly to the 
strain expressing only AsBAS (Figure 5.15 A). Thus, BAS expression appears to be 
the primary cause of burden. 
To investigate the causes of this burden further, it will be essential to determine the 
expression levels of the BASs, CYP716As and ATR2. Similar to what was discussed 
in Chapter 4, variation in expression could explain the different catalytic activities of 
the CYP716As and the differences in growth observed when expressing different 
BASs. Western blots of four CYP716As and ATR2 were unable to detect any protein 
(Figure 5.11 A), while several BASs (except for AsBAS) could be detected using this 
method (see Chapter 4, Figure 4.11 A). This might suggest that the BASs were more 
highly expressed than the CYP716As and ATR2, which could explain why the 
additional expression of a CYP716A and ATR2 does not appear to substantially 
increase burden. However, quantitative information cannot be obtained from these 
western blots, which were preliminary experiments performed without replicates or 
loading controls. Further work to detect the CYP716As and ATR2 and compare their 
expression levels with the BASs is therefore required to confirm this hypothesis. 
Chapter 5: Comparison of CYP716As for oleanolic acid production 
 176 
To determine expression levels therefore, the western blots could be repeated and 
loading controls included. However, many replicates might be needed due to the 
inherent error in quantitative western blotting (Hoshino, 2017). As discussed in 
Chapter 4, the use of untargeted proteomics may be a better approach for comparing 
relative expression levels and may allow the detection of poorly expressed proteins. 
Indeed, a preliminary experiment was able to detect both CYP716AL1 and ATR2, as 
well as AaBAS, in MD-OA15 (Table 5.3). Although replicates were not included and 
quantification was not performed, the data indicate that AaBAS may indeed be more 
abundant than CYP716AL1 and ATR2, based on the number of peptide matches. 
Although this metric does not represent protein abundance, it does have a rough 
correspondence with abundance. AaBAS had 24 peptide matches, while CYP716AL1 
and ATR2 had 7 and 5, respectively. Such large differences typically indicate 
differences in abundance, with a greater number of matches corresponding to higher 
abundance. Nevertheless, additional replicates will be required to perform 
quantification and thus obtain an accurate measure of relative expression levels. 
In addition to determining expression levels, it would be interesting to investigate the 
burden caused by the expression of the CYP716As and ATR2 without BAS 
expression. For example, the growth of strains expressing a CYP716A and ATR2 but 
no BAS, a CYP716A only, or ATR2 only could be monitored. This would allow the 
burden caused by CYP716A and ATR2 expression to be investigated in the absence 
of a BAS, to better understand the individual contributions of these enzymes to the 
observed burden. 
Although differences in expression may explain variation in the total catalytic activity 
of the CYP716As, they should not influence the product profiles. Instead, variations 
in product profiles are most likely caused by differences in the sequences of the 
CYP716As. Although in silico analyses of the CYP716A sequences were performed, 
there were no apparent amino acid variants that might explain the observed 
differences in product profiles. Indeed, little is known about the catalytic mechanism 
of the CYP716A subfamily beyond the current understanding of P450 catalysis 
broadly. P450 substrate binding and recognition regions are highly variable (Werck-
Reichhart and Feyereisen, 2000), which is not surprising given the diverse substrates 
utilised by the P450 superfamily. Thus, subfamily-specific knowledge is required to 
explain the substrate and product specificities of individual P450s. Nevertheless, the 
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use of homology and substrate docking models may allow the differences in product 
profiles to be probed further. 
In addition to using culture vials, fermentations were performed in shake flasks and a 
BioLector micro fermenter. However, these failed to boost production, with titres 
generally being similar for all three experiments (Figure 5.18). Interestingly, 
erythrodiol titres for MD-OA15 were lower for the BioLector fermentations than for the 
culture vials and shake flasks. Furthermore, oleanolic acid titres for this strain were 
lower in both shake flasks and the BioLector than the culture vials. The reason for this 
is unclear, although it could be explained by differences in aeration. The CYP716As 
require molecular oxygen to oxygenate their substrates, and it is possible that 
inadequate aeration leading to lower intracellular oxygen availability could affect the 
oxygenation of β-amyrin by these enzymes, altering the product profile. However, as 
discussed earlier, the BioLector provides a high level of agitation and aeration to the 
cells, which would not be expected to reduce erythrodiol and oleanolic acid titres. 
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Table 5.3. Preliminary proteomics analysis of MD-OA15 
Protein Peptide matches 
(unique matches) 
Peptides 
AaBAS(Sc) 24 (13) VDFWNHR 
  HEVKPSSDVLWR 
  HEVKPSSDVLWR 
  IPDYLWVAEDGMK 
  IPDYLWVAEDGMK 
  IPDYLWVAEDGMK 
  WILDHGSVTTIPSWGK 
  WILDHGSVTTIPSWGK 
  DELYAQPYDEIKWR 
  KEIENFLLGSSGYLEK 
  KEIENFLLGSSGYLEK 
  CCLLFATMPPEIVGEK 
  QIWEFDPNYGTPEER 
  QIWEFDPNYGTPEER 
  SNLVHTAWAMMGLIHSR 
  KWILDHGSVTTIPSWGK 
  KWILDHGSVTTIPSWGK 
  KWILDHGSVTTIPSWGK 
  KKEIENFLLGSSGYLEK 
  KKEIENFLLGSSGYLEK 
  FLLETQLEDGGWGESYK 
  FLLETQLEDGGWGESYK 
  GSWTFSDQDHGWQVSDCTAEALK 
  GSWTFSDQDHGWQVSDCTAEALK 
   
CYP716AL1(Sc) 7 (6) STLPGPLPPGR 
  YIGLMDQIAQK 
  YSWNVACEVLR 
  MLPNFLKPEALQR 
  MLPNFLKPEALQR 
  IVVDPMPIPEKGLPVR 
  SHLLGEPAAVFCGAIGNK 
   
AtATR2(Sc) 5 (5) SENCSSAPIFVR 
  VEPLKPLVIKPR 
  MDFIYEEELQR 
  IVDLDDYAADDDEYEEK 
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Chapter 6: Production of Oleanane Saponins 
6.1 Introduction 
In addition to oxygenations, triterpenoids are often subject to glycosylations catalysed 
by UDP-glycosyltransferases (UGTs) (Thimmappa et al., 2014). The resulting product 
is called a saponin, and glycosylations contribute to the diverse bioactivities found in 
this family of metabolites (Augustin et al., 2011; Thimmappa et al., 2014). Triterpenoid 
aglycones are typically hydrophobic, and the addition of a large polar moiety (the 
sugar) to the aglycone increases polarity and influences solubility (Thimmappa et al., 
2014; Augustin et al., 2011). Glycosylation thus has a dramatic effect on the 
physicochemical properties of the triterpenoid, and is responsible for many of their 
activities, such as the ability to act as surfactants and foaming agents and the 
insecticidal activities of some saponins (Moses et al., 2014a; Augustin et al., 2012; 
Nielsen et al., 2010). Indeed, many saponins are believed to form pores in cell 
membranes due to their amphipathic structures, resulting in their haemolytic activities 
(Augustin et al., 2011; Moses et al., 2014a). 
Glycosylations occur at oxygenated positions of the triterpenoid, most commonly at 
the C-3 hydroxyl group and the C-28 carboxyl group (Thimmappa et al., 2014). Most 
triterpenoids possess the C-3 hydroxyl, which is derived from the epoxide of 2,3-
oxidosqualene, while a cytochrome P450 with C-28 oxidase activity is required to form 
the C-28 carboxyl (see Chapter 5). Triterpenoids can be glycosylated at multiple 
positions with different sugars, and the sugar chains can vary in length and be linear 
or branched (Moses et al., 2014a). The UGTs involved in saponin biosynthesis 
generally have high regiospecificities but a broader substrate range, glycosylating a 
number of structurally related triterpenoid substrates and sometimes non-triterpenoid 
substrates (Meesapyodsuk et al., 2007; Naoumkina et al., 2010; Achnine et al., 2005; 
Thimmappa et al., 2014; Augustin et al., 2012; Erthmann et al., 2018). Most saponins 
are monodesmosidic, having a single sugar chain, and many bidesmosidic saponins 
are also known, while saponins that are glycosylated at more than two positions are 
rare (Augustin et al., 2011). Sugar chain lengths typically range from two to five 
sugars, and common sugars include glucose, galactose and glucuronic acid, although 
many different sugars are possible (Augustin et al., 2011). Sugar chains are built up 
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by the sequential addition of monosaccharides to the triterpenoid, rather than the 
addition of a previously synthesised oligosaccharide (Augustin et al., 2011). The 
sugars can also be subject to further modifications by tailoring enzymes, such as 
acylations (Ragupathi et al., 2011). 
The combined action of P450s (catalysing oxygenations), UGTs (catalysing 
glycosylations) and various tailoring enzymes (e.g. catalysing acylations) therefore 
allows plants to produce highly complex saponins (Moses et al., 2014a). For example, 
QS-21, a mixture of two saponins derived from a Quillaja saponaria extract, has a 
branched trisaccharide chain (glucuronic acid, xylose, galactose) at the C-3 hydroxyl 
and a linear tetrasaccharide chain at the C-28 carboxyl (fucose, rhamnose, xylose 
and either apiose or xylose). This tetrasaccharide is acylated at the fucose moiety, 
and the acyl group is itself glycosylated with an arabinose (Ragupathi et al., 2011). 
Plants also produce many simple saponins such as 3-O-Glc-oleanolic acid, which has 
a single glucose moiety at the C-3 hydroxyl (Augustin et al., 2012). 
Many saponins have medically or industrially useful properties (Moses et al., 2014a). 
For example, glycyrrhizin is a sweetener produced by Glycyrrhiza glabra (liquorice) 
that has emulsifying and anti-viral activities (Ma et al., 2018; Fiore et al., 2008). 
Meanwhile, hederacolchiside A (Pulsatilla koreana) showed a stronger antitumour 
activity than the anticancer drugs doxorubicin and taxol in a mouse model (Bang et 
al., 2005). Quil A, a saponin extract from Quillaja saponaria, has been used in 
veterinary vaccines (Sun et al., 2009) while QS-21, a fraction derived from this extract, 
shows immunostimulatory activity (Moses et al., 2014a). QS-21 is used as an adjuvant 
in a vaccine against feline leukaemia virus (Sun et al., 2009) and also served an 
adjuvant in the anti-malarial vaccine RTS,S, although this vaccine showed low 
efficacy in a phase III clinical trial (Gosling and von Seidlein, 2016; Mahmoudi and 
Keshavarz, 2017). In addition, numerous saponins have been shown to have 
insecticidal or anti-feedant activities. For example, saponins derived from oleanolic 
acid and hederagenin acted as feeding deterrents against the plant pests Phyllotreta 
nemorum (flea beetle) and Plutella xylostella (diamondback moth), and this activity 
was dependent on the sugar moieties (Shinoda et al., 2002; Nielsen et al., 2010; 
Augustin et al., 2012). For more information, see section 1.2 and Figure 1.6.  
Due to their diverse bioactivities it is desirable to develop microbial platforms for 
saponin production. However, only a limited range of saponins have been produced 
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in yeast, with most studies focusing on the production of triterpenoid aglycones. Only 
two β-amyrin-derived saponins (oleanane saponins) have been produced in yeast to 
date, and both were monoglucosides (Moses et al., 2014b; Arendt et al., 2017). 3-O-
Glc-echinocystic acid is derived from β-amyrin by two P450-catalysed oxygenations 
and a single glycosylation at the C-3 hydroxyl (Moses et al., 2014b), while the 
production of 28-O-Glc-medicagenic acid involved three oxygenations and a 
glycosylation at the C-28 carboxyl (Arendt et al., 2017). Although oleanane saponins 
containing multiple sugars have not yet been produced in yeast, production of the 
diglycoside saponin Ginsenoside Rg3, which is derived from the tetracyclic triterpene 
dammarenediol-II, was recently demonstrated (Wang et al., 2015). Ginsenoside Rg3 
has a Glc-Glc disaccharide chain at its C-3 hydroxyl, and its biosynthesis involves a 
dammarenediol synthase, a P450 and two UGTs. Nevertheless, as discussed above, 
many saponins that occur in nature are far more complex, having undergone many 
oxygenations, glycosylations and other modifications. Therefore, to access the 
diversity and realise the commercial potential of saponins, platforms that can produce 
such complex saponins must be developed. 
Here, various UGTs (Table 6.1) were expressed in yeast strains engineered to 
produce β-amyrin or oleanolic acid, and saponin production was monitored by TLC 
and LC-MS. β-amyrin contains only the C-3 hydroxyl group, while oleanolic acid also 
possess the C-28 carboxyl group. UGTs expected to transfer a glucose moiety to 
these groups (UGT73C10 and UGT73F3) were tested (Figure 6.1), as well as two 
UGTs known to glycosylate triterpenoids but whose regiospecificities were unknown 
(UGT71G1 and UGT73K1) (Naoumkina et al., 2010; Augustin et al., 2012; Achnine et 
al., 2005). In addition, the co-expression of UGT73C10 and UGT73P2 was tested for 
the production of monodesmosidic saponin diglycosides (i.e. containing a 
disaccharide sugar chain at a single position). UGT73C10 adds a glucose to the C-3 
hydroxyl, while UGT73P2 adds a galactose to the C-3 glucuronic acid of 
soyasapogenol B monoglucuronide in the biosynthesis of soyasaponin I (Shibuya et 
al., 2010; Augustin et al., 2012), and has also been shown to add a galactose to the 
C-3 glucose of 3-O-Glc-oleanolic acid (Figure 6.1) (Thomas Louveau, personal 
communication). 
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Table 6.1. UGTs tested in this study 
UGT Activity* Species Accession 
number 
Reference 
UGT73C10 C-3, Glc Barbarea vulgaris  AFN26666 Augustin et al., 2012 
UGT73K1 Glc Medicago truncatula AAW56091 Achnine et al., 2005 
UGT71G1 Glc M. truncatula AAW56092 Achnine et al., 2005 
UGT73P2 C-2', Gal Glycine max BAI99584 Shibuya et al., 2010 
UGT73F3 C-28, Glc M. truncatula ACT34898 Naoumkina et al., 2010 
*The position of glycosylation and the sugar added are shown. Glc: glucose; Gal: 
galactose; C-2’: carbon-2 of glucose. 
Figure 6.1. UGT-catalysed glycoslyations of triterpenoids. The glycosylation of oleanolic 
acid by UGT73C10, UGT73F3 and UGT73P2 are shown. UGT73C10 and UGT73F3 are 
expected to transfer a glucose moiety to the C-3 hydroxyl and C-28 carboxyl, respectively. 
UGT73P2 is expected to transfer a galactose to the glucose of 3-O-Glc-oleanolic acid, 
producing neosaponin. OA: oleanolic acid. 
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6.2 TLC indicates strains are producing saponins  
To generate yeast strains capable of producing saponins, strains MD-BA5 
(expressing EtBAS) and MD-OA7 (expressing EtBAS, CYP716A12 and ATR2) were 
transformed with plasmids expressing various UGTs (Table 6.1). UGT73C10 is a 
promiscuous UGT that can glycosylate a variety of triterpenoids at the C-3 hydroxyl 
group (Augustin et al., 2012). UGT73K1 and UGT71G1 were shown to glycosylate 
certain triterpenoids in vitro but their regiospecificities were not determined; it 
appeared likely that they glycosylated at the C-3 hydroxyl or C-28 carboxyl groups 
(Achnine et al., 2005). UGT73P2 can add a galactose to an existing glucose at the C-
3 position (such as that added by UGT73C10), generating a disaccharide sugar chain 
(Thomas Louveau, personal communication). To date, the only oleanane saponins 
that have been produced in yeast were monoglycosides, containing a single sugar. 
Functional expression of UGT73C10 and UGT73P2 in yeast would thus allow the first 
production of a diglycoside saponin in yeast. It was shown that co-expression of 
UGT73C10 and UGT73P2 with genes for oleanolic acid biosynthesis in the tobacco 
plant Nicotiana benthamiana allows production of a novel saponin called neosaponin, 
which consists of an oleanolic acid aglycone with a Gal-Glc disaccharide at the C-3 
hydroxyl (Thomas Louveau, personal communication). Neosaponin is so-called 
because it has not been observed in nature before, its production being enabled by 
the expression of a novel combination of enzymes in a heterologous host. 
To monitor saponin production, yeast expressing the saponin biosynthetic pathways 
were grown for 90 h in galactose-supplemented medium. Butanol extractions were 
performed on both cells and the spent medium, and the extracts were analysed by 
TLC (Figure 6.2). MD-BA5, MD-OA7 and the empty vector control strain MD-N2 were 
also analysed, as were 0.6 µg of authentic β-amyrin, oleanolic acid and 3-O-Glc-
echinocystic acid standards. 3-O-Glc-echinocystic acid is a saponin that is structurally 
similar to 3-O-Glc-oleanolic acid, having an additional hydroxyl group at C-16, and so 
should serve as a suitable control; standards for the saponins potentially produced by 
the strains in the present work were not available. The metabolite extraction and TLC 
methods were based on protocols provided by Thomas Louveau (Anne Osbourn lab, 
John Innes Centre). Bands were not observed for the β-amyrin and oleanolic acid 
standards, indicating that any bands observed in the samples are unlikely to 
correspond to triterpenoid aglycones (Figure 6.2). As expected, a band was observed 
for 3-O-Glc-echinocystic acid. 
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Figure 6.2. Thin layer chromatography (TLC) indicates saponin production. TLC was 
performed on extracts of cells co-expressing various UGTs with either EtBAS (for β-amyrin 
production) or an oleanolic acid pathway (EtBAS, CYP716A12 and ATR2). Strains expressing 
EtBAS alone (MD-BA5), the oleanolic pathway alone (MD-OA7) or carrying empty vectors 
(MD-N2) were analysed as controls. Authentic standards of β-amyrin, oleanolic acid and the 
saponin 3-O-Glc-echinocystic acid (0.6 µg each) were also analysed. Top: cell extracts. 
Bottom: spent media extracts. The enzymes expressed by each strain are indicated. 
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Strain MD3, expressing EtBAS and UGT73C10, had a unique band that was not 
present for MD-BA5 (expressing only EtBAS) that may correspond to 3-O-Glc-β-
amyrin. This band was only present in the cell extract (Figure 6.2). MD10 expressed 
EtBAS, UGT73C10 and UGT73P2, so was expected to produce both 3-O-Glc-β-
amyrin and 3-O-[Gal-Glc]-β-amyrin. However, only a single unique band, similar to 
MD3 and visible only in the cell extract, was observed. MD10 may therefore only 
produce 3-O-Glc-β-amyrin. 
Strain MD14, expressing an oleanolic acid pathway (EtBAS, CYP716A12 and ATR2) 
and UGT73C10, was expected to produce glycosylated derivatives of β-amyrin, 
oleanolic acid and the intermediates erythrodiol and oleanolic aldehyde. This strain 
had two unique bands, one that migrated a similar distance as that in the MD3 and 
MD10 cell extracts, and the other not present in those strains (Figure 6.2). Therefore, 
the first band may correspond to 3-O-Glc-β-amyrin, while the other may correspond 
to glycosylated erythrodiol, oleanolic aldehyde or oleanolic acid. The additional 
expression of UGT73P2 (strain MD21) was expected to produce neosaponin (3-O-
[Gal-Glc]-oleanolic acid) and possibly other saponin diglycosides derived from β-
amyrin, erythrodiol or oleanolic aldehyde. However, this strain appeared identical to 
MD14, indicating that diglycosides either were not present or were not detected. 
Both unique bands in strains MD14 and MD21, including that putatively belonging to 
3-O-Glc-β-amyrin, were present in the cell and spent medium extracts. Interestingly, 
this contrasted with strains MD3 and MD10, where the putative 3-O-Glc-β-amyrin 
band was observed only in the cell extract (Figure 6.2). It is possible that production 
of glycosylated derivatives of oleanolic acid (or the intermediates erythrodiol or 
oleanolic aldehyde) results in secretion of 3-O-Glc-β-amyrin into the growth medium, 
for example by cell lysis caused by production of these saponins. Indeed, some 
oleanane saponins are reported to have haemolytic properties, lysing red blood cells, 
and saponins are believed to be capable of permeabilising cells membranes 
(Augustin et al., 2011). Furthermore, oleanane saponins produced by Medicago 
truncatula are classified as haemolytic and non-haemolytic saponins, and the 
haemolytic saponins all contain a C-28 carboxyl group, while the non-haemolytic 
saponins do not possess this moiety (Moses et al., 2014a). Alternatively, it is possible 
that one or more of the additional saponins potentially produced by MD14 and MD21 
(i.e. derived from erythrodiol, oleanolic aldehyde and/or oleanolic acid) have the same 
Chapter 6: Production of Oleanane Saponins 
 186 
retention time as 3-O-Glc-β-amyrin, and it is these more oxidised saponins that are 
being secreted into the growth medium, rather than 3-O-Glc-β-amyrin. To test these 
hypotheses, it will be necessary to perform LC-MS to enable the identification of each 
saponin. 
No products were detected in the strains expressing UGT73K1 or UGT71G1 (strains 
MD5, MD6, MD16 and MD17) (Figure 6.2), indicating that these UGTs may not be 
able to glycosylate β-amyrin or its C-28 oxygenated derivatives. These UGTs were 
previously shown to glycosylate certain triterpenoids derived from oleanolic acid in an 
in vitro assay but were not tested with other triterpenoids (Achnine et al., 2005). It is 
also possible that they did have activity against these substrates but the products 
were not abundant enough to be detected by TLC. Finally, strains MD7 (expressing 
EtBAS and UGT73P2) and MD18 (expressing the oleanolic acid pathway and 
UGT73P2) did not produce any detectable products. This was expected, because 
UGT73P2 is reported to only extend an existing sugar chain at the C-3 hydroxyl, and 
is not able to glycosylate a triterpenoid aglycone (Shibuya et al., 2010). 
6.3 LC-MS confirms saponin production and allows 
identification of individual saponins 
The TLC results indicated that some strains produced saponins, however, it did not 
provide information on their identities. Therefore, LC-MS was performed to identify 
which saponins were produced. In addition to confirming the identity of metabolites 
through analysis of their mass spectra, the high sensitivity of this technique should 
also allow the detection of low abundance saponins that may not have been detected 
by TLC. 
The current study used a PFP reverse phase column with a methanol gradient (i.e. a 
hydrophobic stationary phase and polar mobile phase). Hydrophobic analytes should 
thus elute later as they interact more strongly with the column, and saponins that have 
undergone more glycosylations or oxygenations should elute earlier than those that 
have not. Thus neosaponin (3-O-[Gal-Glc]-oleanolic acid), which has two sugars, 
should elute earlier than 3-O-Glc-oleanolic acid, while 3-O-Glc-β-amyrin should elute 
even later, as C-28 is a methyl group instead of a carboxyl like oleanolic acid. The 
soft ionisation technique (electrospray ionisation; ESI) used by the current LC-MS 
system results in less fragmentation of the analyte compared with the hard ionisation 
techniques employed in the GC-MS assays. As such, saponins that are analysed by 
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LC-MS do not undergo retro Diels-Alder (rDA) fragmentations, and the main ions 
observed should be the parent ion and fragment ions resulting from the loss of sugars 
and carboxyl groups. 
In addition to the above strains analysed by TLC, another strain generated by the 
transformation of MD-OA7 with a plasmid containing UGT73F3 was tested. UGT73F3 
was reported to transfer a glucose to the C-28 carboxyl of the oleanolic acid 
derivatives hederagenin and medicagenic acid (Naoumkina et al., 2010; Arendt et al., 
2017), and may therefore glycosylate oleanolic acid at this position. Strains were 
cultured and metabolites extracted as before, and the cell and spent media extracts 
were analysed by LC-MS (positive ion mode). Hannah Florance (University of 
Edinburgh) provided help in developing the LC-MS protocol. Extracted ion 
chromatograms (EICs) were generated for each expected saponin. EICs differ from 
total ion chromatograms (TICs) in that the intensity of only the specified ion is plotted 
in an EIC, whereas the total intensity of all ions are plotted in a TIC. Because they 
plot the intensity of only a single ion, EICs can be used to identify compounds whose 
peaks are otherwise hidden by noise. For each expected saponin, the sodium adduct 
of the parent ion was used to generate EICs. A summary of the results is shown in 
Table 6.2 and Table 6.3.  
Although mass spectra were analysed, only the parent ion could be observed, 
indicating that the saponins underwent little or no fragmentation using the current 
method (Figure 6.3). The mass spectra therefore provide little additional information 
over the EICs. The lack of observed fragmentation therefore means that saponins 
cannot be absolutely identified, as less information is available for each observed 
peak. Nevertheless, the LC-MS method still provides additional information over the 
TLC in the form of the parent ion. 
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Table 6.2. Summary of LC-MS analyses (cell extracts) 
Strain Enzymes m/z 611  
(3-O-Glc-β-
amyrin) 
m/z 627  
(3/28-O-Glc-
erythrodiol) 
m/z 625  
(3-O-Glc-
OAld) 
m/z 641  
(3/28-O-Glc-
OA) 
m/z 773  
(3-O-[Gal-Glc] 
-β-amyrin) 









MD3 UGT73C10 13.4’ - - - - - - - 
MD5 UGT71G1 - - - - - - - - 
MD6 UGT73K1 - - - - - - - - 
MD10 UGT73C10 + 
UGT73P2 
13.4’ - - - - - - - 
MD14 CYP716A12 + 
UGT73C10 
13.4’ 10.8’ (3) 
10.9’ (28?) 
11.8’ 10.9’ (3) - 9.9’ (Glc-Glc) - 9.6’ (Glc-Glc) 
MD15 CYP716A12 + 
UGT73F3 
- 10.9’ (28?) - 10.6’ (28) - 9.9’ (Glc-Glc) - 9.6’ (Glc-Glc) 
MD16 CYP716A12 + 
UGT71G1 
- - - - - - - - 
MD17 CYP716A12 + 
UGT73K1 
- - - - - - - - 
MD21 CYP716A12 + 
UGT73C10 + 
UGT73P2 
13.4’ 10.8’ (3) 
10.9’ (28?) 
11.8’ 10.9’ (3) - 9.9’ (Glc-Glc) 
10.5’ (Gal-Glc) 
- 9.6’ (2x Glc) 
10.5’ (Gal-Glc) 
All strains expressed EtBAS. The m/z value refers to the sodium adduct of the parent ion, [M+Na]+, of the corresponding saponin. Retention times (min) 
of the observed peaks are shown. The potential position of the sugar (3 or 28) or the hypothesised sugar chain (Glc-Glc, Gal-Glc) are shown in brackets. 
OAld: oleanolic aldehyde; OA: oleanolic acid; Glc: glucose; Gal: galactose; 3-O-[Gal-Glc]-OA: neosaponin. 
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Table 6.3. Summary of LC-MS analyses (spent media) 
Strain Enzymes m/z 611  
(3-O-Glc-β-
amyrin) 
m/z 627  
(3/28-O-Glc-
erythrodiol) 
m/z 625  
(3-O-Glc-
OAld) 
m/z 641  
(3/28-O-Glc-
OA) 
m/z 773  
(3-O-[Gal-Glc] 
-β-amyrin) 









MD3 UGT73C10 - - - - - - - - 
MD5 UGT71G1 - - - - - - - - 
MD6 UGT73K1 - - - - - - - - 
MD10 UGT73C10 + 
UGT73P2 
- - - - - - - - 
MD14 CYP716A12 + 
UGT73C10 
13.4’ 10.8’ (3) 
10.9’ (28?) 
11.8’ 10.9’ (3) - 9.9’ (Glc-Glc) - 9.6’ (Glc-Glc) 
MD15 CYP716A12 + 
UGT73F3 
- 10.9’ (28?) - 10.6’ (28) - 9.9’ (Glc-Glc) - 9.6’ (Glc-Glc) 
MD16 CYP716A12 + 
UGT71G1 
- - - - - - - - 
MD17 CYP716A12 + 
UGT73K1 
- - - - - - - - 
MD21 CYP716A12 + 
UGT73C10 + 
UGT73P2 
13.4’ 10.8’ (3) 
10.9’ (28?) 
11.8’ 10.9’ (3) - 9.9’ (Glc-Glc) 
10.5’ (Gal-Glc) 
- 9.6’ (Glc-Glc) 
10.5’ (Gal-Glc) 
All strains expressed EtBAS. The m/z value refers to the sodium adduct of the parent ion, [M+Na]+, of the corresponding saponin. Retention times (min) 
of the observed peaks are shown. The potential position of the sugar (3 or 28) or the hypothesised sugar chain (Glc-Glc, Gal-Glc) are shown in brackets. 
OAld: oleanolic aldehyde; OA: oleanolic acid; Glc: glucose; Gal: galactose; 3-O-[Gal-Glc]-OA: neosaponin 
Chapter 6: Production of Oleanane Saponins 
 190 
  
Figure 6.3. Mass spectra of selected peaks. Only the parent ions were visible, indicating 
that little or no fragmentation occurred. (A) Mass spectrum of the peak at 13.4 min in sample 
MD3 (cell extract), potentially corresponding to 3-O-Glc-β-amyrin. (B) Mass spectrum of the 
peak at 10.9 min of MD14 (cell extract), potentially corresponding to 28-O-Glc-erythrodiol (m/z 
627 parent ion) and 3-O-Glc-oleanolic acid (m/z 641 parent ion). (C) Mass spectrum of the 
peak at 10.5 min in MD21 (cell extract), potentially corresponding to neosaponin (3-O-[Gal-
Glc]-oleanolic acid). The putative saponin parent ions are in bold and underlined.
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6.3.1 Analysis of saponin monoglycosides 
Strains MD3 (expressing EtBAS and UGT73C10) and MD10 (EtBAS, UGT73C10 and 
UGT73P2) had peaks potentially corresponding to 3-O-Glc-β-amyrin in the cell extract 
but not in the spent medium (Figure 6.4 A-B). By contrast, MD14 (oleanolic acid 
pathway plus UGT73C10) and MD21 (oleanolic acid pathway plus UGT73C10 and 
UGT73P2) had such a peak in both the spent medium and the cell extract (Figure 6.4 
A-B). There were small differences in the retention time of these peaks, which may 
result from experimental error. The other strains did not have any unique peaks, 
indicating that they did not produce 3-O-Glc-β-amyrin. 
Analysis of EICs for the 627 m/z ion, which should correspond to glycosylated 
erythrodiol, showed two peaks (at 10.8 min and 10.9 min) for MD14 and MD21 and 
one peak (at 10.9 min) for MD15 (oleanolic acid pathway with UGT73F3) in both the 
cell extracts and spent media (Figure 6.4 C-D). While a small peak at 10.8 min was 
present in the cell extracts of all strains, this peak was considerably larger for MD14 
and MD21 (Figure 6.4 C), indicating that it represented a metabolite unique to these 
strains. The peak at 10.8 min was the dominant peak in MD14 and MD21 and was 
not observed for MD15. UGT73C10 (expressed by MD14 and MD21) is reported to 
glycosylate the C-3 hydroxyl, while UGT73F3 (expressed by MD15) is reported to 
glycosylate only at C-28 and did not glycosylate β-amyrin (Figure 6.4 A-B), which has 
only a C-3 hydroxyl. This indicates that the peak at 10.8 min may correspond to 3-O-
Glc-erythrodiol. The peak at 10.9 min might therefore result from the glycosylation of 
erythrodiol at the C-28 hydroxyl, with UGT73C10 showing some weak activity towards 
this reaction. Although UGT73C10 was only reported to have C-3 glycosylation 
activity, other members of the UGT73C subfamily from Barbarea vulgaris also 
performed C-28 glycosylation (Augustin et al., 2012; Erthmann et al., 2018). Both 3- 
and 28-O-Glc-erythrodiol would have the same molecular weight, and would therefore 
be observed in the same EIC. 
A putative 3-O-Glc-oleanolic aldehyde peak (m/z 625) was observed in both the cell 
extracts and spent media for MD14 and MD21 at 11.8 min (Figure 6.4 E-F). Some 
additional peaks unique to these strains were also present in the spent media. In the 
cell extracts the peak at 11.8 min was more abundant for MD14 than MD21, while in 
the spent media it was more abundant for MD21. MD21 putatively produced saponin 
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diglycosides (see below), and it is possible that this enhanced secretion of saponins, 
resulting in this difference between MD14 and MD21.  
The EICs for the m/z 641 ion, which would correspond to both 3- and 28-O-Glc-
oleanolic acid, showed a peak at 10.9 min for MD14 and MD21 and at 10.6 min for 
MD15 (for both cell extract and spent media) (Figure 6.4 G-H). These may correspond 
to 3- and 28-O-Glc-oleanolic acid, respectively. If so, this would indicate that 
UGT73C10 glycosylated oleanolic acid only at the C-3 hydroxyl and not at C-28, while 
UGT73F3 only glycosylated the C-28 carboxyl. This contrasts with what was observed 
for glycosylated erythrodiol (Figure 6.4 C-D), where it appeared that UGT73C10 may 
have glycosylated erythrodiol at the C-28 hydroxyl. A peak at 10.9 min was also 
observed in the EICs of the m/z 627 ion for MD14, MD15 and MD21, which potentially 
corresponded to 28-O-Glc-erythrodiol (see above). In this case, 28-O-Glc-erythrodiol 
and 3-O-Glc-oleanolic acid would be co-eluting. 
The results suggest that MD14 and MD21 potentially accumulate 3-O-Glc-β-amyrin, 
-erythrodiol, -oleanolic aldehyde and -oleanolic acid in both the spent media and 
within the cells, while MD3 and MD10 accumulate 3-O-Glc-β-amyrin only in the cells 
(Figure 6.4 A-H). This is consistent with the TLC results, where 3-O-Glc-β-amyrin was 
only detected in the spent medium in MD14 and MD21 (Figure 6.2), and suggests that 
the production of glycosylated erythrodiol, oleanolic aldehyde or oleanolic acid may 
allow the secretion of saponins into the growth media. 
No saponins were detected for the strains expressing UGT71G1 or UGT73K1 in either 
the β-amyrin or oleanolic acid strains (MD5-6 and MD16-17). These UGTs were 
reported to glycosylate a variety of oxidised triterpenoids in vitro, but they were not 
tested against β-amyrin or its derivatives erythrodiol, oleanolic aldehyde or oleanolic 
acid (Achnine et al., 2005). The present results indicate that they do not have activity 
against these triterpenoids. 
6.3.2 Analysis of saponin diglycosides 
EICs corresponding to the saponin diglycosides 3-O-[Gal-Glc]-β-amyrin, -erythrodiol, 
-oleanolic aldehyde and -oleanolic acid (neosaponin) were also analysed. For MD21, 
two peaks (at 9.6 min and 10.5 min) were observed in the EIC for neosaponin in both 
the cell extracts and spent media (Figure 6.4 O-P). The first peak was in low 
abundance and was also observed for MD14 and MD15, suggesting that it may result 
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from the addition of two glucose molecules by UGT73C10 (for MD14 and MD21) or 
UGT73F3 (for MD15). Indeed, other members of the UGT73C from Barbarea vulgaris 
have been shown to add multiple glucose groups to their substrates (Augustin et al., 
2012; Erthmann et al., 2018). Because glucose and galactose are isomers and 
therefore have the same molecular weight, oleanolic acid with a Glc-Glc sugar chain 
would give a parent ion with the same m/z value as a neosaponin, and both would 
therefore be observed in the same EIC. 
A similar result was observed with the EIC for 3-O-[Gal-Glc]-erythrodiol. MD21 had 
two peaks (at 9.9 min and 10.5 min) in both the cell extract and spent media, and the 
first peak was also observed for MD14 and MD15 (Figure 6.4 K-L). No peaks 
corresponding to 3-O-[Gal-Glc]-oleanolic aldehyde were observed for any strains 
(Figure 6.4 M-N). The EICs for this saponin showed many peaks that were also 
present in the control strains (MD-OA7 and the empty vector control MD-N2). This 
likely corresponds to noise from a background ion that has the same m/z as the 3-O-
Glc-oleanolic aldehyde parent ion. No 3-O-[Gal-Glc]-β-amyrin was observed for MD10 
or MD21. Because both MD10 and MD21 potentially produced 3-O-Glc-β-amyrin 
(Figure 6.4 A-B), this indicates that UGT73P2 may not be able to glycosylate this 
saponin. 
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Figure 6.4. LC-MS analysis of strains engineered for saponin production. See next page 
for full figure legend. 
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6.4 Discussion 
Here, yeast strains were engineered to produce saponins derived from β-amyrin and 
oleanolic acid. TLC indicated that saponins were produced, and LC-MS analysis 
supported this conclusion. Importantly, it should be noted that the LC-MS analysis 
was not able to absolutely confirm the identities of the saponins, and therefore does 
not represent a final confirmation of saponin production. The saponins underwent little 
apparent fragmentation, meaning that they could only be identified on the basis of 
their parent ions and the presence of peaks that were absent in the negative controls. 
Furthermore, as this was a preliminary experiment, strains were run without 
replicates. The data also contained a large amount of noise. While such noise was 
observed in some of the EICs (e.g. see Figure 6.4 E), it was especially apparent when 
analysing the mass spectra, where many peaks that did not appear to represent 
fragment ions were present (Figure 6.3). As such, to confirm production of these 
saponins, the LC-MS method must be improved to reduce the noise and allow 
fragmentation to facilitate proper identification. 
To further facilitate saponin identification, tandem mass spectrometry (LC-MS/MS) 
could be performed, which allows selected ions to be targeted for further 
fragmentation. These additional MS/MS spectra thus provide more information about 
the analyte, facilitating identification. Alkaline hydrolysis of saponin extracts should 
also allow glycosylation at C-3 and C-28 to be distinguished. This specifically cleaves 
ester bonds, resulting in the loss of the sugar chain at the C-28 carboxyl group. 
Figure 6.4. LC-MS analysis of strains engineered for saponin production. Shown are 
overlays of the following extracted ion chromatograms (EICs) corresponding to Na+ adducts: 
m/z 611, corresponding to 3-O-Glc-β-amyrin (A-B); m/z 627, corresponding to 3- or 28-O-
Glc-erythrodiol (C-D); m/z 625, corresponding to 3-O-Glc-oleanolic aldehyde (E-F); m/z 641, 
corresponding to 3- or 28-O-Glc-oleanolic acid (G-H); m/z 773, corresponding to 3-O-[Gal-
Glc]-β-amyrin (I-J); m/z 789, corresponding to 3-O-[Gal-Glc]-erythrodiol (K-L); m/z 787, 
corresponding to 3-O-[Gal-Glc]-oleanolic aldehyde (M-N); and m/z 803, corresponding to 3-
O-[Gal-Glc]-oleanolic acid (i.e. neosaponin) (O-P). Both extracts from the cells and the spent 
media are shown. Peaks potentially corresponding to saponins are labelled with their retention 
times (min). MD-BA5 expressed EtBAS, MD-OA7 expressed EtBAS, CYP716A12 and ATR2, 
and MD-N2 was an empty vector control. See Table 6.2 and Table 6.3 for the enzymes 
expressed by the saponin production strains. 
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(Augustin et al., 2012). As it does not hydrolyse ether bonds, the sugar chain at the 
C-3 hydroxyl is unaffected. Thus, depletion of saponins after alkaline hydrolysis would 
indicate that glycosylation had occurred at the C-28 carboxyl group. The use of 
standards corresponding to the expected saponins (e.g. of 3-O-Glc-oleanolic acid 
etc.) would allow absolute identification of these saponins by LC-MS. Unfortunately, 
such standards were not available for the present study. In the future, these could be 
produced through the glycosylation of commercially available triterpenoid aglycones 
as described by Augustin et al., incubating the aglycone with extracts of E. coli 
expressing the relevant UGT (Augustin et al., 2012). 
The ability to identify saponins through analysis of TICs allows untargeted analyses 
to be performed. Because the fragment ions must be specified when using EICs, they 
are generally limited to targeted approaches in which the expected metabolites are 
known. It is therefore difficult to use EICs (and thus the method used in the present 
study) to detect unexpected compounds because it requires a fragment ion for every 
possible compound to be specified, meaning that any unexpected compounds would 
be missed. The ability to perform untargeted analyses would thus greatly expand the 
range of saponins that can be detected. This would enable combinatorial experiments 
where different biosynthetic enzymes are ‘mixed-and-matched’ in novel combinations, 
potentially allowing the production of a diverse range of saponins. 
The production of neosaponin reported here represents the first production of an 
oleanane diglycoside saponin in yeast, and is an important step towards the 
production of complex bioactive saponins in this microorganism. However, the 
saponins produced in this work were simple in structure, containing only one or two 
sugar moieties and being oxygenated only at up to a single position (the C-28 moiety). 
Many bioactive saponins are far more complex, containing multiple sugar chains of 
different lengths, composed of multiple sugars, and with varying branching patterns 
(Bang et al., 2005; Moses et al., 2014a; Augustin et al., 2011; Ragupathi et al., 2011). 
Furthermore, saponins are often oxygenated at multiple positions and are sometimes 
modified by other tailoring enzymes (e.g. methyl- or acyltransferases) (Moses et al., 
2014a; Thimmappa et al., 2014). QS-21 provides a great example of such a complex 
saponin, containing a branched trisaccharide at the C-3 hydroxyl, an acylated linear 
tetrasaccharide at the C-28 carboxyl, being oxygenated at three positions on the 
aglycone, and containing a total of six different sugars (Ragupathi et al., 2011). 
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Pertinently, the co-expression of UGT73C10 and UGT73F3 may allow the production 
of bidesmosidic saponins glycosylated at both the C-3 and C-28 positions. Production 
of such saponins has not been demonstrated in yeast before. Six UGTs of the 
UGT73C subfamily were recently identified from Barbarea vulgaris (Erthmann et al., 
2018). In vitro characterisation using E. coli extracts expressing the UGTs indicated 
that four were able to glycosylate oleanolic acid or hederagenin, the C-23 hydroxy 
derivative of oleanolic acid, at both the C-3 hydroxyl and C-28 carboxyl groups. These 
are therefore also excellent candidates for the production of bidesmosides in yeast.  
The co-expression of three or more UGTs for the production of saponins with longer 
sugar chains should also be explored. For example, soyasaponin I, which contains a 
rhamnose-galactose-glucuronic acid sugar chain at the C-3 hydroxyl, might be 
produced through the co-expression of UGT73P2, UGT91H4 and a 
glucuronosyltransferase (transferring a glucuronic acid moiety). UGT73P2 and 
UGT91H4 are involved in soyasaponin I biosynthesis in Glycine max, with UGT91H4 
transferring a rhamnose to the existing Gal-GlcA sugar chain (Shibuya et al., 2010). 
Although a glucuronosyltransferase has yet to be identified, two human UGTs were 
found to transfer a glucuronic acid to the C-3 or C-28 moiety of the triterpenoid ursolic 
acid (regiospecificity undetermined) (Gao et al., 2016). UGT91H4 might also be able 
to glycosylate neosaponin, which has a Gal-Glc sugar chain. 
Importantly, glycosylation of triterpenoids requires the appropriate UDP-sugar, which 
is used as a donor by the UGT that catalyses the reaction (Thimmappa et al., 2014; 
Augustin et al., 2011). While saponins can contain a variety of different sugars, S. 
cerevisiae natively produces only three UDP-sugars: UDP-glucose, UDP-galactose 
and UDP-N-acetylglucosamine (Oka and Jigami, 2006). Indeed, QS-21 contains the 
sugars xylose, glucuronic acid, galactose, fucose, rhamnose and apiose (Ragupathi 
et al., 2011), meaning that the pathways for five UDP-sugars would need to be 
expressed in addition to the saponin biosynthetic pathway. It is therefore important to 
develop yeast strains capable of producing such UDP-sugars. As plants are known to 
encode a huge number of UGTs (Lairson et al., 2008; Caputi et al., 2012), they are 
likely an excellent source of UDP-sugar biosynthetic genes. Indeed, the pathways for 
UDP-glucuronic acid and UDP-xylose have successfully been expressed in yeast, 
using genes from Arabidopsis thaliana (Oka and Jigami, 2006). Future work should 
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thus explore the co-expression of UDP-sugar and saponin biosynthetic pathways to 
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Chapter 7: Final discussion 
The aim of this work was to produce triterpenoids in Saccharomyces cerevisiae. Yeast 
natively produces the triterpene precursor 2,3-oxidosqualene but to produce 
triterpenoids a heterologous pathway must be expressed. Triterpenoid biosynthesis 
comprises three key steps: (i) cyclisation of 2,3-oxidosqualene by an OSC, producing 
a triterpene; (ii) oxygenation of the triterpene by cytochromes P450 to produce a 
triterpenoid; and (iii) glycosylation of the triterpenoid by UGTs, producing a 
triterpenoid saponin (Thimmappa et al., 2014). Additional tailoring reactions (e.g. 
acylations) can also occur (Thimmappa et al., 2014) but these were not the focus of 
this research. 
In Chapter 3, a GC-MS method to monitor and quantify the production of triterpene 
and triterpenoid aglycones was presented. In Chapter 4, twelve β-amyrin synthases 
(BASs) were compared for their ability to cyclise 2,3-oxidosqualene to β-amyrin when 
expressed in yeast, and the effect on growth rate was assessed. Similarly, in Chapter 
5, sixteen P450s of the CYP716A subfamily were compared for their ability to oxidise 
β-amyrin to oleanolic acid, and different combinations of BAS and CYP716A were 
also analysed. Finally, in Chapter 6, UGTs were additionally expressed in yeast 
engineered to produce β-amyrin or oleanolic acid, and saponin production was 
monitored by TLC and LC-MS. 
In this chapter the following are discussed: (i) the impact of the BAS and CYP716A 
homologue on growth and productivity, (ii) understanding the differences in activities 
and the causes of burden, and (iii) the production of oleanane saponins in yeast. 
7.1 The choice of homologue is important for strain 
development 
Chapters 4-5 highlighted the benefits of comparing enzyme variants during strain 
development. The comparison of BASs found that β-amyrin titres ranged over 10-fold, 
while in the comparative analysis of CYP716As erythrodiol and oleanolic acid titres 
ranged 18.7- and 6.8-fold. Product ratios also varied depending on the homologues 
used. For example, strain MD-OA15 expressing CYP716AL1 from Catharanthus 
roseus accumulated the greatest amounts of oleanolic acid (14.1 mg/L) and oleanolic 
aldehyde (titre undetermined) (Figure 5.7 A-B). Meanwhile, the strain expressing 
CYP716A75 produced a surprisingly high amount of erythrodiol (20.9 mg/L) and very 
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little oleanolic aldehyde or oleanolic acid (titres undetermined) (Figure 5.7 A-B), 
indicating that it is highly specific for C-28 hydroxylation when using β-amyrin as a 
substrate. These differences in activity were not predictable from analysis of the 
amino acid sequences. 
Strains expressing combinations of BASs and CYP716As with high (AaBAS, 
CYP716AL1) and low (SlBAS, CYP716A52v2) productivities were compared (Figure 
5.12). Following 96 h growth in SC-URA + 2 % D-galactose media, strain MD-OA15 
expressing the most productive homologues (AaBAS and CYP716AL1, with ATR2) 
yielded 8.2 mg/L β-amyrin, 7.3 mg/L erythrodiol and 8.5 mg/L oleanolic acid. 
Comparing MD-OA15 with strain MD-OA30 (expressing SlBAS and CYP716AL1 with 
ATR2), differing from MD-OA15 only in the BAS used, showed that switching to the 
low productivity SlBAS substantially reduced triterpenoid production; this strain 
yielded 2.5 mg/L β-amyrin, 1.7 mg/L erythrodiol and 2.9 mg/L oleanolic acid. Similarly, 
using a low productivity CYP716A also limited production, as both strains expressing 
CYP716A52v2 (MD-OA16 and MD-OA31) produced low quantities of oleanolic 
aldehyde and oleanolic acid compared with CYP716AL1, regardless of the BAS 
expressed. 
Strikingly, replacing AaBAS with the less burdensome AsBAS (strain MD-OA29) 
resulted in almost complete conversion of β-amyrin to oleanolic acid (Figure 5.14 A-
B). Furthermore, this strain grew at a similar rate as the strain expressing AsBAS 
alone (and thus also at a similar rate to the empty vector control strain) (Figure 5.15 
A). Thus, the data demonstrate that the BAS and CYP716A variant can have a major 
impact on strain performance. 
Comparative studies of other enzymes have previously been reported. Moses et al. 
(2014b) compared eight P450s of the CYP93E subfamily, which oxidise β-amyrin at 
the C-24 methyl group. Similar to the present work, the P450s displayed a range of 
activities and product ratios. Although 24-hydroxy-β-amyrin was the major product in 
all cases, smaller amounts of 24-carboxy- and 24-oxo-β-amyrin were also produced. 
By contrast, the CYP716As tested here showed a greater variety of product ratios, 
with erythrodiol often being the major product instead of oleanolic acid. More recently, 
Zhu et al. (2018) compared two C-11 oxidase (CYP88D6, Uni25647) and two C-30 
oxidase (CYP72A154, CYP72A63) P450s for the production of glycyrrhetinic acid, 
which is derived from β-amyrin through two oxygenations. The combination of 
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Uni25647 and CYP72A63 increased production of the intermediate 11-oxo-β-amyrin 
but did not significantly increased glycyrrhetinic acid production (Zhu et al., 2018). 
All oleanolic acid strains in the present study expressed the Arabidopsis thaliana CPR 
ATR2. A. thaliana CPRs are often used for functional expression of P450s in yeast 
(Urban et al., 1997; Zhao et al., 2016; Dai et al., 2013, 2014; Moses et al., 2014a; 
Arendt et al., 2017; Gavira et al., 2013; Wang et al., 2015), however, numerous other 
CPRs have been characterised. For example, CPRs from Lotus japonicus, Medicago 
truncatula, Catharanthus roseus and Artemisia annua have been used to supply 
electrons to plant P450s expressed in yeast (Seki et al., 2008; Miettinen et al., 2017; 
Brown et al., 2015; Ro et al., 2006). The interaction between the P450 and CPR and 
the electron transfer to the P450 (coupling) is important for catalytic activity (Zhao et 
al., 2016; Renault et al., 2014), and it is possible that CPRs other than ATR2 might 
confer higher activity. The optimal CPR might also depend on the P450s expressed, 
with some P450/CPR pairs having better coupling than others. Indeed, Yan et al. 
(2014) compared ATR2 and two CPRs from Panax ginseng (PgCPR1 and PgCPR2) 
for the production of the triterpenoid protopanaxadiol, which is derived from the 
triterpene dammarenediol-II by a P450-catalysed oxygenation. PgCPR1 and PgCPR2 
showed similar activities as judged by the protopanaxadiol titre, with PgCPR1 being 
slightly greater, while ATR2 showed considerably lower activity (approximately 2-
fold).  
More recently, Zhu et al. (2018) compared six CPRs from A. thaliana (ATR1, ATR2), 
M. truncatula (MTR2, MTR3), L. japonicus (LjCPR1) and Glycyrrhiza uralensis 
(GuCPR1) for the production of glycyrrhetinic acid in yeast. The choice of CPR had a 
large impact on productivity, with MTR3 producing very little glycyrrhetinic acid and 
GuCPR1 increasing production 5.6-fold compared with the commonly used ATR1 
(Zhu et al., 2018). Meanwhile, ATR2, which was used in the present study, gave the 
second highest glycyrrhetinic acid titre (Zhu et al., 2018). Furthermore, the strain 
expressing GuCPR1 accumulated far less β-amyrin compared with ATR1, indicating 
that flux was increased through the P450-catalysed parts of the pathway (Zhu et al., 
2018). These differences in productivities could be explained by differences in the 
interaction between P450 and CPR, and it is therefore possible that GuCPR1 would 
not be the optimal CPR for all P450s.  
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Zhao et al. (2018) compared four CPRs (ATR1, MtCPR, LjCPR and GuCPR) in a 
strain expressing GgBAS and CYP716A12 for the production of oleanolic acid. They 
found that MtCPR gave the highest oleanolic acid titres. It is possible that using a 
CPR from the same species as the P450 can give higher production, as both MtCPR 
and CYP716A12 are from M. truncatula. Indeed, in the comparison of CPRs for 
glycyrrhetinic acid production performed by Zhu et al. (2018), the optimal CPR 
(GuCPR) was from the same species as the expressed P450s (G. uralensis). 
Furthermore, the comparison of ATR2, PgCPR1 and PgCPR2 by Yan et al. (2014), 
which found PgCPR1 and PgCPR2 (from P. ginseng) to have considerably higher 
activities than ATR2 (from A. thaliana), was performed with the P. ginseng P450 
CYP716U1. These studies, together with the present work, highlight how comparing 
enzyme variants can be a useful strategy to optimise strains for triterpenoid 
production. 
With the exception of MD-OA29, all oleanolic acid strains accumulated a significant 
amount of β-amyrin, indicating that the P450-catalysed reactions were rate-limiting. 
As suggested by the work described above, testing various CPRs could prove an 
effective strategy to relieve this bottleneck (Yan et al., 2014; Zhao et al., 2018; Zhu et 
al., 2018). Another possible strategy is to fuse the P450 and CPR. This may improve 
coupling, enhancing electron transfer from the CPR to the P450 and reducing the 
generation of reactive oxygen species through electron leakage (Zangar et al., 2004; 
Renault et al., 2014). Zhao et al. (2016) successfully applied this strategy to boost the 
production of protopanaxadiol. Fusion of CYP716U1 (C-12 hydroxylase) with ATR1 
resulted in almost complete conversion of dammarenediol-II to protopanaxadiol, while 
the non-fused variants accumulated a significant amount of dammarenediol-II (Zhao 
et al., 2016). 
Interestingly, the co-expression of AsBAS (instead of AaBAS) with CYP716AL1 and 
ATR2 (strain MD-OA29) resulted in almost complete conversion of β-amyrin to 
oleanolic acid (Figure 5.14 A-B). Expression of AsBAS alone had little effect on growth 
rate compared with an empty vector control strain (MD-N1), and MD-OA29 also grew 
very similarly to MD-N1 (Figure 5.15 A). This apparent lack of burden could explain 
the improved the conversion of β-amyrin to oleanolic acid. AsBAS may be expressed 
at a lower level than AaBAS, causing less burden on the ER (to which it may be 
localised) and so allowing for greater P450 activity (the P450s and ATR2 are also 
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believed to be localised to the ER), increasing conversion of β-amyrin to oleanolic 
acid. 
Expression of the CYP716As and ATR2 had little effect on growth rate, which could 
be explained by low expression levels. Indeed, they were not observed by western 
blot (Figure 5.11 A) and preliminary proteomics experiments also indicated that 
CYP716AL1 and ATR2 might be expressed at lower levels than AaBAS (Table 5.3). 
However, to confirm this hypothesis, further work will be required to detect the 
CYP716A and ATR2 proteins and compare their levels with those of the BASs. 
7.2 Understanding differences in activities and the 
causes of burden 
As noted above, expression of the BAS variants resulted in a variety of growth rates. 
Most grew more slowly than the empty vector control strain (MD-N1), indicating that 
BAS expression caused considerable metabolic burden. Interestingly, AsBAS grew at 
a similar rate to MD-N1, and PgBAS1 and BvBAS also grew relatively quickly. There 
are various explanations for this burden, including due to diversion of resources 
towards BAS expression, burden on the unfolded protein response due to misfolding 
of the BAS, toxicity caused by accumulation of β-amyrin, or depletion of endogenous 
metabolites due to β-amyrin production (e.g. 2,3-oxidosqualene and sterols). 
Depletion of ergosterol is perhaps unlikely, because ergosterol levels were not 
noticeably depleted in any of the BAS strains at the end of the 96 h culture period. 
However, it is possible that ergosterol levels were lower at earlier time points, only 
reaching levels similar to the wild-type by 96 h. 
The smaller effect on growth rate of AsBAS, PgBAS1 and BvBAS expression could 
possibly be explained by lower expression levels and/or less misfolding, leading to 
less burden on the unfolded protein response. Furthermore, these strains had 
relatively low specific β-amyrin titres (Figure 4.8 D), indicating that cellular β-amyrin 
levels were low in these strains. If β-amyrin accumulation is toxic, this might explain 
why these strains grew more quickly. However, while synthetic formiate and acetate 
derivatives of β-amyrin were found to inhibit growth of the yeast Candida albicans 
(Johann et al., 2007), to date there are no reports on the toxicity of β-amyrin to S. 
cerevisiae. Notably, the strain expressing GhBAS also had a low specific β-amyrin 
titre yet grew slowly (Figure 4.8 D, Figure 4.10 A), suggesting that other factors likely 
contribute to the differences in growth rate. 
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To investigate the causes of toxicity, the growth of a strain expressing a catalytically 
inactive variant of AaBAS (dAaBAS) was monitored. Any burden observed in this 
strain would not be expected to be caused by the accumulation of β-amyrin. This 
strain grew more quickly compared with wild-type AaBAS, reaching stationary phase 
after ~ 60 h instead of ~ 80 h, but more slowly than MD-N1 (which reached stationary 
phase after ~ 30 h) (Figure 4.15 A). This indicates that both production of the BAS 
protein and conversion of 2,3-oxidosqualene to β-amyrin slows yeast growth. 
However, it should be noted that expression levels were not accounted for. Decreased 
expression of dAaBAS would be expected to cause less burden and so could explain 
the observed results. Thus, to conclusively interpret these results, the relative 
expression levels of dAaBAS and AaBAS must be determined. 
The additional expression of a CYP716A and ATR2 had little impact on growth. 
Generally, strains expressing oleanolic acid pathways with different BASs grew at a 
similar rate to the corresponding strains expressing only a BAS (Figure 5.10 A, Figure 
5.13 A, Figure 5.15 A). Thus, MD-OA29 (expressing AsBAS, CYP716AL1 and ATR2) 
grew at a similar rate to the strain expressing AsBAS alone (and thus to MD-N1) 
(Figure 5.15 A). By contrast, MD-OA15 (expressing AaBAS, CYP716AL1 and ATR2) 
grew much more slowly, at a similar rate to the strain expressing AaBAS alone (Figure 
5.15 A). 
The small effect on growth of CYP716A and ATR2 expression could be due to lower 
expression levels of these enzymes compared with the BASs. Western blots were 
able to detect five BASs (out of six tested) but could not detect the CYP716As or 
ATR2 (Figure 4.11 A, Figure 5.11 A). Furthermore, preliminary proteomics 
experiments indicated that CYP716AL1 and ATR2 might be expressed at a lower level 
than AaBAS (Table 5.3). The GAL3 promoter (pGAL3), from which ATR2 was 
expressed, was reported to be weaker than the GAL10 and GAL1 promoters (pGAL1 
and pGAL10) (Paddon et al., 2013), possibly explaining the potentially low protein 
level of ATR2. However, both pGAL1 and pGAL10 are reported to have similar 
strengths (Weinhandl et al., 2014), so it was unexpected that CYP716AL1 (expressed 
from pGAL10) should be in lower abundance than AaBAS (expressed from pGAL1). 
Thus, the relatively high expression of the BASs could be responsible for the observed 
reductions in growth, while the additional expression of CYP716AL1 and ATR2 would 
have little effect due to their low protein levels. The minimal effect on growth rate of 
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AsBAS expression could also be explained by low protein levels, and is possibly 
supported by the western blot which could not detect AsBAS despite the five other 
tested BASs being observed (Figure 4.11 A). 
7.3 Production of oleanane saponins in yeast 
Expression of various UGTs in yeast strains engineered to produce β-amyrin or 
oleanolic acid resulted in the tentative production of oleanane mono- and diglycoside 
saponins, as determined by TLC and LC-MS. In these preliminary experiments, 
saponin identities could not be confirmed due to limitations in the LC-MS method: 
fragmentation of the saponins was not observed (Figure 6.3), meaning that they could 
only be identified on the basis of their parent ion. While this allowed for putative 
confirmation of saponin production, confirmation of their identities would require 
optimisation of the method such that fragmentation can be observed, and ideally the 
use of authentic standards, which were not available for the current study. 
Diglycosides of erythrodiol and oleanolic acid were tentatively observed by LC-MS. If 
confirmed, this would represent the first production of oleanane diglycoside saponins 
in yeast. Only five other oleanane saponins have been produced in yeast and all were 
monoglucosides (Moses et al., 2014b; Arendt et al., 2017). By contrast, production of 
the diglycoside dammarane-type saponin ginsenoside Rg3 in yeast was recently 
reported, with a yield of 3.5 μmol/g dry cell weight (Wang et al., 2015). 
Due to the lack of available standards, saponin titres were not reported here. To date, 
titres for oleanane saponins produced in yeast have not been reported, and in fact 
relatively few studies have produced oleanane saponins in yeast (Moses et al., 2014b; 
Arendt et al., 2017). By contrast, ginsenosides, saponins that are derived from the 
tetracyclic dammarane triterpenoids, have been produced more extensively in yeast 
(Wang et al., 2015; Wei et al., 2015; Yan et al., 2014; Zhuang et al., 2017b). Titres of 
93 mg/L and 42 mg/L were reported for ginsenosides Rh1 and F1, respectively, which 
are derived from the triterpene dammarenediol-II through the action of two P450s and 
a UGT (Wei et al., 2015). Meanwhile, a titre of 292 mg/L was reported for ginsenoside 
Rh2, which is produced from dammarenediol-II through the action of one P450 and 
one UGT (Zhuang et al., 2017b). 
Chapter 7: Final Discussion 
 213 
7.4 Future work 
7.4.1 Determining protein levels and investigating differences 
in activities 
This work has highlighted the differences in activities between BAS and CYP716A 
homologues. However, more work is needed to determine the reasons for these 
differences. As noted above, expression levels could explain the observed differences 
in activities and growth rates of the strains, yet these could not be determined through 
the course of this work. Preliminary western blot and proteomics experiments 
indicated that AsBAS may be expressed at a lower level than the other BASs, and 
that the CYP716As and ATR2 may also be expressed at lower levels. Nevertheless, 
a more comprehensive analysis is required to investigate the difference in protein 
expression levels between the BAS and CYP716A homologues. This is especially 
important for interpreting the results of the catalytically inactive AaBAS (dAaBAS) 
experiment, which indicated that β-amyrin production may indeed be a cause of 
burden. Relative protein levels might be effectively compared using an untargeted 
proteomics approach, which may also allow the observation of low abundance 
proteins that cannot be detected by western blot. Specific triterpenoid production 
could then be determined by dividing triterpenoid titres by relative protein expression, 
as proposed by Hoshino, (2017). 
Following determination of relative protein levels, the generation of homology and 
substrate docking models of homologues with different specific activities might allow 
these differences in activities to be investigated. Analysis of the BAS amino acid 
sequences identified several residues in AsBAS that could affect activity, and this 
analysis would be enhanced by knowledge of specific activity. By contrast, due to the 
low sequence conservation of P450s, no obvious amino acid variants could be 
identified for the CYP716As that might explain the differences in activities. Thus, for 
the CYP716As especially, homology and substrate docking models should be 
analysed. Any potentially important residues identified from these analyses could then 
be subjected to mutagenesis studies to confirm their importance for enzyme activity. 
Such studies might even identify mutants with enhanced catalytic activities or altered 
product ratios. 
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7.4.2 Metabolic and process engineering for enhanced 
triterpenoid production 
As noted before, the strains used in the present study were not metabolically 
engineered to enhanced triterpenoid production, and expressed only the triterpenoid 
biosynthetic pathway. Triterpenoid titres have been boosted considerably using 
traditional metabolic engineering strategies, with oleanolic acid titres as high as 607 
mg/L (in a fermenter) being reported (Zhao et al., 2018). This strain expressed 
GgBAS, CYP716A12 and MtCPR (the oleanolic acid pathway), and further 
overexpressed the MEV and early sterol pathway genes tHMG1, ERG9 and ERG1. 
The tHmg1p enzyme catalyses the reduction of HMG-CoA to mevalonate, the rate-
limiting step of the mevalonate pathway, while ERG9 and ERG1 encode squalene 
synthase and squalene epoxidase, which are together responsible for the conversion 
of two FPP molecules to 2,3-oxidosqualene (see section 1.1.1). Their overexpression 
should thus boost flux towards 2,3-oxidosqualene, providing more substrate for 
triterpenoid biosynthesis. With the exception of GgBAS and tHMG1, these genes 
were expressed from galactose-inducible promoters (pGAL1 or pGAL10), similar to 
the strains in the present work (Zhao et al., 2018). The GAL1 and GAL80 genes, 
which are responsible for metabolism of galactose and repression of the GAL 
promoters in the absence of galactose, were also knocked out, which should increase 
expression from the GAL promoters (Zhao et al., 2018). Titres of 186 mg/L oleanolic 
acid were obtained in shake flasks when grown in rich media supplemented with both 
galactose and glucose (with only 11.6 mg/L β-amyrin accumulating) (Zhao et al., 
2018). Batch fermentation in a 5 L bioreactor then boosted titres to 607 mg/L oleanolic 
acid (Zhao et al., 2018). 
In addition to overexpressing MEV and early sterol pathway genes, the repression of 
ERG7 has also been shown to redirect flux towards triterpene biosynthesis (Kirby et 
al., 2008; Moses et al., 2014b). The ERG7 gene encodes lanosterol synthase, which 
would compete with the triterpene synthase (e.g. β-amyrin synthase) for 2,3-
oxidosqualene substrate. An alternative approach employed by Arendt et al. (2017) 
knocked out the PAH1 gene (encoding phosphatidic acid phosphatase), which was 
previously shown to induce an expansion of the ER (Santos-Rosa et al., 2005). 
Because enzymes involved in the biosynthesis of triterpenoids are believed to localise 
to the ER, this should increase the capacity of yeast to express these enzymes and, 
indeed, levels of CYP716A12 protein were shown to be considerably higher in the 
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pah1 mutant strain (Arendt et al., 2017). This mutation increased β-amyrin titres 8-
fold, triterpenoid titres up to 6-fold, and titres of the saponin 28-O-Glc-medicagenic 
acid 16-fold (Arendt et al., 2017). However, only titres of the triterpenoid medicagenic 
acid, whose biosynthesis involves three P450-catalysed oxygenations, were reported 
(27 mg/L) (Arendt et al., 2017). 
Optimising the culture conditions is another promising strategy for increasing 
triterpenoid production. Moses et al. (2014a) explored the use of cyclodextrins to 
sequester triterpenoids into the culture media. Cyclodextrins are toroidal shaped 
molecules with hydrophobic interiors and hydrophilic exteriors that may allow them to 
encapsulate and solubilise the hydrophobic triterpenoids. Addition of cyclodextrins to 
the media should thus sequester the triterpenoids to the growth medium, preventing 
any toxicity or feedback inhibition that may arise from their intracellular accumulation. 
Indeed, the addition of methyl-β-cyclodextrin resulted in the accumulation of 
substantial amounts of triterpenoids in the culture medium, and increased β-amyrin 
titres ~ 1.5-fold (Moses et al., 2014b). 
A conceptually similar strategy that has been applied to the production of the 
dammarane-type triterpenoid protopanaxadiol is two-phase fermentation (Dai et al., 
2013; Zhao et al., 2016). Here, an organic solvent is added to the culture medium and 
acts to extract triterpenoids from the cells throughout the fermentation process. Using 
methyl oleate as the solvent, Dai et al. (2013) increased protopanaxadiol titres from 
812 mg/L to 1189 mg/L. However, titres of dammarenediol-II, the triterpene precursor 
to protopanaxadiol, also increased from 776 mg/L to 1548 mg/L, indicating that 
extraction of this more hydrophobic triterpene was favoured. Zhao et al. (2016) 
observed a similar effect when using dodecane as the solvent, with protopanaxadiol 
titres actually decreasing from 1437 mg/L to 312 mg/L when two-phase fermentation 
was applied. Meanwhile, dammarenediol-II titres increased from 19.7 mg/L to 312 
mg/L (Zhao et al., 2016). Thus, two-phase fermentation strategies should be used 
with caution, and careful attention should be paid to the choice of organic solvent to 
ensure that extraction of the product of interest is favoured. 
Finally, using an extensive process engineering strategy, Czarnotta et al. (2017) were 
able to boost titres of betulinic acid, the C-28 carboxy derivative of the triterpene 
lupeol, from 28 mg/L to 182 mg/L. While growth in shake flasks with glucose as the 
carbon source produced 28 mg/L betulinic acid, the use of a fermenter and the 
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application of an ethanol feed doubled titres to 57 mg/L. Subsequently, the use of 
nitrogen-free resting cell fermentations increased titres to 182 mg/L. Here, cells were 
first grown to high biomass with glucose, before being transferred to nitrogen-free 
media with an ethanol feed. The cells were unable to grow in the nitrogen-free media, 
and the increase in betulinic acid titres might be explained by the resulting redirection 
of metabolic flux from biomass generation to triterpenoid production (Czarnotta et al., 
2017). 
Thus, numerous strategies have been successfully employed to boost the production 
of a variety of triterpenoids in yeast. These strategies should be applicable to enhance 
the production of oleanolic acid and its derived saponins in the strains presented in 
the current study. 
7.4.3 Expanding saponin production in yeast 
To further facilitate saponin identification, alkaline hydrolysis could be performed to 
distinguish between C-3 and C-28 glycosides. This results in the loss of the sugar 
chain at the C-28 carboxyl group, due to the specific cleavage of ester bonds (sugar 
chains at the C-3 hydroxyl are joined via an ether linkage, which is not cleaved) 
(Augustin et al., 2012). Absolute confirmation of saponin structure could be achieved 
by nuclear magnetic resonance spectroscopy (NMR) (Moses et al., 2014b). 
Following confirmation of the oleanane saponins produced in the present study, there 
are numerous directions this work could be taken. Many saponins are far more 
complex than those produced here, containing multiple linear or branched sugar 
chains consisting of many different sugars (Thimmappa et al., 2014; Augustin et al., 
2011). For example, QS-21 has two sugar chains containing six different sugars 
(glucuronic acid, xylose, galactose, fucose, rhamnose and apiose) (Ragupathi et al., 
2011). By contrast, S. cerevisiae only natively produces three UDP-sugars: UDP-
glucose, UDP-galactose and UDP-N-acetylglucosamine (Oka and Jigami, 2006). 
Indeed, only one of the sugars in QS-21 (UDP-galactose) is natively produced by 
yeast. Thus, to further expand saponin production in yeast, the pathways for UDP-
sugar biosynthesis must be functionally expressed in yeast. Biosynthetic pathways 
for UDP-glucuronic acid and UDP-xylose from Arabidopsis thaliana have been 
functionally expressed in yeast, but these were not used for saponin production (Oka 
and Jigami, 2006). To date, only saponins containing glucose and galactose sugars 
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have been produced in yeast (Moses et al., 2014a; Arendt et al., 2017; Wei et al., 
2015; Wang et al., 2015; Yan et al., 2014; Zhuang et al., 2017; present work). 
7.5 Closing comments 
In this work, a panel of twelve BASs were compared for the production of β-amyrin in 
yeast, in order to optimise this first committed step in the biosynthesis of oleanane 
triterpenoids and saponins. Subsequently, sixteen P450s of the CYP716A subfamily 
were compared for their ability to oxygenate β-amyrin to oleanolic acid, a key 
oleanane triterpenoid that is a precursor to numerous bioactive products. In both 
cases, activities varied widely, with AaBAS from Artemisia annua and CYP716AL1 
from Catharanthus roseus producing the greatest amounts of β-amyrin and oleanolic 
acid, respectively. Furthermore, the co-expression of AsBAS from Avena strigosa and 
CYP716AL1 resulted in almost complete conversion of β-amyrin to oleanolic acid, a 
result that may be linked to the negligible impact on growth caused by AsBAS 
expression. Finally, oleanane saponins derived from β-amyrin and its oxygenated 
derivatives erythrodiol, oleanolic aldehyde and oleanolic acid were produced in yeast. 
This work thus represents a step towards the commercial production of industrially 
and medically relevant oleanane triterpenoids and saponins. Ultimately, the ability to 
produce complex saponins such as QS-21 will require the co-expression of multiple 
P450s and UGTs, various UDP-sugar biosynthesis enzymes, and undoubtedly 
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